Automated solution-phase synthesis of HIV- and Leishmanias-associated oligosaccharides to probe structure-dependent immune responses

Eun-ho Song
Iowa State University

Follow this and additional works at: http://lib.dr.iastate.edu/etd
Part of the Chemistry Commons

Recommended Citation
http://lib.dr.iastate.edu/etd/11053
Automated solution-phase synthesis of HIV- and *Leishmania*-associated oligosaccharides to probe structure-dependent immune responses

by

Eun-Ho Song

A dissertation submitted to the graduate faculty

in partial fulfillment of the requirements for the degree of

DOCTOR OF PHILOSOPHY

Major: Organic Chemistry

Program of Study Committee:
Nicola L. Pohl, Major Professor
Richard C. Larock
Malika Jeffries-EL
Emily A. Smith
Christine A. Petersen

Iowa State University

Ames, Iowa

2009
# TABLE OF CONTENTS

**LIST OF ABBREVIATIONS**

**ABSTRACT**

**CHAPTER 1.** General introduction and review of fluorous-based carbohydrate microarrays

1. Dissertation organization

2. Fluorous-based small-molecule microarrays for protein, antibody and enzyme screening

3. Overview of fluorous-based microarrays

4. Immobilization strategies for microarray fabrication

5. Noncovalent fluorous-based microarrays

6. Fluorous-based microarrays for protein and antibody screening

7. Fluorous-based microarrays for enzyme screening

8. Linking fluorous-based arrays to automated synthesis

9. References

**CHAPTER 2.** Automated synthesis of HIV-associated linear $\alpha$-1,2-linked pentamannose

10. Introduction

11. Results and discussion

12. Conclusion

13. Experimental section

14. References

**CHAPTER 3.** Automated synthesis of *Leishmania*-associated carbohydrates and fluorous-based microarrays

15. Introduction

16. Results and discussion

17. Conclusion

18. Experimental section

19. References

**CHAPTER 4.** Development of automated synthesis and screening of phosphate-linked *Leishmania*-associated carbohydrates

20. Introduction
<table>
<thead>
<tr>
<th>Chapter 5. Synthesis of multivalent Leishmania-associated capping carbohydrates and evaluation of structure-dependent immune responses in IL-12 production</th>
<th>135</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>135</td>
</tr>
<tr>
<td>Results and discussion</td>
<td>138</td>
</tr>
<tr>
<td>Conclusion</td>
<td>145</td>
</tr>
<tr>
<td>Experimental section</td>
<td>146</td>
</tr>
<tr>
<td>References</td>
<td>165</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 6. Modification of degradable polymeric particles with carbohydrates for the study of in-vitro activation of dendritic cells</th>
<th>168</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>168</td>
</tr>
<tr>
<td>Results and discussion</td>
<td>170</td>
</tr>
<tr>
<td>Conclusion</td>
<td>176</td>
</tr>
<tr>
<td>Experimental section</td>
<td>176</td>
</tr>
<tr>
<td>References</td>
<td>184</td>
</tr>
</tbody>
</table>

| Chapter 7. Conclusions and future directions | 187 |

| ACKNOWLEDGMENTS | 189 |

<table>
<thead>
<tr>
<th>Appendix A. Chapter 2 (^1)H and (^13)C NMR spectra</th>
<th>190</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Appendix B. Chapter 3 (^1)H and (^13)C NMR spectra</th>
<th>193</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Appendix C. Chapter 4 (^1)H and (^13)C NMR spectra</th>
<th>222</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Appendix D. Chapter 5 (^1)H and (^13)C NMR spectra</th>
<th>263</th>
</tr>
</thead>
</table>

| Appendix E. Chapter 6 \(^1\)H and \(^13\)C NMR spectra | 288 |
LIST OF ABBREVIATIONS

ACN  acetonitrile
AcOH  acetic acid
ESI-MS  electrospray ionization mass spectrometry
FMOC  fluorenlymethoxycarbonyl
FT-IR  Fourier transform-infrared
Gal  galactose
Glc  glucose
FITC  fluorescein isothiocyanate
GlcNAc  N-acetylglucosamine
Hepes  N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
HPLC  high pressure liquid chromatography
(iPr)2NP(OBn)2  dibenzyl N,N-diisopropyl phosphoramidite
ITC  isothermal titration calorimetry
IPP  inorganic pyrophosphatase
IPTG  isopropyl thiogalactoside
MALDI-TOF-MS  matrix assisted laser desorption time-of-flight mass spectrometry
Man  mannose
mCPBA  3-chloroperbenzoic acid
m/z  mass/charge ratio
NAD+  nicotinamide adenine dinucleotide
NADH  nicotinamide adenine dinucleotide, reduced form
NBS  N-bromosuccinimide
NDP  nucleotide diphosphate
NIS  N-iodosuccinimide
PEG  polyethylene glycol
P,  phosphate
PP,  pyrophosphate
SIM  selected ion monitoring
TBDPS  tert-butyldiphenylsilyl
TEA  triethylamine
TFA  trifluoroacetic acid
TfOH  trifluoromethanesulfonic acid
TMSOTf  (trimethylsilyl)methanesulfonic acid
Infectious disease associated-oligosaccharides are important target molecules for synthesis to enable studies of their functions in infection mechanisms both in humans and animals. Unlike solid-phase automated chemical syntheses of oligonucleotides and oligopeptides that serve to provide these molecules for systematic structure-function relationships, automated chemical synthesis of oligosaccharides has been restricted due to the need to manage stereochemistry of each linkage and to the greater complexity of the monomeric carbohydrate building blocks. A new solution-phase automation platform that relies on fluorous solid-phase extraction (FSPE) to purify intermediates potentially offers easier access to complicated oligosaccharides with several features such as simpler monitoring of reactions, only 2-3 equivalents of building block usage per glycosylation cycle, labor savings, and easier access to previously constructed compounds. In addition, the fluorous allyl-tag used to simplify purification in the automation platform also allows not only direct incorporation into microarrays but also ready modification of the tag for facile conjugation to polymeric vehicles. Herein are reported the development of methods for this automation platform for the first construction of HIV- and *Leishmania*-associated
oligosaccharides. Automated methods to make phosphate-linked sugars as well as conventional glycosidic linkages are demonstrated. Several *Leishmania*-associated oligosaccharides—including capping structures, phosphate-linked capping structures and phosphoglycan repeats—were synthesized as probes for carbohydrate microarrays to screen sera of infect animals. The further development of efficient conjugation chemistry allowed the multivalent modification of latex beads and degradable micro-/nanoparticles with these bioactive oligosaccharides to probe carbohydrate-related structure/function relationships in the stimulation of cellular immune responses.
CHAPTER 1

General introduction and review of fluorous-based carbohydrate microarrays

Portions of this chapter have been published as a special report in Future Medicinal Chemistry (2009), 1, 889-896. (Copyright 2009 Future Science)

1. Dissertation organization

This dissertation consists of seven chapters. The first chapter is a review published in Future Medicinal Chemistry in 2009. Chapter 1 includes not only recent progress in microarray fabrication methods in order to perform fluorous-based microarrays on both covalent and non-covalent immobilized slides but also applications of fluorous-based microarrays in the screening of protein, antibody and enzyme activities. Chapter 2 describes the first automated solution-phase synthesis of HIV-associated linear α-1,2-linked pentamannose. Unlike solid phase-based automation platforms, the solution phase-based automation method allows the construction of oligosaccharides with easy reaction monitoring through conventional techniques such as thin layer chromatography (TLC) and high performance liquid chromatography (HPLC), fewer equivalents of building blocks per coupling cycle (1.5 ~ 2
equivalents), and less laborious work. Chapter 3 discusses the automated synthesis of *Leishmania*-associated carbohydrates and fluorous-based microarray for antibody screening. Six different fluorous-tagged *Leishmania*-associated carbohydrates were synthesized either through automated synthesizer or iterative synthesis for antibody screening of serum using a fluorous-based microarray. Chapter 4 discusses the synthesis of phosphate-linked *Leishmania*-associated carbohydrates by using an H-phosphonate strategy in order to investigate the role of phosphate-linkages in lipophosphoglycans (LPG). Importantly, the first automated synthesis of phosphoglycan repeats of *L. donovani* was achieved in a solution-based platform with the development of general protocols for this type of phosphate-linked carbohydrate. Chapter 5 includes the synthesis of multivalent *Leishmania*-associated capping carbohydrates for the collaborative evaluation of carbohydrate structure-dependent immune responses. Chapter 6 describes protocols for the modification of degradable polymeric particles with carbohydrates for the collaborative investigation of dendritic cell (DC) activation against carbohydrates-modified polymeric particles. Chapter 7 provides conclusions for this dissertation as well as future directions for carbohydrate research.
2. Fluorous–based small-molecule microarrays for protein, antibody and enzyme screening.

Carbohydrates are one of the most abundant biomolecules on the surface of the cell membrane and thereby are crucial for the interactions of cells with one another and with pathogens such as viruses, bacteria, and fungi. Although several functions such as generating energy, mediating signal transduction between different organisms, and providing recognition makers and structural components have long been appreciated roles for carbohydrates, their regulation mechanisms are still not clear. Furthermore, the structural complexity of carbohydrates, which are derived from the incredible diversity of regiochemistries and stereochemistries possible between furanose and pyranose rings, adds to the difficulty in studying carbohydrate binding partners such as proteins, enzymes and antibodies. Given the limitations in accessing large quantities of pure structurally well-defined carbohydrates, carbohydrate microarrays are increasingly used as a versatile tool for unveiling the possible binding associates for carbohydrates since the first glycan array was reported in 1985.

2.1 Overview of fluorous-based microarrays.
Small molecules are an important tool for the elucidation of biological recognition processes. Currently, the best way to design molecules that have biological activities for soluble proteins without structural information is to screen an assortment of possible structures. With increasing demand for useful tools for small molecule screening, small molecule microarrays have become increasingly important. Microarray techniques allow quick assessments of possible binding partners for biomolecules including nucleic acids, proteins and carbohydrates, with small amounts of sample and therefore lower costs than multiwell plate types of screening methods. Small molecule microarrays are particularly valuable for creating and probing multivalent displays of molecules such as saccharides that mimic the multivalent displays of cell-surface bound compounds.

For example, carbohydrate microarrays have clearly played a key role in facilitating access to information about carbohydrate-protein interactions. After a general discussion of immobilization techniques used for small molecule microarray fabrication using carbohydrates as an example, a more detailed discussion of microarrays based on noncovalent fluorocarbon interactions will be surveyed to highlight the unique potential of fluorine in this context.
2.2 Immobilization strategies for microarray fabrication

Figure 1. Representative covalent and noncovalent immobilization strategies for small molecules for microarray fabrication: a) Immobilization of thiol-functionalized molecules to maleimide-modified slides, b) Immobilization of amine-functionalized molecules to N-hydroxysuccinimide ester-modified slides, c) Immobilization of azide-functionalized molecules to alkyne-modified slides by Huisgen cycloaddition, d) Immobilization through photochemical activation of natural products to aryl-diazirin-coated slides, e) Immobilization of lipid-containing molecules to nitrocellulose, f) Immobilization of amine-functionalized molecules to noncovalently modified...
polystyrene wells containing lipid-linked isocyanates, g) Immobilization of DNA-tagged compounds to complementary strands on surface; h) Immobilization of fluorocarbon-tagged molecules to fluoroalkyl-modified slides.

Immobilization techniques for microarray formation can be divided into two main categories that describe the method of attachment of the molecules to the slide surface: covalent immobilization and noncovalent immobilization of the molecules to the slide surface. (Figure 1) A basic overview of these methods using carbohydrate immobilization as an example follows. Among covalent immobilization techniques, forming a stable bond between maleimide-functionalized slides and thiol-containing molecules is common, as well as reactions of amine-functionalized molecules with $N$-hydroxysuccinimde (NHS)-activated glass slides. Applications of Cu(I)-mediated 1,3-dipolar Huisgen cycloadditions between azide-containing molecules and alkynylated glass slides have also been utilized to covalently attach carbohydrates or small molecules to slide surfaces for screening. When products contain hydroxyl or carboxylate moieties, photoinduced cross-linking based immobilization techniques have been introduced to array small molecules on diazirin-coated glass slides. Conditions (pH, time, temperature, etc.) have to be
optimized to maximize reaction yields of the covalent-bond forming step. The subsequent challenge is quantification of those yields to know the concentration of the molecules that will be screened. Each of these methods, of course, requires the introduction of the necessary functional group into both the molecules to be screened and the slides themselves. In certain cases in which the small molecules have unique reactive functional handles, at least unmodified molecules can be used with specially-modified slides. For example, in addition to the photocrosslinking strategy mentioned above, the direct immobilization of unmodified reducing sugars recently has been shown using hydrazide- and aminoxy-derivatized glass slides.\textsuperscript{15} (Figure 2) Fifty-eight unmodified glycans including mono-, oligo- and polysaccharides were then directly arrayed on the specially derivatized slides and then tested for binding of the sugars to lectins, antibodies, and bacterial cells. Although undesired products such as acyclic adducts from hydrazide-derivatized slides and acyclic adducts with mixture of alpha/beta anomers from aminoxy-derivatized slides can be present at each microarray spot to complicate data interpretation, this one-step immobilization technique can be used to probe carbohydrate-protein binding, carbohydrate-antibody
binding and quantification of carbohydrate-protein binding without prior modification of the carbohydrates.

Figure 2. One-step direct immobilization of unmodified reducing sugars to hydrazide- and aminooxy-modified slide surfaces.

Although covalent immobilization techniques have provided powerful tools for investigating the binding properties of molecules in microarray formats, noncovalent immobilization techniques are also being investigated (Figure 1). In contrast to covalent immobilization techniques, non-covalent techniques should render compounds on the slide surface more flexible, thus allowing them to move for optimal binding with a protein, antibody, or enzyme target. Moreover, non-covalent
immobilization techniques have the potential advantage of allowing the recycling and reuse of slides.

Several strategies have emerged for such noncovalent schemes to create carbohydrate microarrays. An intriguing noncovalent strategy involves attachment of a nucleic acid strand to a compound and then immobilization of that compound onto a specific location of a slide where a complementary nucleic acid strand is located. The authors found their DNA-directed strategy to have a lower detection limit than a noncovalent strategy for detecting immobilized glycoconjugates. Older noncovalent immobilization strategies include the attachment of neoglycolipids (NGLs) on nitrocellulose and noncovalent arrays using long hydrocarbon chains. The latter method requires amine-functionalized carbohydrates for an isocyanate-mediated capture strategy to attach the long hydrocarbon chains. Unfortunately, the use of such large hydrocarbon tags to noncovalently anchor compounds to the slide surface can be problematic, for example when detergents are required in bioassay buffers.

2.3 Noncovalent fluorous-based microarrays
More recently, noncovalent immobilization based on fluorophobic rather than hydrophobic effects has been tested in the context of microarray formation. Selective immobilization of a polyfluorocarbon (C8F17) chain attached to a carbohydrate to a fluorinated surface has been shown to be surprisingly robust enough for the screening of carbohydrate-protein binding screening (Figure 3). Prior to this work, such noncovalent fluorous interactions had been used to facilitate the purification of fluorous-tagged compounds from compounds that do not contain any fluorous content using fluorous solid-phase extraction (FSPE). Washing of fluorous-modified silica gel with aqueous/organic solvent mixtures allows retention of fluorous-tagged molecules, whereas non-fluorous compounds are eluted from the column. Organic solvents such as MeOH or THF then can elute fluorous-containing compounds. With this method, a compound with only a small fraction of fluorocarbon content (such as a single C6F13-containing tag) can be reliably purified. Although this tagging and
purification strategy has been used for the production of a range of bioactive molecules\textsuperscript{25}, the fluorous tag normally has to be removed from compounds in order to use traditional screening methods. The first demonstration that this fluorous tag can be directly incorporated into a microarray platform opens new avenues to think about the production and screening of compounds and other uses for fluorous tags in biological applications.\textsuperscript{26, 27} To date, fluorous-based small molecule microarrays have shown utility for protein, antibody and enzyme screening.

2.4 Fluorous-based microarrays for protein and antibody screening

Noncovalent fluorous-based microarrays possess unique features: 1) surface blocking steps after immobilization are rendered unnecessary and 2) high signal to noise ratios and low-nonspecific binding can be achieved with fewer washing steps than required with more reactive slide surfaces. In addition, the fluorocarbon tag itself does not complicate proton NMR spectra. The initial concept was developed in the context of carbohydrate microarray fabrication. Namely, fluorous-tagged monosaccharides were noncovalently immobilized by fluorous-fluorous interactions on a glass slide surface specially modified with C8F17 chains\textsuperscript{22}. The immobilized
monosaccharides were screened with the common fluorescein isothiocyanate (FITC)-
labeled lectin concanavalin A (FITC-ConA) that is known to bind to alpha-linked
mannose, glucose and N-acetylglucosamine. Indeed, specific binding of ConA to
immobilized mannose and N-acetylglucosamine was observed by fluorescence
imaging. More surprisingly, the use of detergents in the buffer used for screening of
the sugars to a different lectin did not completely destroy the noncovalent interactions.
Noncovalent fluorous-based arrays can clearly withstand detergents not tolerated by
noncovalent hydrocarbon-based arrays. In further experiments, fluorous-based
carbohydrate microarrays proved not only binding of ConA with two new
carbohydrate ligands—both diastereomers of glycerol-D-manno-heptoses—but also
facilitated the quantitative assessment of these carbohydrate-protein interactions.\textsuperscript{21}

Spring’s group\textsuperscript{28} has reported another application of fluorous-based microarrays
for screening and probed the chain length requirement of the fluorous tag. By
comparison of C8F17-tagged biotin with C6F13-tagged biotin, the longer C8F17-tag
was considered more reliable for the attachment of biotin to the fluorous-coated glass
slide. Enhanced biotin-avidin interactions on the fluorous-coated slide were achieved
using a polyethylene glycol spacer between the biotin and the fluorous tag (C8F17).
This work demonstrated that not only very hydrophilic carbohydrates could be screened successfully in this new fluorous-based format, but also more lipophilic molecules such as biotin could be reliably immobilized. In addition, efficient protocols for recycling slides by washing with organic solvents such as methanol and dichloromethane were presented.

![Diagram](image)

**Figure 4.** Application of fluorous-based microarrays for antibody screening.

Microarrays are also showing promise as possible diagnostic tools in their detection of specific antibodies, for example against Globo-H antigens in human cancer sera\(^\text{11}\) or against *Salmonella* O-antigens in sera from *Salmonella* infected patients\(^\text{29}\). Recently, fluorous-tagged carbohydrate antigens associated with infectious diseases were synthesized using automated synthesis (see below). Serum samples from infected animals were incubated with the noncovalently immobilized sugars and then binding was visualized using fluorescently labeled secondary antibodies (Figure
The fluorous-based platform proved robust for the diagnosis of animals containing antibodies against the disease agent. These initial experiments show that fluorous-based microarrays can be used to diagnose animal exposure to pathogens.

### 2.5 Fluorous-based microarrays for enzyme screening

Fluorous-based microarrays have also shown their use in screening for enzyme inhibitors and for enzyme activity. Small molecule microarrays were designed with compound to target a specific class of enzymes called histone deacetylases (HDACs).

To screen for inhibitors of this enzyme that catalyzes the hydrolysis of \( N \)-acetyl groups on lysine residues, fluorous-tagged compounds were printed on the fluorous-coated glass surface and screened with HDAC2, HDAC3/NCoR3 peptide complex and HDAC8. Incubation of the arrays with alexa-647-labeled anti-His antibodies subsequently permitted visualization of HDAC binding by fluorescence imaging. This approach, which takes advantage of detecting native HDACs from whole cell lysates, could serve as the basis for the discovery of a range of new HDAC inhibitors.
More recently, fluorous-tagged metabolites were applied to Nanostructure-Initiator Mass Spectrometry (NIMS) for "on-chip" enzymatic assays. (Figure 5) The use of fluorous-phase immobilization for the attachment of enzyme substrates to fluorous-coated surfaces not only allowed high signal-to-noise ratios (S/N) in the analysis of the enzymatic reactions, but also allowed conformational flexibility to the substrates that likely enhance enzymatic activities. Specifically, immobilized fluorous–tagged lactose on the NIMS surface was used for direct characterization of beta-1,4-galactosidase activity from a thermophilic microbial community lysate. With the advances being made in mass spectrometry-based enzymatic assays based on
fluorous-phase immobilization and NIMS, the construction of printed microarrays can also be imagined for the direct screening of enzymatic activity and inhibitors of that activity.

2.6 Linking fluorous-based arrays to automated synthesis

![Solution-phase Automation Platform vs Solid-phase Automation Platform](image)

Figure 6. Solution-phase automation platform vs Solid-phase automation platform.

All microarray formats are limited by the number of compounds that can be readily produced for inclusion in the particular array format. To date, no fluorous-based microarray has incorporated hundreds or thousands of compounds. However, recent developments in the automation of multistep synthetic routes using fluorous-
phase rather than solid-phase protocols promises to rapidly expand the availability of compounds already containing fluorous-tags required for their incorporation into fluorous-based microarrays (Figure 6).33,34 Although noncovalent fluorous interactions have been shown to be clearly robust enough to create a range of microarrays, the robustness of these interactions for repetitive robotics-based separations of a wide range of compounds is not obvious. However, these noncovalent interactions have proven reliable enough to separate intermediates in oligosaccharide synthesis on an automation platform with the same programmed protocol after investigations of parameter ranges. This new automation platform based on fluorous solid-phase extractions has been used to synthesize not only linear oligosaccharides, but also branched oligosaccharides. More recently, mono- and di-fluorous-tagged glucosamines have been examined for sequential separation using FSPE.35 Elution conditions could be found to obtain the desired di-tagged compound separate from the mono-tagged starting materials, thereby opening more possibilities for the automation of synthetic schemes that include less than optimal coupling results. Further applications of FSPE-based automation are now in progress for the construction of a
range of oligosaccharides to probe the scope and range of this new method to provide compounds already tagged for incorporation into fluorous-based screening protocols.

References


30 Chen G, Pohl NLB, *unpublished results*. 


CHAPTER 2

Automated synthesis of HIV-associated linear α-1,2-linked pentamannose

Eun-Ho Song and Nicola L. Pohl

Introduction

Facile synthesis of oligosaccharide has been an issue both in organic synthesis and biomedical research due to difficulties in the construction of complicated oligosaccharides. With this demand, carbohydrate chemistry and automation method have quickly consolidated their position as practical and versatile method for the construction of oligosaccharide.

Figure 1. α–(1-2) linked pentamannose
Oligomannose has been considered as an important target molecule due to its unique structure and function as a GPI anchors in nature.\textsuperscript{1} In addition, poly α-mannose has been well known as ligand for concanavalin A (Con A)\textsuperscript{2}, one of important cell wall components\textsuperscript{3,4} and HIV-associated carbohydrates on gp120\textsuperscript{5}.

Although the synthesis of oligomannose in an automation platform using solid phase has previously been reported by Seeberger’s group\textsuperscript{6}, the efficiency of automation on the solid phase was not reliable due to several reasons such as consuming too much reagents (5 ~ 10 equiv of glycosyl donor per cycle) and difficulties of monitoring reaction. Recently, iterative synthesis of α–(1-2) linked tetramannose has been reported to probe the utilization of fluorous solid-phase extraction (FSPE) protocol in oligosaccharides synthesis.\textsuperscript{7} To increase the efficiency of automated platform, FSPE technique has been employed in automation platform and newly developed solution-phase automation platform\textsuperscript{8} enables using only 1.5 ~ 2 equivalents of donor building blocks, monitoring the completion of reaction by TLC as well as easy purification through FSPE for facile synthesis of α–(1-2) linked pentamannose (Figure 1).
Herein, we present the utilization of solution-phase automation platform as a useful tool for the construction of HIV-associated linear oligomannose.

**Results and discussion**

![Automated Synthesis of α-(1-2) linked pentamannose](image)

**Figure 2.** Automated synthesis of α-(1-2) linked pentamannose

Fluorous-tagged mannose acceptor 4⁹ has been prepared to improve the efficiency of
puriﬁcation through FSPE\textsuperscript{10}. Only 1.5 equivalent of trichloroacetimidate\textsuperscript{11} 1 which can be activated under acidic condition (TMSOTf) has also been used as a glycosyl donor. The reaction has been done 3.5 cycles (4 x glycosylation, 3 x deacetylation and 4 x FSPE) for 24 h 56 min 39 sec without any labor since automated platform was ready to run the synthesizer for making linear pentamannose. (Figure 2) Strikingly, not only 2 equiv of glycosyl donor per one cycle was consumed for the completion of glycosylation, but the purity of crude product 5 (18 mg) shown in HPLC traces (supporting information) after 7 steps (24 h 56 min 39 sec) was also remarkable even without further purification. Simple prep TLC gave us highly pure product (15 mg, 73 % per step) to have reasonable \textsuperscript{1}H-, \textsuperscript{13}C-NMR and mass spectroscopy data. We evaluated the efficacy of solution-phase approach with a direct comparison of yield based on the glycosyl donor. While 27 % yield per glycosylation/deprotection cycle was produced in the solution-phase automation platform, only a 5 % per cycle yield was produced in the traditional solid-phase approach. Over many cycles, huge differences in building block loss will be produced.

\textbf{Conclusion}
First solution-phase automated synthesis of HIV-associated linear pentamannose was achieved in the new solution-phase automation platform. In particular, fluorous-tagged oligosacchrides from solution-phase automation platform can be incorporated into microarrays for screening antibody and protein in terms of diagnostic tool. These successful results suggest that the automation of oligosaccharide can be performed with small amount of reagents (2 equiv of glycosyl donor per cycle), less laborious work, and high purity of products. From these achievements, other complicated oligosaccharide can be introduced to the same automated platform.

**Experimental section**

**General methods**

Solvents were reagent grade and in most cases dried prior to use. All other commercially available reagents were used as received unless otherwise noted. The organic extracts were dried over anhydrous MgSO\(_4\). Tetrahydrofuran (THF) was distilled from lithium aluminum hydride (LiAlH\(_4\)) prior to use. Methylene chloride (CH\(_2\)Cl\(_2\)), and triethylamine (Et\(_3\)N) were distilled from calcium hydride. Diethyl ether (Et\(_2\)O) was distilled from sodium-benzophenone ketyl.
$^1$H and $^{13}$C spectra NMR were obtained at 400 MHz and 100 MHz on Varian VXR-400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosytems QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per million downfield relative to tetramethysilane (δ 0.00) and coupling constants are reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.

![Chemical structures](image)

**Synthesis of 3-(Perfluorooctyl)propanyloxybutenyl-2-O-acetyl-3,4,6-O-benzyl-$\alpha$-D-mannopyranoside (2)$^9$**

To a solution of 2-O-acetyl-3,4,6-O-benzyl-$\alpha$-D-mannopyranosyl trichloroacetimidate 1$^{11}$ (0.3 g, 0.47 mmol) and 3-(perfluorooctyl)propanyloxybutenyl alcohol$^9$ (0.13 g, 0.24 mmol) in dry
dichloroethane (5 mL) was added TMSOTf (8.5 µL, 0.05 mmol) at 25 °C. The reaction mixture was stirred at room temperature for 30 min. The reaction was quenched with triethylamine (0.5 mL) and concentrated under reduced pressure. The crude product was purified by solid phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced pressure to obtain the desired product 2 (0.20 g, 84 %).

![Chemical structures](image)

Synthesis of 3-(Perfluorooctyl)propanyloxybutenyl-3,4,6-O-benzyl-2-hydroxy-α-D-mannopyranoside (3)

To a solution of 3-(perfluorooctyl)propanyloxybutenyl-2-O-acetyl-3,4,6-O-benzyl-α-D-mannopyranoside 2 (0.2 g, 0.2 mmol) in methanol was added Na (45 mg). The reaction mixture was stirred at 25 °C for 1 h and concentrated under reduced pressure. The crude product 3 was purified to obtain the desired product (0.19 g,
100 %) by silica column chromatography.

**ASW Pentamannose method run**

After FSPE, the methanol elution collected in the vial was removed from the instrument and concentrated. Solvent was removed under reduced pressure to obtain the crude product (18 mg, 13 %) as colorless oil. In order to obtain pure product 5 (15 mg, 11 %) for $^1$H NMR, $^{13}$C NMR and mass spectrum, further purification was performed using prep TLC.

$R_f$ (ethyl acetate/hexane): 0.75 (25/75)

$^1$H NMR (CDCl$_3$, 400 MHz): $\delta$ (ppm) 7.35-7.11 (m, 75 H), 5.61-5.58 (m, 2H), 5.55-5.54 (m, 1H), 5.24 (d, $J = 1.6$, 1H), 5.23 (d, $J = 1.2$, 1H), 5.15 (d, $J = 0.8$, 1H), 5.03 (d, $J = 0.8$, 1H), 4.98 (d, $J = 1.6$, 1H), 4.88-4.71 (m, 5H), 4.68-4.33 (m, 23 H), 4.22-4.06 (m, 6H), 3.98-3.42 (m, 29 H), 3.33 (t, $J = 6.4$, 2H), 2.13-2.04 (m, 2H), 2.12 (s, 3H), 1.82-1.74 (m, 2H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 170.3 (C=O), 138.8-138.2 (m, C$_q$-Aryl), 128.6-127.5 (m, CH-Aryl), [101.6, 101.0, 99.7, 99.5, 98.7 (CH$_{anemic}$)], 79.9, 78.8, 78.5, 77.5, 76.5, 75.8, 75.5, 75.3, 75.2, 75.1, 74.9, 74.5, 73.5, 73.4, 73.0, 72.8, 72.4,
72.2, 72.1, 72.0, 71.9, 71.8, 69.9, 69.7, 68.9, 68.8, 66.7, 66.6, 62.9, 28.5, 28.2, 28.0, 21.4, 21.1.

**HRMS-ESI (m/z):** \([M+Na]^+\) Calcd for \(C_{152}H_{155}F_{17}O_{28}Na\), 2775.8423; Found, 2775.1026.

- 3.5 cycles (24 h 56 min) completed for the synthesis of pentamannose.

<table>
<thead>
<tr>
<th>Step</th>
<th>Task</th>
<th>Reagent/ Operation</th>
<th>Operation Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Glycosylation</td>
<td>2 equivalent donor (100 (\mu)mol) in 0.5 mL Toluene, 1 equivalent F-tagged acceptor (50 (\mu)mol) in 1 mL Toluene; 0.1 equivalent TMSOTf, rt</td>
<td>30 min</td>
</tr>
<tr>
<td>2</td>
<td>TLC sample</td>
<td>30 (\mu)l of crude reaction mixture withdrawn</td>
<td>45 min</td>
</tr>
<tr>
<td>3</td>
<td>Quenching</td>
<td>0.5 ml TEA, 40 °C</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Deacetylation</td>
<td>3 equivalent of NaOMe solution</td>
<td>2 h</td>
</tr>
<tr>
<td>6</td>
<td>TLC sample</td>
<td>30 (\mu)l of crude reaction mixture withdrawn</td>
<td>45 min</td>
</tr>
<tr>
<td>7</td>
<td>Evaporation</td>
<td>0.3 ml 0.5 M Acetic acid solution in MeOH, 50 °C</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>FSPE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Step</td>
<td>Process</td>
<td>Details</td>
<td>Time</td>
</tr>
<tr>
<td>------</td>
<td>---------------------------------</td>
<td>----------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>9</td>
<td>Sample loading</td>
<td>0.4 ml DMF</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Sample loading</td>
<td>0.7 ml crude sample transferred to cartridge</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Wash</td>
<td>4.7 ml 80% methanol wash</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Wash</td>
<td>1.5 ml methanol wash (repeated 3 times)</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Wash</td>
<td>4.7 ml collected sample transferred to clean vial</td>
<td>45 min</td>
</tr>
<tr>
<td>14</td>
<td>Transfer</td>
<td>50 °C</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Evaporation Transfer</td>
<td>2 ml toluene added</td>
<td>45 min</td>
</tr>
<tr>
<td></td>
<td>Evaporation Transfer</td>
<td>50 °C</td>
<td></td>
</tr>
</tbody>
</table>

- HPLC traces of pentamannose run
References


CHAPTER 3

Automated synthesis of *Leishmania*-associated carbohydrates and fluorous-based carbohydrate microarrays

A paper to be submitted to *Chemical Communications*

Eun-Ho Song and Nicola L. Pohl

**Introduction**

The increasing demand for oligosaccharides in the field of biomedical research led to the development of synthetic methods for the complicated oligosaccharide synthesis in the field of organic chemistry. Although several approaches, such as one-pot solution-phase synthesis and solid-phase based automated synthesis, have been developed for facile synthesis of oligosaccharides,\(^1,2\) structurally complicated oligosaccharides are still not readily available in the market due to difficulties in the formation of a stereocenter upon connection with other sugars while customized DNA sequences and peptides are commercialized in the market.
We have recently developed the first automation platform to carry out iterative synthesis based on fluorous-solid-phase extraction (FSPE) protocol\textsuperscript{3}, rather than solid-phase-based purification (Scheme 1). This new automation platform allows the use of 5 to 10-fold lower building block amounts than the solid-phase approaches, but also enables easy monitoring of reaction by TLC. More importantly, fluorous-tagged products from fluorous phase-based automation platform are not only directly applicable in microarrays, but also capable of conjugation to ligands or other carriers.

Leishmaniasis has been known as a parasitic disease caused by infection with over 15 species of \textit{Leishmania}. Leishmaniasis is mostly endemic throughout Africa, India, southern Europe, and Central and South America with an estimated 12 – 15 million
individuals and 2 million new cases each year. In order to prevent leishmaniasis, WHO have designated it as a category I (emerging and uncontrolled) disease. In spite of the significant effort made in the development of leishmaniasis vaccine, no vaccine against leishmaniasis is being made to support the prevention of disease.

Cell-surface glycoconjugates are not only significant in the survival of the Leishmania parasite, it also can be used as target in order to unveil the role of carbohydrates on the mechanism of infection. Lipophosphoglycan (LPG) is known as one of the major glycoconjugates in Leishmania. As shown in Figure 1, structure analysis of LPG has shown that it has three domains, a glycosylphosphatidylinositol (GPI) anchor, a repeating phosphorylated saccharide region, and an oligosaccharide cap structure.

But, the identification of structure-function relationship of the extracellular domain in LPG is still a challenge for both chemists and biologists. Although earlier reports for the synthesis of Leishmania capping structures have been featured in the construction of desired capping structures with different synthetic routs, synthesized capping structures have never been prepared for microarrays. Early successes in microarrays for antibody binding were dedicated to detect specific
antibodies against Globo-H antigens in cancer patients’ sera\textsuperscript{14} or \textit{Salmonella} \textit{O-}
antigen in \textit{Salmonella} infected patients’ sera\textsuperscript{15}. However, because of limitations in 
availability of defined carbohydrate antigens and reliable tools, identifying 
interactions between carbohydrate antigens associated infectious diseases and 
antibody in serum from infected animals or human has been difficult.

In this context, facile synthesis of oligosaccharides should be accomplished as 
prerequisite in order to economically achieve the rapid development of fluorous-based 
microarray technique which enables detection of various \textit{Leishmania} species in a 
short time,

Herein, we report the first solution-phase automated synthesis of \textit{Leishmania} 
tetrasaccharide and iterative synthesis of \textit{Leishmania} capping structures for the 
fluorous-based microarray of \textit{Leishmania} capping structures as a possible diagnostic 
tool for the detection of antibodies in serum.

\textbf{Results and discussion}
Figure 1. Fluorous alcohol and building blocks for the automated fluorous-phase synthesis of *Leishmania* tetrasaccharide.

The automated synthesis of *Leishmania* tetrasaccharide was designed to use just two building blocks: a known activated mannose building block\(^{16}\) and a building block obtained from lactose (Figure 1).

Scheme 2. Synthesis of key disaccharide building block. (a) (i) CH\(_2\)=CHCH\(_2\)OH, TfOH, (ii) Na, MeOH (87 %); (b) (i) DMP DCM, (ii) NaBH\(_4\), CH\(_2\)Cl\(_2\)/MeOH (92 %);
(c) \(\text{Ac}_2\text{O}, \text{DMAP}, \text{TEA}, \text{CH}_2\text{Cl}_2\) (91 %); (d) [Ir] cat., \(\text{H}_2\), THF (94 %); (e) (i) \(\text{HgO}, \text{HgCl}_2, \text{O}=(\text{CH}_3)_2/\text{H}_2\text{O}\) (10/1), (ii) TCA, DBU, \(\text{CH}_2\text{Cl}_2\) (89 %).

The key intermediate hexa-\(\text{O}\)-benzyl orthoester 1\(^\text{17}\) was prepared by orthester formation and followed by benzylation from lactose in good yield. One-step allylation under mild conditions using allyl alcohol and TfOH produced mainly 2-\(\text{O}\)-unprotected saccharide 2 along with 2-\(\text{O}\)-acetylated saccharide. Further deprotection by NaOMe gave the desired 2-\(\text{O}\)-unprotected saccharide 2 in high yield (87% over 2 steps). Conversion of \(\beta\)-glucoside 2 to \(\alpha\)-mannoside 3 was achieved by a two-step oxidation-reduction process. Initial attempts to obtain 2-ulose 3 via Swern oxidation were unsatisfactory. Known oxidation condition\(^\text{18}\) using \(\text{Ac}_2\text{O}/\text{DMSO}\) gave desired product in ~ 70 % yield, but it required long reaction time (48 h) and produced acetylated side product (5 ~ 10 %). However upon changing the oxidation conditions to Dess-Martin periodate, the reaction went smoothly at 35 °C for 3 h in quantitative yield. Further reduction with \(\text{NaBH}_4\) to invert the stereochemistry of the C2 position gave the desired disaccharide 3 in high yield (92 % over 2 steps). Acetylation of 3 was performed under DMAP condition in 91 % yield. The allyl group 4 was removed.
by isomerization to propenyl ether 5 with an iridium catalyst\textsuperscript{19} and subsequent hydrolysis\textsuperscript{20} under non-acidic conditions using HgO/HgCl\textsubscript{2}. The desired activated glycosyl donor 6 was then prepared as needed with trichloroacetonitrile/DBU.

The important features of this approach include a suitable protecting group strategy, the transformation of glucose (Glc) to mannose (Man), and a fluorous solid-phase extraction (FSPE) technique for automation platform as an efficient purification method.

Fluorous-tag 7 has been prepared to improve the efficiency of purification through FSPE. Trichloroacetimidates 6 and 8 that can be activated under acidic condition (TMSOTf) have also been used as a glycosyl donor. The reaction has been done 2.5 cycles for 17 h 31 min without any labor since automated platform was ready to run the synthesizer for making \textit{Leshimania} tetrasaccharide. (Scheme 3) Strikingly, not only 2 eq of glycosyl donor per one cycle was consumed for the completion of glycosylation, but the purity of crude product 11 (30 mg) shown in HPLC traces (supporting information) after 5 steps (17 h 31 min) was also remarkable even without further purification. Simple prep TLC gave us highly pure product (21 mg, 71 % per step) to have reasonable \textsuperscript{1}H-, \textsuperscript{13}C-NMR and mass spectroscopy data.
Scheme 3. Automated fluorous-phase synthesis of *Leishmania* tetrasaccharide.

These successful results demonstrated that the automation of oligosaccharide can be performed with small amount of reagents, less labor, and high purity of product. From these achievements, other oligosaccharide can be introduced to the same automated platform.

Fully deprotected Fluorous-tagged branched trisaccharide 10-1 and tetrasaccharide 11-1 were prepared after deacetylation, followed by simultaneous debenzylation and reduction of alkene with Pd/C/H₂.

Iterative synthesis of Leishmania capping structures

Leishmania species such as L. major, L. donovani and L. mexicana have linear α-1,2-linked mannose oligomer and lactose capping structures. Iterative synthesis of linear α-1,2-linked mannose oligomers has been done in order to complete libraries for Leishmania capping structures. Each glycosylation was performed with 1.1 equivalent of donor rather than 1.5 equivalent of donor in toluene at 25 °C for 5 min. Facile purification of crude product by FSPE enabled easy preparation of desired
linear $\alpha$-1,2-linked dimannose 13 and trimannose 14 in high yield.

**Scheme 5.** Iterative synthesis of linear mannose oligomer.

Deacetylation, followed by simultaneous debenzylation and reduction of alkene with Pd/C/H$_2$, gave desired fully deprotected fluorous–tagged $\alpha$-1,2-linked di- and tri-mannose in high yield (Scheme 6).
Although iterative synthesis of linear α-1,2-linked dimannose 13 and trimannose 14 has previously been reported in good yield, these oligomers have never been produced for the application in fluorous-based microarrays.

Fully deprotected fluorous-tagged galactose 15 and lactose 16 as *L. donovani* capping structures were also prepared as reported in the literature.²²

**Conclusion**
In conclusion, we have shown that fully deprotected *Leishmania* capping structures for *L. donovani* and *L. major* were efficiently synthesized either through fluorous-based automation platform or iterative synthesis using FSPE. Conversion of β-glucoside to α-mannoside as a key step for the synthesis of disaccharide building block was achieved by Dess-Martin oxidation, followed by reduction with NaBH₄ in high yield. Most importantly, automated fluorous-phase synthesis of *Leishmania* tetrasaccharide enabled facile synthesis of target oligosaccharides in order to be incorporated into fluorous-based microarray with high purity, less chemicals and less laborious work. This fluorous-based automated platform might be a powerful tool for the construction of carbohydrate library for the study of structure-function relationships.

**Experimental section**

**General methods**

Solvents were reagent grade and in most cases dried prior to use. All other commercially available reagents were used as received unless otherwise noted. The organic extracts were dried over anhydrous MgSO₄. Tetrahydrofuran (THF) was distilled from lithium aluminum hydride (LiAlH₄) prior to use. Methylene chloride
(CH₂Cl₂), and triethylamine (Et₃N) were distilled from calcium hydride. Diethyl ether (Et₂O) was distilled from sodium-benzophenone ketyl.

¹H and ¹³C NMR spectra were obtained at 400 MHz and 100 MHz on Varian VXR-400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosystems QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per million downfield relative to tetramethylsilane (δ 0.00) and coupling constants are reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.

**Synthesis of disaccharide building block**

![Synthesis of disaccharide building block](attachment:image)

**Synthesis of 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-1,2,3,6-tetra-O-acetyl-D-glucopyranoside.**¹⁹

To a solution of lactose (1 g, 2.8 mmol) in acetic anhydride (10 mL) was added
catalytic amount of iodine (14 mg, 0.1 mmol) at 25 °C. The reaction mixture was stirred at room temperature for 1 h. The dark brown reaction mixture was poured into a separatory funnel containing dichloromethane, aqueous sodium thiosulfate solution and crushed ice. The colorless solution from a separatory funnel was washed with H$_2$O (2 x 50 mL) and sat.NaHCO$_3$ (2 x 50 mL). It was dried with Na$_2$SO$_4$ and then concentrated under reduced vacuum to obtain the desired product with quantitative yield.

![Chemical Structures](image)

**Synthesis of 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-3,6-di-O-acetyl-1,2-O-(1-methoxyethylidene)-β-D-glucopyranoside**.$^{19}$

To a solution of 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-1,2,3,6-tetra-O-acetyl-D-glucopyranoside (1.5 g, 2.2 mmol) in dichloromethane (5 mL) was added 33 % HBr (5 mL, 28.6 mmol) in acetic acid for 10 min. The reaction mixture was stirred at 25 °C for 1 h and then checked TLC to check the completion of reaction.
After completion of reaction, the mixture was washed with cold water three times and then followed by washed with saturated sodium bicarbonate solution three times. The neutralized solution was dried with sodium sulfate and concentrated under reduced pressure. The crude product was used for next step without further purification. To a solution of hepta-acetyl lactosyl bromide in dichloromethane was added triethylamine (0.62 mL, 4.4 mmol), Bu₄NBr (0.71 mg, 2.2 mmol) and methanol (0.077 mL, 2.64 mmol). The reaction mixture was stirred at 40 °C for 16 h and then washed with H₂O (1 x 50 mL). The solution was dried with Na₂SO₄ and then concentrated under reduced vacuum. The crude product was purified to obtain the desired product (1.19 g, 83 % over 2 steps) by silica column chromatography.

Synthesis of 2,3,4,6,-Tetra-O-benzyl-β-D-galactopyranosyl-(1-4)-3,6-di-O-benzyl-1,2-O-(1-methoxyethyliene)-β-D-glucopyranoside 1.¹⁹

To a solution of 2,3,4,6,-tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-3,4-di-O-acetyl-
1,2-\(O\)-(1-methoxyethylidene)-\(\beta\)-D-glucopyranoside (1g, 1.5 mmol) in MeOH (5 mL) was added catalytic amount of Na (3.5 mg, 0.15 mmol). The reaction mixture was stirred at 25 °C for 6 h and then concentrated under reduced vacuum to yield the crude deacetylated product as yellow foam. To a solution of deacetylated product in DMF (10 mL) was added 60 % NaH (0.47 g, 11.5 mmol), followed by addition of benzyl bromide (2.06 mL, 11.5 mmol) and tetrabuylammonium iodide (0.57 g, 1.5 mmol) at 0 °C. The reaction mixture was warmed up to 25 °C and stirred for 12 h. The reaction mixture was diluted with dichloromethane (20 mL) and then washed with \(\text{H}_2\text{O}\) (2 x 50 mL). The organic layer was dried with \(\text{Na}_2\text{SO}_4\) and concentrated under reduced vacuum. The crude product was purified by flash silica column chromatography to afford the desired product (1) (1.28 g, 89 % over 2 steps).

![Chemical Structure Image]

**Synthesis of Allyl \(O\)-(2,3,4,6-tetra-O-benzyl-\(\beta\)-D-galactopyranosyl)-(1-4)-2-O-hydroxy-3,6-di-O-benzyl-\(\beta\)-D-glucopyranoside 2.**
A solution of 2,3,4,6-Tetra-O-benzyl-β-D-galactopyranosyl-(1-4)-3,6-di-O-benzyl-1,2-O-(1-methoxyethylidiene)-β-D-glucopyranoside (1) (1 g, 1.1 mmol) and allyl alcohol (0.45 mL, 6.6 mmol) in dichloromethane (10 mL) was cooled to – 40 °C and TfOH (6 µL, 0.07 mmol) was added dropwise over 10 min. The reaction mixture was stirred at – 40 °C for 30 min and allowed to 25 °C for 1 h followed by, addition of triethylamine to neutralize a solution. The crude product was obtained after concentration of solvent under reduced vacuum. To a crude product in MeOH was added Na (5 mg, 0.22 mmol). The reaction mixture was stirred at 25 °C for 1 h and then concentrated under reduced vacuum. The crude product was purified by flash silica column chromatography to afford the desired product (2) (0.86 g, 87 % over 2 steps).

**Rf (ethyl acetate/haxane):** 0.50 (25/75)

**1H NMR (CDCl3, 400 MHz):** δ (ppm) 7.36-7.18 (m, 30H, aromatics), 6.09-5.99 (m, 1H, CH₂CH=CH₂), 5.33 (dd, 1H, J = 17.1, 1.2 Hz, CH=CH₂), 5.22 (dd, 1H, J = 10.3, 1.2 Hz, CH=CH₂), 5.08 (d, 1H, J = 11.1 Hz), 4.97 (d, 1H, J = 11.5 Hz), 4.82 (dd, 2H, J = 20.4, 11.1 Hz), 4.71 (dd, 2H, J = 22.8, 6.8 Hz), 4.70 (d, 1H, J = 5.3 Hz), 4.56 (dd, 2H, J = 11.5, 4.4 Hz), 4.43 – 4.43 (d, 1H anomeric, J = 7.6 Hz), 4.40 (m, 3H), 4.34 (d,
1H anomeric, $J = 7.2$ Hz), 4.48 (d, 1H, $J = 11.8$ Hz), 4.15 (dd, 1H, $J = 12.7$, 6.4 Hz), 3.96 (d, 1H, $J = 9$ Hz), 3.92 (d, 1H, $J = 2.7$ Hz), 3.81 – 3.70 (m, 3H), 3.57 – 3.46 (m, 3H), 3.41 – 3.34 (m, 4H), 2.39 (br, 1H, OH).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) [139.2, 139.1, 138.9, 138.7, 138.5, 138.2 (C$_q$-Aryl)], 134.1 (CH$_2$CH=CH$_2$), 128.6 – 127.5 (m, CH-Aryl), 118.0 (CH=CH$_2$), 103.0 (CH anomeric), 101.7 (CH anomeric), 83.0, 82.7, 80.1, 76.5, 75.6, 75.5, 74.9, 74.8, 73.7, 73.7, 73.3, 73.2, 72.8, 70.3, 68.4.

HRMS-ESI (m/z): [M+Na]$^+$ Calcd for C$_{57}$H$_{62}$NaO$_{11}$, 945.4190; Found, 945.5140.

Synthesis of Allyl O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-2-O-hydroxy-3,6-di-O-benzyl-β-D-mannopyranoside 3.

To a solution of allyl O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-3,6-di-O-benzyl-β-D-glucopyranoside (2) (0.1 g, 0.11 mmol) in dichloromethane (5 mL) was added dess-martin periodinane (92 mg, 0.22 mmol). The reaction mixture was stirred at 35 °C for 4 h and then diluted with dichloromethane (10 mL). The diluted solution
was washed with sat. NaHCO$_3$ (2 x 10 mL), H$_2$O (1 x 10 mL), and brine (1 x 10 mL). The organic layer was dried with Na$_2$SO$_4$ and then concentrated under reduced vacuum. The crude residue was dissolved in dichloromethane/MeOH (1/1) and cooled to 0 °C. NaBH$_4$ (50 mg, 1.35 mmol) was added and then the reaction mixture was allowed to 25 °C over 1 h. The mixture was diluted with dichloromethane (10 mL) and washed with H$_2$O (1 x 10 mL), 1 % aqueous citric acid (1 x 10 mL) and brine (1 x 10 mL). The solvent was evaporated under reduced vacuum and dried with Na$_2$SO$_4$. The crude product was purified by flash silica column chromatography to afford the desired product (3) (92 m g, 92 % over 2 steps).

$R_f$ (ethyl acetate/haxane): 0.45 (25/75)

$^1$H NMR (CDCl$_3$, 400 MHz): $\delta$ (ppm) 7.36-7.21 (m, 30H), 5.97-5.87 (m, 1H, \(\text{CH}_2\text{CH}=\text{CH}_2\)), 5.29 (dd, 1H, $J = 16.5$, 1.6 Hz, \(\text{CH}=\text{CH}_2\)), 5.20 (dd, 1H, $J = 10.4$, 1.6 Hz, \(\text{CH}=\text{CH}_2\)), 4.97 (d, 1H, $J = 11.5$ Hz), 4.81 (d, 1H, $J = 2$ Hz), 4.78 (d, 1H, $J = 2.8$ Hz), 4.75 (d, 1H, $J = 10.8$ Hz), 4.72-4.66(m, 4H), 4.60 (d, 1H, $J = 11.5$ Hz), 4.50 (d, 1H$_{\text{anomeric}, J = 1.2$ Hz}), 4.47 (d, 1H, $J = 10.8$ Hz), 4.45 (d, 1H$_{\text{anomeric}, J = 7.9$ Hz}), 4.41-4.37 (m, 3H), 4.30 (d, 1H, $J = 11.6$ Hz), 4.12-4.07 (m, 3H), 3.92 (d, 1H, $J = 2.8$ Hz), 3.84 (dd, 1H, $J = 10.8$, 2.8 Hz), 3.76-3.72 (m, 2H), 3.63(t, 1H, $J = 8.68$ Hz), 3.56 (dd,
1H, J = 8.4, 3.6 Hz), 3.51-3.39 (m, 4H), 2.39 (br, 1H, OH).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) [139.1, 138.9, 138.7, 138.7, 138.6, 138.1 (C$_q$-Aryl)], 134.1 (CH$_2$CH=CH$_2$), 128.6 – 127.6 (m, CH-Aryl), 118.0 (CH=CH$_2$), 103.4 (CH$_{anomeric}$), 98.7 (CH$_{anomeric}$), 82.8, 80.1, 79.5, 75.5, 75.4, 73.7, 73.6, 73.3, 73.2, 72.8, 72.6, 70.0, 69.2, 68.9, 68.6,

HRMS-ESI (m/z): [M+Na]$^+$ Calcd for C$_{57}$H$_{62}$NaO$_{11}$, 945.4190; Found, 945.5131.

![Image of chemical structures](image)

**Synthesis of Allyl $O$-(2,3,4,6-tetra-$O$-benzyl-$\beta$-D-galactopyranosyl)-(1-4)-2-$O$-acetyl-3,6-di-$O$-benzyl-$\beta$-D-mannopyranoside 4.**

To a allyl $O$-(2,3,4,6-tetra-$O$-benzyl-$\beta$-D-galactopyranosyl)-(1-4)-3,6-di-$O$-benzyl-$\beta$-D-mannopyranoside (3) (80 mg, 0.09 mmol) in dichloromethane (5 mL) was added DMAP (6 mg, 0.05 mmol), triethylamine (0.02 mL, 0.18 mmol) and acetic anhydride (0.01 mL, 0.011 mmol). The reaction mixture was stirred at 25 °C for 1 h and then concentrated under reduced vacuum. The crude residue was dried with Na$_2$SO$_4$ and purified by flash silica column chromatography to afford the desired product (4) (76
mg, 91 %)

R_f (ethyl acetate/haxane): 0.70 (25/75)

^1^H NMR (CDCl_3, 400 MHz): δ (ppm) 7.30-7.18 (m, 30H), 5.92-5.82 (m, 1H, CH_2CH=CH_2), 5.58 (dd, 1H, J = 2.8, <1 Hz, CHCH(OAc)CH), 5.27 (dd, 1H, J = 17.2, 1.6 Hz, CH=CH_2), 5.18 (dd, 1H, J = 10, 1.2 Hz, CH=CH_2), 4.80 (d, 1H, J = 10.8 Hz), 4.73-4.61 (m, 4H), 4.58 (d, 1H, J = 8 Hz), 4.54 (d, 1H, J = 3.6 Hz), 4.53 (d, 1H_anomeric, J = <1 Hz), 4.51 (d, 1H_anomeric, J = 12 Hz), 4.42-4.32 (m, 3H), 4.24 (d, 1H, J = 11.6 Hz), 4.10 (dd, 1H, J = 13.2, 6.4 Hz), 4.98 (t, 1H, J = 9.2 Hz), 3.85 (dd, 2H, J = 11.2, 2 Hz), 3.79-3.68 (m, 2H), 3.60-5.53 (m, 2H), 3.49-3.45 (m, 1H), 3.41-3.39 (m, 2H), 3.33 (t, 1H, J = 6.8 Hz), 2.03 (s, 3H, OC(O)CH_3).

^1^3^C NMR (CDCl_3, 100 MHz): δ (ppm) 170.8 (C=O), [139.0, 138.9, 138.7, 138.6, 138.5, 138.2 (C_q-Aryl)], 133.8 (CH_2CH=CH_2), 128.6 – 127.4 (m, CH-Aryl), 117.8 (CH=CH_2), 115.5, 103.0 (CH_anomeric), 97.7 (CH_anomeric), 82.9, 80.1, 78.5, 75.8, 75.3, 74.8, 74.6, 73.7, 73.6, 73.4, 72.7, 71.8, 70.0, 69.3, 68.9, 68.6, 21.2(CH_3).

HRMS-ESI (m/z): [M+Na]^+ Calcd for C_{59}H_{64}NaO_{12}, 987.4295; Found, 987.3006.
Synthesis of Vinyl $O$-(2,3,4,6-tetra-$O$-benzyl-$\beta$-D-galactopyranosyl)-(1-4)-2-$O$-acetyl-3,6-di-$O$-benzyl-$\beta$-D-mannopyranoside 5.

To a solution of allyl $O$-(2,3,4,6-tetra-$O$-benzyl-$\beta$-D-galactopyranosyl)-(1-4)-2-$O$-acetyl-3,6-di-$O$-benzyl-$\beta$-D-mannopyranoside (4) (80 mg, 0.08 mmol) in THF (3 mL) was added catalytic amount of (1,5-Cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (2 mg, 0.002 mmol). The stirred solution was degassed, placed under $N_2$ and degassed. The reaction mixture was placed under $H_2$ for 5 min and degassed once more to prevent further reduction. The mixture was stirred at 25 $^\circ$C for 30 min under $N_2$ and then concentrated under reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the desired product (5) (75 mg, 94%).

$R_f$ (ethyl acetate/hexane): 0.72 (25/75)

$^1$H NMR (CDCl$_3$, 400 MHz): $\delta$ (ppm) 7.31-7.19 (m, 30H), 6.23 (d, 1H, $J = 12.3$ Hz, OCH=CH), 5.60 (dd, 1H, $J = 2.6$, <1 Hz, CHCH(OAc)CH), 5.15-5.07 (m, 1H, CH=CHCH$_3$), 4.96 (d, 1H, $J = 11.4$ Hz), 4.82 (d, 1H, $J = 10.9$ Hz), 4.74-4.62 (m, 5H), 4.71 (d, 1H$_{anomeric}$, $J = <1$ Hz), 4.59-4.55 (m, 2H), 4.51 (d, 1H$_{anomeric}$, $J = 17.4$ Hz), 4.49-4.35 (m, 3H), 4.25 (d, 1H, $J = 11.7$ Hz), 4.00 (t, 1H, $J = 9.1$ Hz), 3.89 (d, 2H, $J = 7.2$ Hz).
10.5 Hz), 3.78-3.70 (m, 2H), 3.64 (dd, 1H, \( J = 8.6, 3.2 \) Hz), 3.56-3.53 (m, 2H), 3.44-3.40 (m, 1H), 3.35 (t, 1H, \( J = 6.3 \) Hz), 2.04 (s, 3H, OC(O)CH\(_3\)), 1.54 (d, 3H, \( J = 6.54 \) Hz, CHCH\(_3\)).

\(^{13}\)C NMR (CDCl\(_3\), 100 MHz): \( \delta \) (ppm) 170.7 (C=O), 143.4(OC\(\text{H}=\text{CH}\)), [139.0, 138.8, 138.7, 138.5, 138.2 (C\(_q\)-Aryl)], 128.6 – 127.4 (m, CH-Aryl), 104.9 (CH=CHCH\(_3\)) 103.0 (CH\(_\text{anomeric}\)), 97.8 (CH\(_\text{anomeric}\)), 82.9, 80.0, 78.2, 76.1, 75.4, 74.8, 74.5, 73.7, 73.4, 72.8, 71.9, 69.2, 68.9, 68.1, , 21.2(CH\(_3\)), 12.6 (CHCH\(_3\)).

HRMS-ESI (m/z): [M+Na]\(^+\)Calcd for C\(_{59}\)H\(_{64}\)NaO\(_{12}\), 987.4295; Found, 987.3076

![Chemical structure](image)

**Synthesis of 2,3,4,6-Tetra-O-benzyl-β-D-galactopyranosyl-(1-4)-2-O-acetyl-3,6-di-O-benzyl-α-D-mannopyranosyl trichloroacetimidate 6.**

To a vinyl \( O-(2,3,4,6,\text{-tetra-O-benzyl-β-D-galactopyranosyl})-(1-4)-2-O-acetyl-3,6-di-O-benzyl-β-D-mannopyranoside (7) (75 mg, 0.08 mmol), and mercury oxide (24 mg, 0.1 mmol) in 3 mL of acetone/H\(_2\)O (10 mL /1mL) was added a solution of
mercuric chloride (23 mg, 0.09 mmol) in 2 mL of acetone/H₂O (10 mL/1mL) for 1 min. The reaction mixture was stirred at 25 °C for 3 h. The crude residue was filtered through celite and diluted with dichloromethane (5 mL). The organic layer was washed with sat. KI (1 x 5 mL), H₂O (1 x 5 mL) and brine (1 x 5 mL). The solvent was concentrated under reduced vacuum and dried with Na₂SO₄. To a crude residue in dichloromethane (5 mL) was added Cs₂CO₃ (25 mg, 0.08 mmol) and followed by addition of trichloroacetonitrile (0.016 mL, 0.16 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min and then concentrated under reduced vacuum and purified by flash silica column chromatography to afford the desired product (6) (74 mg, 89 % over 2 steps).

\( R_f \) (ethyl acetate/haxane): 0.80 (25/75)

\(^1\text{H NMR (CDCl}_3, 400 \text{ MHz)}: \delta (ppm) 8.66 (s, 1H, \text{NH}=C), 7.32-7.17 (m, 30H), 6.24 (d, 1H\text{anomeric, } J = 1.8 Hz), 5.43 (dd, 1H, \text{J} = 3.1, 2.8 Hz, \text{CHCH(OAc)CH}), 4.97 (d, 1H, \text{J} = 11.6 Hz), 4.81 (d, 1H, \text{J} = 10.8 Hz), 4.76 (d, 1H, \text{J} = 12 Hz), 4.69-4.65 (m, 3H), 4.57 (d, 1H, \text{J} = 11.2 Hz), 4.44 (d, 1H, \text{J} = 7.6 Hz), 4.40 (d, 1H, \text{J} = 11.6 Hz), 4.38 (d, 1H, \text{J} = 11.2 Hz), 4.28-4.22 (m, 2H), 3.95 (dd, 2H, \text{J} = 8.9, 3.2 Hz), 3.87 (dd, 1H, \text{J} = 8.9, 7.8 Hz), 3.63-3.54 (m, 2H), 3.46-3.36 (m, 3H), 1.98 (s, 3H, OAc).
$^{13}$ C NMR (CDCl$_3$, 100 MHz): δ (ppm) 170.4 (C=O), 160.1 (C=NH), [139.1, 138.9, 138.7, 138.6, 138.5, 138.4 (C$_q$-Aryl)], 128.7 – 127.6 (m, CH-Aryl), 103.2 (CH$_{anomeric}$), 95.4 (CH$_{anomeric}$), 82.8, 80.0, 75.5, 75.4, 74.9, 74.6, 74.0, 73.9, 73.7, 73.4, 72.9, 72.8, 69.1, 68.5, 68.2, 21.1 (CH$_3$).

**ASW Leishmania-tetrasaccharide method run**

After FSPE, the methanol elution collected in the vial was removed from the instrument and concentrated. Solvent was removed under reduced pressure to obtain the crude product (30 mg) as colorless oil. In order to obtain pure product (5) (21 mg, 16 %) for $^1$H NMR, $^{13}$ C NMR and mass spectrum, further purification was performed using prep TLC.

**Synthesis of 3-(perfluoroctyl)propanoxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside 11.**

$R_f$ (ethyl acetate/haxane): 0.75 (20/80)
H NMR (CDCl₃, 400 MHz): δ (ppm) 7.33-7.11 (m, 30H), 5.62 (br, 2H), 5.47 (s, 1H), 5.08 (s, 1H), 4.92 (d, 2H, J = 15.6 Hz), 4.82-4.77 (m, 3H), 4.70-4.59 (m, 6H), 4.55-4.44 (m, 10H), 4.41-4.36 (m, 3H), 4.26 (d, 1H, J = 12 Hz), 4.21-4.18 (d, 1H, J = 12.4 Hz), 4.15 (m, 1H), 4.05-3.98 (m, 2H), 3.92-3.82 (m, 10H), 3.78-3.69 (m, 8H), 5.57 (t, 2H, J = 10 Hz), 3.41 (t, 2H, J = 9.2 Hz), 3.32-3.29 (m, 3H), 2.15-2.04 (m, 2H), 2.08 (s, 3H), 1.80-1.73 (m, 2H).

13C NMR (CDCl₃, 100 MHz): δ (ppm) 170.2 (C=O), [139.4, 139.2, 139.0, 138.9, 138.8, 138.7, 138.6, 138.6, 138.2, 138.2 (C₈-Aryl)], 128.5 – 127.2 (m, CH-Aryl), [103.1, 101.2, 99.6, 98.2 95.4 (CH anomeric)], 83.0, 80.3, 79.7, 78.2, 75.4, 75.3, 75.2, 75.0, 74.8, 74.5, 73.5, 73.4, 73.2, 72.7, 72.4, 72.3, 72.1, 72.0, 71.9, 69.7, 69.0, 98.8, 68.5, 66.7, 63.0, 28.4, 28.3, 28.0, 21.3(CH₃).

HRMS-MALDI (m/z): [M+Na]⁺Calcd for C₅H₁₂₇F₁₇NaO₂₃ 2341.8394; Found, 2341.3591.

- 2.5 cycles (17h 31 min 39) completed for the synthesis of *Leishmania*-tetrasaccharide.
<table>
<thead>
<tr>
<th>Step</th>
<th>Process</th>
<th>Details</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Glycosylation</td>
<td>2 equivalent donor (100 µmol) in 0.5 mL Toluene, 1 equivalent F-tagged acceptor (50 µmol) in 1 mL Toluene; 0.1 equivalent TMSOTf, rt</td>
<td>30 min</td>
</tr>
<tr>
<td>2</td>
<td>TLC sample</td>
<td>30 µl of crude reaction mixture withdrawn</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Quenching</td>
<td>0.5 ml TEA</td>
<td>45 min</td>
</tr>
<tr>
<td>4</td>
<td>Evaporation</td>
<td>40 °C</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Deacetylation/Quenching</td>
<td>0.7 ml crude sample transferred to cartridge</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Evaporation</td>
<td>4.7 ml collected sample transferred to clean vial</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Evaporation</td>
<td>4.7 ml 80% methanol wash</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>FSPE preparation</td>
<td>0.4 ml DMF</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Sample loading</td>
<td>1.5 ml methanol wash (repeated 3 times)</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Wash</td>
<td>0.7 ml crude sample transferred to cartridge</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Wash</td>
<td>0.3 ml 0.5 M Acetic acid solution in MeOH</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Transfer</td>
<td>0.4 ml collected sample transferred to clean vial</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Evaporation</td>
<td>0.4 ml collected sample transferred to clean vial</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Transfer</td>
<td>4.7 ml 80% methanol wash</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Evaporation</td>
<td>4.7 ml collected sample transferred to clean vial</td>
<td></td>
</tr>
</tbody>
</table>

- HPLC trace for crude product.
Peak results:

<table>
<thead>
<tr>
<th>Index</th>
<th>Name</th>
<th>Time (Min)</th>
<th>Quantity (%)</th>
<th>Area (% Area)</th>
<th>Area %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>UNKNOWN</td>
<td>0.09</td>
<td>14.38</td>
<td>0.0</td>
<td>14.381</td>
</tr>
<tr>
<td>2</td>
<td>Trimer</td>
<td>1.89</td>
<td>16.93</td>
<td>0.0</td>
<td>16.932</td>
</tr>
<tr>
<td>3</td>
<td>Tetrramer</td>
<td>1.99</td>
<td>68.69</td>
<td>0.1</td>
<td>68.587</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>100.00</td>
<td>0.1</td>
<td>100.000</td>
</tr>
</tbody>
</table>

3-(perfluorooctyl)propanoyloxybutanyl-4-O-[β-D-galactopyranosyl]-2-O-[2-O-(2-
**O-α-D-mannopyranosyl)-α-D-mannopyranosyl]-α-D-mannopyranoside 11-1.**

To a 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-β-D-mannopyranoside (11) (50 mg, 0.02 mmol) in MeOH (3 mL) was added Na (1 mg, 0.07 mmol) and stirred at 25 °C for 30 min. The reaction mixture was neutralized with Dowex-ion-exchange resin and filtered through Celite pad. purified by solid phase extraction using fluoro flash column. The solvent was removed under reduced pressure to obtain deacetylated product. To a solution of deacetylated product in MeOH (3 mL) was added 10 % Pd/C (50 mg). The reaction mixture was stirred at 25 °C under hydrogen atmosphere for 12 h. The desired (11-1) was obtained through Celite filtration followed by evaporation of solvent under reduced pressure in good yield (25 mg, 96 %).

**1H NMR (CD$_3$OD, 400 MHz):** δ (ppm) [5.33 (s, 1H), 5.01 (s, 1H), 4.96 (s, 1H), 4.35 (d, 1H, J = 8 Hz) CH$_{anomeric}$], 4.01-3.1 (m, 30H), 2.31-2.18 (m, 2H), 1.89-1.78 (m, 2H), 1.84-1.53 (m, 4H).

**13C NMR (CD$_3$OD, 100 MHz):** δ (ppm) [103.9, 102.9, 101.0, 98.7 (CH$_{anomeric}$)], 79.2,
78.0, 77.6, 73.8, 73.8, 73.6, 71.8, 71.2, 70.7, 70.6, 70.5, 69.9, 69.1, 68.9, 68.0, 67.6, 67.3, 62.1, 62.0, 61.3, 61.0, 26.4, 26.1.

HRMS-MALDI (m/z): [M+Na]^+ Calcd for C_{39}H_{55}F_{17}NaO_{22} 1221.2811; Found, 1220.1206.

Iterative synthesis of Leishmania-capping structures

Synthesis of 3-(perfluorooctyl)propanoyloxybutenyl-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-]α-D-mannopyranoside 6-1.

To a solution of 2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-(1-4)-2-O-acetyl-3,6-di-O-benzyl-α-D-mannopyranosyl trichloroacetimidate (6) (0.1 g, 0.09 mmol) and 3-(perfluorooctyl)propanoyloxybutenyl alcohol (7) (62 mg, 0.11 mmol) in dry toluene (3 mL) was added TMSOTf (2 µL, 0.01 mmol) at 25 °C. The reaction mixture was stirred at room temperature for 10 min. The reaction was quenched with triethylamine
(0.01 mL) and concentrated under reduced pressure. The crude product was purified by solid phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80% MeOH/water and the desired product was eluted by 5 mL 100% MeOH. The solvent was removed under reduced pressure to obtain the desired product (6-1) (0.13 g, 92%).

**Rf (ethyl acetate/hexane):** 0.75 (20/80)

**1H NMR (CDCl₃, 400 MHz):** δ (ppm) 7.30-7.17 (m, 30H), 5.75-5.65 (m, 2H), 5.29 (s, 1H), 4.95 (d, 1H, J = 11.4 Hz), 4.82 (d, 1H, J = 11 Hz), 4.81 (d, 1H, J = <1 Hz), 4.70-4.62 (m, 5H), 4.57-4.47 (m, 2H), 4.39 (d, 1H, J = 5.6 Hz), 4.36 (d, 1H, J = 5.2 Hz), 4.24 (d, 1H, J = 11.8 Hz), 4.18 (d, 1H, J = 4.3 Hz), 4.10-4.06 (m, 2H), 4.01-4.00 (m, 2H), 3.90-3.85 (m, 2H), 3.80 (d, 2H, J = 8.7 Hz), 3.72 (t, 2H, J = 8.1 Hz), 3.55 (t, 1H, J = 9 Hz), 3.43-3.32 (m, 5H), 2.20-2.03 (m, 2H), 1.95 (s, 3H), 1.85-1.78 (m, 2H).

**13C NMR (CDCl₃, 100 MHz):** δ (ppm) 170.6 (C=O), [139.0, 138.9, 138.9, 138.5, 138.5, 138.2 (Cq-Aryl)], 130.6, 128.5 – 127.3 (m, CH-Aryl), [103.1, 96.8 (CHanomeric)], 82.0, 80.1, 76.3, 75.3, 74.8, 74.7, 73.7, 73.6, 73.3, 72.7, 72.2, 71.5, 69.6, 69.1, 69.9, 68.9, 68.9, 66.6, 62.9, 28.2, 28.0, 21.1(CH₃).

**HRMS-MALDI (m/z):** [M+Na]⁺ Calcd for C₇₁H₁₇₁F₁₇NaO₁₃ 1478.2783; Found,

To a solution of 3-(perfluorooctyl)propanoxybutenyl-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-](1-4)-2-O-acetyl-3,6-di-O-benzyl-α-D-mannopyranoside (6-1) (0.1 g, 0.07 mmol) in MeOH (3 mL) was added Na (1 mg, 0.07 mmol) and stirred at 25 °C for 30 min. The crude product was purified by solid phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced pressure to obtain the desired product (10) (95 mg, 98 %).

R_f (ethyl acetate/haxane): 0.45 (25/75)

^1H NMR (CDCl₃, 400 MHz): δ (ppm) 7.34-7.21 (m, 30H), 5.76-5.67 (m, 2H), 4.98 (d, 1H, J = 11.6 Hz), 4.91 (d, 1H, J = 11.6 Hz), 4.89 (d, 1H, J = <1 Hz), 4.82 (d, 1H, J
= 11.2 Hz), 4.75-4.69 (m, 3H), 4.63-4.50 (m, 3H), 4.43 (d, 1H, \( J = 10 \) Hz), 4.40-4.36 (m, 2H), 4.28 (d, 1H, \( J = 11.6 \) Hz), 4.21 (dd, 1H, \( J = 12, 3.2 \) Hz), 4.13-4.07 (m, 2H), 4.03-4.01 (m, 2H), 3.90 (d, 1H, \( J = 2.4 \) Hz), 3.79-3.69 (m, 5H), 3.58 (t, 1H, \( J = 8.8 \) Hz), 3.46-3.37 (m, 5H), 2.21-2.08 (m, 2H), 1.85-1.79 (m, 2H).

\(^{13}C\) NMR (CDCl\(_3\), 100 MHz): \( \delta \) (ppm) [139.1, 138.9, 138.8, 138.6, 138.2 (C\(_q\)-Aryl)], 130.5, 128.6 – 127.6 (m, CH-Aryl), [103.3, 98.3 (CH\(_{anomeric}\))], 82.8, 80.1, 78.2, 75.4, 74.5, 73.7, 73.7, 73.3, 73.0, 72.8, 71.4, 69.5, 68.9, 68.9, 68.7, 66.7, 62.7, 28.2.

HRMS-MALDI (m/z): [M+Na]\(^+\)Calcd for C\(_{69}\)H\(_{69}\)F\(_{17}\)NaO\(_{12}\) 1435.4415; Found, 1435.3106.

Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-\( \beta\)-D-galactopyranosyl]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl- \( \alpha \) -D-
mannopyranosyl]-α-D-mannopyranoside 10.

To a solution of 3-(perfluoroctyl)propanoylethyl-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl]-[1-4]-2-O-hydroxy-3,6-di-O-benzyl-α-D-mannopyranoside (9) (90 mg, 0.06 mmol) and 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl trichloroacetimidate (42 mg, 0.07 mmol) in dry toluene (3 mL) was added TMSOTf (2 µL, 0.01 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 10 min. The reaction was quenched with triethylamine (0.1 mL) and concentrated under reduced pressure. The crude product was purified by solid phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced pressure to obtain the desired product (10) (0.11 g, 89 %).

R<sub>f</sub> (ethyl acetate/hexane): 0.75 (20/80)

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ (ppm) 7.31-7.29 (m, 45H), 5.64-5.61 (m, 2H), 5.50 (dd, 1H, J = 2.8, 1.6 Hz), 5.05 (d, 1H, J = 1.2 Hz), 4.89 (d, 1H, J = 11.2 Hz), 4.83-4.77 (m, 4H), 4.68 (d, 1H, J = 11.2 Hz), 4.64-4.57 (m, 5H), 4.53 (d, 1H, J = 5.6 Hz), 4.51-4.45 (m, 3H), 4.42 (d, 1H, J = 7.6 Hz), 4.38 (d, 1H, J = 5.2 Hz), 4.33 (d, 1H, J = 10.8 Hz), 4.29 (d, 1H, J = 12.4 Hz), 4.21 (d, 1H, J = 12 Hz), 4.16-4.12 (m, 1H), 4.06
(d, 1H, J = 8.8 Hz), 4.02-4.00 (m, 1H), 3.97-3.91 (m, 4H), 3.85-3.82 (m, 3H), 3.80 (d, 1H, J = 9.6 Hz), 3.75-3.62 (m, 6H), 3.51 (t, 1H, J = 8.8 Hz), 3.44 (d, 1H, J = 2.8 Hz), 3.41-3.29 (m, 4H), 2.17-2.01 (m, 2H), 2.04 (s, 3H), 1.81-1.75 (m, 2H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 170.0 (C=O), [139.4, 139.2, 139.1, 138.9, 138.7, 138.7, 138.5, 138.3 (C$q$-Aryl)], 130.1, 128.6 – 127.1 (m, CH-Aryl), [103.5, 99.7, 98.2 (CH$_{anomeric}$)], 83.0, 80.3, 78.7m 78.2, 75.5, 87.4, 75.2, 74.8, 74.6, 73.7, 73.1, 72.7, 72.7, 72.2, 72.1, 72.0, 69.5, 69.2, 68.9, 68.6, 68.4, 66.8, 62.9, 28.5, 28.3, 28.1, 21.4.

HRMS-MALDI (m/z): [M+Na]$^+$ Calcd for C$_{98}$H$_{99}$F$_{17}$NaO$_{18}$ 1909.6458; Found, 1909.6699.

Synthesis of 3-(perfluorooctyl)propanyloxybutanyl-4-O-[β-D-galactopyranosyl]-2-O-[2-O-α-D-mannopyranosyl]-α-D-mannopyranoside 10-1.
To a 3-(perfluoroctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-
benzyl-β-D-galactopyranosyl]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-
mannopyranosyl]-α-D-mannopyranoside (10) (50 mg, 0.03 mmol) in MeOH (3 mL)
was added Na (1 mg, 0.07 mmol) and stirred at 25 °C for 30 min. The reaction
mixture was neutralized with Dowex-ion-exchange resin and filtered through Celite
pad. purified by solid phase extraction using fluoro flash column. The solvent was
removed under reduced pressure to obtain deacetylated product. To a slution of
deacetylated product in MeOH (3mL) was added 10 % Pd/C (50 mg). The reaction
mixture was stirred at 25 °C under hydrogen atmosphere for 12 h. The desired (10-1)
was obtained through Celite filtration followed by evaporation of solvent under
reduced pressure in good yield (26 mg, 95 %).

$^1$H NMR (D$_2$O, 400 MHz): $\delta$ (ppm) [4.95 (s, 1H), 4.87 (s, 1H), 4.29 (d, 1H, $J$ = 8 Hz),
CH$_{anomeric}$], 3.92-3.33 (m, 26H), 1.44-1.42 (m, 2H), 1.22-1.20 (m, 2H), 0.76-0.73 (m,
2H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) [103.9, 102.8, 98.7 (CH$_{anomeric}$)], 78.0, 77.7,
75.7, 73.8, 73.6, 71.8, 71.8, 71.4, 71.1, 70.6, 70.5, 69.8, 69.0, 68.9, 67.6, 67.2, 61.8,
61.2, 61.0, 60.2, 31.5, 27.6, 27.4,19.3. 13.0.

Synthesis of 1,2,3,4,6-penta-O-acetyl-D-mannopyranoside

To a solution of monnose (1 g, 5.6 mmol) in acetic anhydride (5 mL) was added catalytic amount of iodine (50 mg, 0.2 mmol) at 25 °C. The reaction mixture was stirred at room temperature for 1 h. The dark brown reaction mixture was poured into a separatory funnel containing dichloromethane, aqueous sodium thiosulfate solution and crushed ice. The colorless solution from a separatory funnel was washed with H₂O (2 x 50 mL) and sat.NaHCO₃ (2 x 50 mL). It was dried with Na₂SO₄ and then concentrated under reduced vacuum to obtain the desired product 1 with quantitative yield.
Synthesis of 3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidene)-α-D- mannopyranoside

To a solution of 1,2,3,4,6-penta-O-acetyl-D-mannopyranoside (2.2 g, 5.6 mmol) in dichloromethane was added HBr (10 mL) for 10 min. The reaction mixture was stirred at 25 °C for 1 h and then checked TLC to check the completion of reaction. After completion of reaction, the mixture was washed with cold water three times and then followed by washed with saturated sodium bicarbonate solution three times. The neutralized solution was dried with sodium sulfate and concentrated under reduced pressure. The crude product was used for next step without further purification. To a solution of hepta-acetyl lactosyl bromide in dichloromethane was added triethylamine (1.6 mL, 11.2 mmol), Bu₄NBr (2.0 g, 6.2 mmol) and methanol (0.2 mL, 6.7 mmol). The reaction mixture was stirred at 40 °C for 16 h and then washed with H₂O (1 x 50 mL). The solution was dried with Na₂SO₄ and then concentrated under reduced vacuum. The crude produce was purified to obtain the desired product (1.56 g, 78 % over 3 steps) by silica column chromatography.
Synthesis of 3,4,6-tri-\(O\)-benzyl-1,2-\(O\)-(1-methoxyethylidene)-\(\alpha\)-D-mannopyranoside

To a solution of 3,4,6-tri-\(O\)-acetyl-1,2-\(O\)-(1-methoxyethylidene)-\(\alpha\)-D-mannopyranoside (1g, 2.8 mmol) in MeOH (5 mL) was added catalytic amount of Na (10 mg, 0.4 mmol). The reaction mixture was stirred at 25 °C for 2 h and then concentrated under reduced vacuum to yield the crude deacetylated product as yellow foam. To a solution of deacetylated product in DMF (10 mL) was added 60 % NaH in mineral oil (1.33g, 11.2 mmol), followed by addition of benzyl bromide (1.31 mL, 11.2 mmol) and tetrabuyl ammonium iodide (31 mg, 0.08 mmol) at 0 °C. The reaction mixture was warmed up to 25 °C and stirred for 12 h. The reaction mixture was diluted with dichloromethane (50 mL) and then washed with H\(_2\)O (2 x 50mL). The organic layer was dried with Na\(_2\)SO\(_4\) and concentrated under reduced vacuum. The crude product was purified by flash silica column chromatography to afford the desired product (1.28 g, 92 %).
Synthesis of 2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl trichloroacetimidate 8\textsuperscript{16}

3,4,6-Tri-O-benzyl-1,2-O-(1-methoxyethylidiene)-\(\alpha\)-D-mannopyranoside (1 g, 2 mmol) was dissolved in 80 \% acetic acid (10 mL) and stirred at 25 °C for 30 min. The reaction mixture was diluted with dichloromethane (20 mL) and washed with \(\text{H}_2\text{O}\) (3 x 20 mL) followed by with sat.\(\text{NaHCO}_3\) (1 x 20 mL). The solution was dried with \(\text{Na}_2\text{SO}_4\) and concentrated under reduced pressure. To a crude residue in dichloromethane was added \(\text{Cs}_2\text{CO}_3\) (0.32 g, 1 mmol) and followed by addition of trichloroacetonitrile (0.4 mL, 4 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min and then concentrated under reduced pressure. The crude residue was dried with \(\text{Na}_2\text{SO}_4\) and purified by flash silica column chromatography to afford the desired product (8) (1.15 g, 92 \%).
Synthesis of 3-(Perfluorooctyl)propanyloxybutenyl-2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranoside \(12\).\(^{21}\)

To a solution of 2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl trichloroacetimidate (8) (0.3 g, 0.47 mmol) and 3-(perfluorooctyl)propanyloxybutenyl alcohol (2) (0.13 g, 0.24 mmol) in dry dichloroethane (5 mL) was added TMSOTf (8.5 µL, 0.05 mmol) at 25 °C. The reaction mixture was stirred at room temperature for 30 min. The reaction was quenched with triethylamine (0.5 mL) and concentrated under reduced pressure. The crude product was purified by solid phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced pressure to obtain the desired product (12) (0.20 g, 84 %).
Synthesis of 3-(Perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside 13\textsuperscript{21}.

To a solution of 3-(perfluorooctyl)propanyloxybutenyl-2-O-acetyl-3,4,6-O-benzyl-α-D-mannopyranoside (12) (0.2 g, 0.2 mmol) in MeOH (5 mL) was added Na (4 mg, 0.2 mmol) and stirred at 25 °C for 30 min. The crude product was purified by solid phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced pressure to obtain the desired product (0.18 g, 94 %). To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-O-benzyl-α-D-mannopyranoside (0.18 g, 0.19 mmol) and of 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl tricholoroacetimidate (0.13 g, 0.21 mmol) in toluene (5 mL) was added TMSOTf (2 µL, 0.11 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 10 min. The reaction was quenched with triethylamine (30 µL) and concentrated under reduced pressure. The crude product was purified by solid phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/H\textsubscript{2}O and the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced pressure to obtain the desired product (13) (0.23 g, 86 %).

To a solution of 3-(perfluoroctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (13) (0.2 g, 0.14 mmol) in MeOH (5 mL) was added Na (3 mg, 0.14 mmol) and stirred at 25 °C for 30 min. The crude product was purified by solid phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/water and the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced pressure to obtain the desired product (0.18 g, 92 %)
To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-\(O\)-benzyl-\(\alpha\)-D-mannopyranosyl-(1-2)-3,4,6-\(O\)-benzyl-\(\alpha\)-D-mannopyranoside (0.18 g, 0.13 mmol) and 2-\(O\)-acetyl-3,4,6-tri-\(O\)-benzyl-\(\alpha\)-D-mannopyranosyl trichloroacetimidate (91 mg, 0.14 mmol) in toluene (5 mL) was added TMSOTf (2 \(\mu\)L, 0.11 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 30 min. The reaction was quenched with triethylamine (30 \(\mu\)L) and concentrated under reduced pressure. The crude product was purified by solid phase extraction using fluoro flash column. Nonfluorous compounds were eluted with 5 mL 80 % MeOH/H\(_2\)O and the desired product was eluted by 5 mL 100 % MeOH. The solvent was removed under reduced pressure to obtain the desired product (14) (0.21 g, 86 %).

![Synthesis of 3-(perfluorooctyl)propanyloxybutanyl--2-\(O\)-(2-\(O\)-\(\alpha\)-D-mannopyranosyl)-\(\alpha\)-D-mannopyranoside 13-1.](attachment:image.png)
To a 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl)- \(\alpha\)-D-mannopyranoside (13) (50 mg, 0.03 mmol) in MeOH (3 mL) was added Na (1 mg, 0.07 mmol) and stirred at 25 °C for 30 min. The reaction mixture was neutralized with Dowex-ion-exchange resin and filtered through Celite pad. purified by solid phase extraction using fluoro flash column. The solvent was removed under reduced pressure to obtain deacetylated product. To a solution of deacetylated product in MeOH (3 mL) was added 10 % Pd/C (50 mg). The reaction mixture was stirred at 25 °C under hydrogen atmosphere for 12 h. The desired (13-1) was obtained through Celite filtration followed by evaporation of solvent under reduced pressure in good yield (29 mg, 95 %).

\(^1\)H NMR (CD\(_3\)OD, 400 MHz): \(\delta\) (ppm) [5.06 (s, 1H), 4.96 (s, 1H) CH\(_{\text{anomeric}}\)], 3.81-3.31 (m, 22H), 2.30-2.18 (m, 2H), 1.87-1.76 (m, 2H), 1.68-1.60 (m, 2H).

\(^{13}\)C NMR (CD\(_3\)OD, 100 MHz): \(\delta\) (ppm) [103.0, 98.7 (CH\(_{\text{anomeric}}\)], 79.5, 73.8, 73.4, 71.2, 71.0, 70.6, 68.9, 67.8, 67.6, 67.1, 61.9, 61.8, 60.2, 27.8, 27.6, 26.4, 26.1.

HRMS-MALDI (m/z): [M+Na\(^+\)]\(^+\) Calcd for C\(_{27}\)H\(_{35}\)F\(_{17}\)NaO\(_{12}\) 897.1289; Found, 897.1755.
Synthesis of 3-(perfluorooctyl)propanyloxybutanyl-2-O-[2-O-(2-O-α-D-
mannopyranosyl)-α-D-mannopyranosyl]-α-D-mannopyranoside 14-1.

To a 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-
3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-
α-D-mannopyranoside (14) (50 mg, 0.03 mmol) in MeOH (3 mL) was added Na (1 mg, 0.07 mmol) and stirred at 25 °C for 30 min. The reaction mixture was neutralized with Dowex-ion-exchange resin and filtered through Celite pad. purified by solid phase extraction using fluoro flash column. The solvent was removed under reduced pressure to obtain deacetylated product. To a solution of deacetylated product in MeOH (3 mL) was added 10 % Pd/C (50 mg). The reaction mixture was stirred at 25 °C under hydrogen atmosphere for 12 h. The desired (14-1) was obtained through
Celite filtration followed by evaporation of solvent under reduced pressure in good yield (26 mg, 93%).

$^1$H NMR (CD$_3$OD, 400 MHz): $\delta$ (ppm) [5.27 (s, 1H), 5.06 (s, 1H), 4.97 (s, 1H) CH$_{anomeric}$], 4.02-3.03 (m, 29H), 2.31-2.17 (m, 1H), 1.87-1.76 (m, 2H), 1.58-1.51 (m, 1H), 1.43-1.35(m, 1H).

$^{13}$C NMR (CD$_3$OD, 100 MHz): $\delta$ (ppm) [102.9, 101.3, 98.6 (CH$_{anomeric}$)], 79.7, 79.1, 73.8, 71.2, 71.0, 70.7, 70.5, 68.9, 68.0, 67.8, 67.6, 67.1, 62.1, 62.0, 61.8, 27.6, 27.4, 26.4, 26.1.

HRMS-MALDI (m/z): [M+Na]$^+$ Calcd for C$_{33}$H$_{45}$F$_{17}$NaO$_{17}$ 1059.2283; Found, 1059.1600.

Synthesis of 3-(perfluorooctyl)proanyloxybutanyl-β-D-galactopyranoside 15$^{22}$. To a solution of 3-(perfluorooctyl)proanyloxybutenyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside$^{22}$ (50 mg, 0.06 mmol) in MeOH (3 mL) was added Na (2 mg, 0.14
mmol) and stirred at 25 °C for 2 h. The reaction mixture was neutralized with Dowex-ion-exchange resin. The desired (15) was obtained through Celite filtration followed by evaporation of solvent under reduced pressure in good yield (39 mg, 97 %).

$^1$H NMR (CD$_3$OD, 400 MHz): $\delta$ (ppm) 4.21 (s, 1H, $J = 7.6$ Hz CH$_{\text{anomeric}}$), 3.92-3.45 (m, 12H), 2.31-2.18 (m, 2H), 1.87-1.80 (m, 2H), 1.72-1.63 (m, 4H).

$^{13}$C NMR (CD$_3$OD, 100 MHz): $\delta$ (ppm) 103.7 (CH$_{\text{anomeric}}$), 75.4, 73.8, 71.3, 70.5, 69.2, 69.0, 68.8, 61.2, 26.3, 26.1.

HRMS-ESI (m/z): [M+Na]$^+$ Calcd for C$_{21}$H$_{25}$F$_{17}$NaO$_7$ 735.1227; Found, 735.1095.

Synthesis of 3-(perfluorooctyl)propanyloxybutanyl-4-O-$\beta$-D-galactopyranosyl-$\beta$-D-glucopyranoside 16.$^{22}$

To a solution of 3-(perfluorooctyl)propanyloxybutenyl-4-O-(2,3,4,6-tetra-O-acetyl-$\beta$-D-galactopyranosyl)-2,3,6-tri-O-acetyl-$\beta$-D-glucopyranoside$^{22}$ (50 mg, 0.04 mmol) in MeOH (3 mL) was added Na (3 mg, 0.21 mmol) and stirred at 25 °C for 4 h. The
reaction mixture was neutralized with Dowex-ion-exchange resin. The desired (16) was obtained through Celite filtration followed by evaporation of solvent under reduced pressure in good yield (36 mg, 96 %).

\(^1\)H NMR (CD\(_3\)OD, 400 MHz): \(\delta\) (ppm) [4.77 (d, 1H, \(J = 3.6 \text{ Hz}\)), 4.34 (s, 1H, \(J = 7.6 \text{ Hz}\)) CH\(_{\text{anomeric}}\)], 3.76-3.69 (m, 9H), 3.51-3.48 (m, 11H), 2.32-2.18 (m, 2H), 1.88-1.81 (m, 2H), 1.72-1.63 (m, 2H).

\(^{13}\)C NMR (CD\(_3\)OD, 100 MHz): \(\delta\) (ppm) [103.8, 98.7 (CH\(_{\text{anomeric}}\)], 79.7, 75.9, 73.6, 72.3, 72.3, 72.0, 71.3, 70.9, 70.5, 69.1, 68.9, 67.7, 61.3, 60.6, 26.4, 26.1.

HRMS-ESI (m/z): [M+Na]\(^+\) Calcd for C\(_{27}\)H\(_{35}\)F\(_{17}\)NaO\(_{12}\) 897.1755; Found, 897.1510.

References


17 Lemanski G, Lindenberg T, Fakhrnabavi H, Ziegler T. *J. Carbohydr. Chem.* 19,


CHAPTER 4

Development of automated synthesis and screening of phosphate-linked Leishmania-associated carbohydrates

Eun-Ho Song and Nicola L. Pohl

Introduction

Since fluous-based automation platform became a reliable tool for automated synthesis of oligosaccharides, automated synthesis of phosphoglycans becomes a challenge due to its unique phosphate-linked structure and function. Unlike glycosylation and deacetylation for the construction of oligosaccharide in an automation platform, forming phosphate-linkage requires three steps; coupling, oxidation and deprotection.

In order to extend the versatility of fluous-based automation platform, we examined its application for the synthesis of phosphoglycan repeats in Leishmania surface glycolipid, lipophosphoglycan (LPG).

The role of lipophosphoglycan (LPG) in parasite virulence has been intensively reported in the field of parasite biology due to its importance during macrophage
infection. Nevertheless, their role in parasite virulence is controversial issue. But, now there is no longer any doubt that *Leishmania* cannot survive in sand flies and macrophages without LPG.

As shown in figure 1, the structure of LPG has been characterized by mass spectrometry and NMR spectroscopy. Phosphoglycan repeats are the most abundant *Leishmania*-surface molecules in LPG due to difference in the length distribution among three domains. Moreover, each species has unique structure of phosphoglycan repeats in LPG. For example, *L. donovani* PGs consists of linear [-6Galp-β 1,4-Manp-α 1-phosphate]$_{n_{avg}=12}$ repeats and *L. major* PGs consists of branched [6-(Gal-β 1,3)-Galp-β 1,4-Manp-α 1-phosphate]$_{n_{avg}=27}$ repeats.

Although there have been several studies made on the identification of phosphoglycan repeats functions such as part of epitopes for recognition by macrophage receptors and playing a key role in parasite survival early in the sand fly, these studies were not performed with pure phosphoglycan repeats due to the impossibility to obtain pure phosphoglycan repeats from LPG. Thus, we can only assume that PGs might play a crucial role in parasite virulence. While there has been
increasing interest in the study of PGs function, specific study has been restricted due to the limited access to pure synthesized PGs.

![Diagram of phosphoglycan repeats](image)

**Figure 1.** Structure of the lipophosphoglycan of *Leishmania donovani*.

Interestingly, capping structures are also linked to phosphoglycan repeats through phosphate. Like capping structure, phosphate groups might serve as distinct epitopes and profoundly affect antibody binding. Given this thought, it can be hypothesized that phosphate-linkages are involved in synergistic antibody bindings. Fluorous-based microarray\(^\text{10}\) can also be used to demonstrate the effect of phosphate-linkages in antibody bindings.

In this regard, rapid and efficient chemical synthesis for the construction of *Leishmania* phosphoglycan repeats and phosphate-linked capping structures has been prerequisite due to its biological interests for unveiling PGs and phosphate specific
functions in parasite virulence and their potential role in immunomodulation for vaccine development.

Several attempts for both chemical synthesis of *L. donovani* PGs\textsuperscript{11-13} and *L. major* PGs\textsuperscript{14-16} have been made through either using monosaccharide building blocks (galactose and mannose) with multiple steps for protection, deprotection, and glycosylation or disaccharide building block. In the study which used disaccharide building block, iterative synthesis of PGs has been achieved by solid-phase\textsuperscript{11}, but the use of automation platform for synthesis of PGs has never been reported. Unlike oligonucleotide and peptides synthesis via a synthesizer, phosphate-linked oligosaccharides such as phosphoglycan have never been synthesized by using an automation platform due to the difficulty of managing anomeric stereochemistry and instability of the anomeric phosphodiester. In order to overcome these limitations, we focused on the development of synthetic methods under H-phosphonate chemistry\textsuperscript{17} and it led to the discovery of an efficient method for the synthesis of phosphate-linked oligosaccharides.
Herein, we reported the first fluorous-based automated synthesis of linear phosphoglycan repeats for *L. donovani* and phosphate-linked *Leishmania*-associated capping structures through a H-phosphonate strategy.

**Results and discussion**

**Synthesis of *L. donovani* phosphoglycan building block**

A known intermediate orthoester\(^{18}\) served as starting material for the synthesis of phosphoglycan donor (Scheme 1). According to the conditions previously developed by Ruhela et al.\(^{11}\), regioselective silylation of 6-position of galactose on orthester was performed by using Bu\(_3\)Sn/MeOH and TBDPSCl in reasonably high yield (80 % 3 steps). Subsequence benzylation gave the benzylated orthoester 1 in 85 % respectively. Lewis acid-mediated allylation by using allyl alcohol and TfOH was followed by reaction with NaOMe to yield 2-0-unprotected disaccharide 2 in high yield (82% over 2 steps). With 2-0-unprotected disaccharide 2, conversion of β-glucoside 2 to α-mannoside 3 was successively accomplished under a two-step oxidation-reduction process by using Dess-Martin periodate and subsequence reduction with NaBH\(_4\).
Further protection of 2-\textit{O}-unprotected disaccharide 3 with Piv-Cl gave fully protected disaccharide 5 in 91\% respectively.

Scheme 1. Synthesis of \textit{L. donovani} phosphoglycan building block

Iridium-catalyzed isomerization\textsuperscript{19} of allyl ether 4 was carried out in order to give trans-propenyl ether 5 and then free anomeric-OH was introduced under non-acidic conditions\textsuperscript{20} using HgO/HgCl\textsubscript{2} to furnish pure α-hemiacetal product in 91\% respectively after removal of β-hemiacetal product through silica column purification.
Scheme 2. Synthesis of *L. donovani* phosphoglycan donor

PCl₃/imidazole reagent²¹ has been widely used as phosphonylating agent for formation of H-phosphonate monoester in carbohydrate due to its high reactivity. However, phsphonylation using PCl₃/imidazole requires not only laborious experimental procedure but also very careful handling of PCl₃ which is classified very toxic and corrosive by EPA.

Instead of using PCl₃/imidazole, phosphorous acid/Piv-Cl system enabled us to accomplish phsphonylation of 6 in good yield (83 %) though pivaloyl chloride-mediated coupling reaction²². H-phposphonate donor 6 was confirmed by unique large coupling constant of $^{31}$P-¹H (doublet, $J_{HP}$= 632.4 Hz in $^1$H NMR), $^{31}$P NMR (1.31 ppm) and HRMS ([M+Na]+ Calcd 1177.4898; Found 1177.0978 ).
In order to optimize conditions for the synthesis of phosphodiester prior to run synthesizer, another pivaloyl chloride mediated coupling reaction for the introduction of fluorous-tag was followed by oxidation with iodine in aqueous pyridine to furnish fluorous-tagged \( \beta \)-D-galactopyranosyl-(1\(\rightarrow\)4)-\( \alpha \)-D-mannopyranosyl phosphodiester 7 in 87% yield.

**Automated synthesis of L. donovani phosphoglycan repeats.**

The automated synthesis of *L. donovani* phosphoglycan repeats was designed to carry out 2 and 2/3 cycles including 3 x coupling for the elongation of disaccharide repeat, 3 x oxidation for the transformation of phosphite to phosphate, 2 x desilylation for the deprotection of TBDPS group and 5 x FSPE for the purification of crude product (Scheme 4). Each reaction cycle was programmed to use only 2 equivalent of
H-phosphonate donor 6 PIV-Cl, iodine and TBAF. As expected, the use of TLC in monitoring reactions enabled us to confirm the completion of each step of the reaction during running synthesizer. After 2.5 automation cycles, 23 mg of crude hexa-phosphoglycan repeats with high purity was obtained from automation platform without further purification. With conventional purification with prep TLC, 19 mg of pure product was provided in overall 10 % yield (75 % per step).

**Scheme 4.** Automated synthesis of *L. donovani* phosphoglycan repeats
Synthesis of phosphate-linked *Leishmania*-associated capping structures

\[ \text{C}_8\text{F}_{17} \text{O} - \text{OH} \xrightarrow{\text{H}_3\text{PO}_3, \text{Piv-Cl}} \text{O} - \text{H} \]

**Scheme 5.** Synthesis of H-phosphonate fluorous-tagged alcohol.

α-Hemiacetal products of *Leishmania*-associated capping structures were prepared as reported in previous study.\(^{24}\) Pivaloyl chloride mediated coupling reaction underwent efficiently to produce H-phosphonate fluorous-tagged alcohol 9 in good yields (82 %). Subsequent coupling reaction of H-phosphonate fluorous-tagged alcohol using phosphorous acid/Piv-Cl with α-hemiacetal intermediates followed by oxidation with iodine in aqueous pyridine resulted in the production of fluorous-tagged *Leishmania* capping phosphodiesters in good yields (81 % – 89 %).
Conclusion

In conclusion, the first automated synthesis of *L. donovani* phosphoglycan repeats demonstrated that phosphate-linked oligosaccharide can be readily available in the
newly developed fluorous-based automation platform within a short period, with low cost and less laborious work. More importantly, the synthesis of phosphate-linked *Leishmania*-associated capping structures for *L. donovani* and *L. major* has led to advances in understanding of the role of phosphate in antibody bindings. The study for the detection of glycolipid specific antibodies in serum from *Leishmania* infected animals using phosphate-linked *Leishmania*-associated capping structures will be exploited.

**Experimental section**

**General methods**

Solvents were reagent grade and in most cases dried prior to use. All other commercially available reagents were used as received unless otherwise noted. The organic extracts were dried over anhydrous MgSO$_4$. Tetrahydrofuran (THF) was distilled from lithium aluminum hydride (LiAlH$_4$) prior to use. Methylene chloride (CH$_2$Cl$_2$), and triethylamine (Et$_3$N) were distilled from calcium hydride. Diethyl ether (Et$_2$O) was distilled from sodium-benzophenone ketyl.

$^1$H and $^{13}$C NMR spectra were obtained at 400 MHz and 100 MHz on Varian VXR-
400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an
Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosytems
QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per
million downfield relative to tetramethylsilane (δ 0.00) and coupling constants are
reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s =
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.

\[
\text{Synthesis of 2,3,4-Tri-} O \text{-benzyl-6-} O \text{-(tert-butyldiphenylsilyl)-} \beta \text{-D-}
\text{galactopyranosyl-(1-4)-3,6-di-} O \text{-benzyl-1,2-} O \text{-(1-methoxyethylidene)-} \beta \text{-D-}
\text{glucopyranoside 1.}
\]

To a solution of 2,3,4,6,-tetra-\text{-acetyl-} \beta \text{-D-galactopyranosyl-(1-4)-3,6-di-} O
\text{-acetyl-1,2-} O \text{-}(1-methoxyethylidene)-\beta \text{-D-glycopyranoside}^{18} \text{ (2 g, 3.1 mmol) in}
MeOH (10 mL) was added catalytic amount of Na (140 mg, 6.2 mmol). The reaction
mixture was stirred at 25 °C for 3 h and then was filtered through a Celite pad. The crude deacetylated product as yellow foam was obtained after concentration of reaction mixture under reduced vacuum. To a solution of deacetylated product in anhydrous MeOH (20 mL) was added Bu$_2$SnO (0.77 g, 3.1 mmol) and then the reaction mixture was heated to reflux for 4 h followed by evaporation of solvent. To a solution of a dibutyltin compound in anhydrous THF was added TBDPSCl (0.72 mL, 3.1 mL) and then the reaction mixture was stirred at 25 °C for 48 h. The solvent was concentrated under reduced vacuum. The crude product was purified by flash silica column chromatography (3 % MeOH in DCM) to afford the desired product 2,3,4-tri-O-hydroxy-6-O-(tert-butyldiphenyilsilyl)-β-D-galactopyranosyl-(1-4)-3,6-di-O-hydroxy-β-D-glucopyranoside (1.88 g, 80 % over 2 steps). To a solution of TBDPS-protected product (1.88 g, 3.0 mmol) in DMF (10 mL) was added 60 % NaH (0.99 g, 30 mmol), followed by addition of benzyl bromide (3.5 mL, 30 mmol) and tetrabuylammonium iodide (1.1 g, 3.0 mmol) at 0 °C. The reaction mixture was warmed up to 25 °C and stirred for 12 h. The reaction mixture was diluted with dichloromethane (20 mL) and then washed with H$_2$O (2 x 20mL). The organic layer was dried with Na$_2$SO$_4$ and concentrated under reduced vacuum. The crude product
was purified by flash silica column chromatography to afford the desired product 1 (2.73 g, 85% over 2 steps).

**Rf** (ethyl acetate/haxane): 0.83 (25/75)

**¹H NMR (CDCl₃, 400 MHz):** δ (ppm) 7.54-7.07 (m, 35H), 5.67 (d, 1H, J = 5.2 Hz), 5.00 (d, 1H, J = 9.6 Hz), 4.85-4.77 (m, 4H), 4.63 (d, 1H, J = 16 Hz), 4.59 (d, 1H, J = 15.2 Hz), 4.55 (d, 1H, J = 12.8 Hz), 4.40 (t, 1H, J = 11.2 Hz), 4.27 (m, 1H), 4.18 (d, 1H, J = 8 Hz), 4.03 (br, 1H), 3.95-3.86 (m, 3H), 3.75-3.58 (m, 5H), 3.72 (dd, 1H, J = 8.8, 2.4 Hz), 3.28-3.25 (m, 1H), 3.22 (s, 3H), 1.54 (s, 3H), 1.02 (s, 9H).

**¹³C NMR (CDCl₃, 100 MHz):** δ (ppm) [139.3, 139.1, 138.9, 138.7, 138.3 (C₉-Aryl)], [130.2-127.8 (m, CH-Aryl)] 135.8, 135.7, [105.6, 97.8 (CH_anomeric)], 82.3, 79.7, 75.3, 74.9, 74.3, 73.4, 72.1, 70.3, 69.4, 62.0, 51.2, 27.3, 20.6, 19.5.

**HRMS-MALDI (m/z):** [M+Na]+ Calcd for C₆₆H₇₄NaO₁₂Si, 1109.4847; Found, 1109.6400.
Synthesis of Allyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-galactopyranosyl)-(1-4)-3,6-di-O-benzyl-2-O-hydroxy-β-D-glucopyranoside 2.

A solution of 2,3,4-Tri-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-galactopyranosyl-(1-4)-3,6-di-O-benzyl-1,2-O-(1-methoxyethylidiene)-β-D-glucopyranoside 1 (2 g, 1.8 mmol) and allyl alcohol (1.25 mL, 18 mmol) in dichloromethane (10 mL) was cooled to –40 °C and TfOH (10 µL, 0.12 mmol) was added dropwise over 10 min. The reaction mixture was stirred at –40 °C for 30 min and allowed to 25 °C for 1 h followed by addition of triethylamine to neutralize a solution. The crude product was obtained after concentration of solvent under reduced vacuum. To a crude product in MeOH was added Na (41 mg, 1.8 mmol). The reaction mixture was stirred at 25 °C for 1 h and then concentrated under reduced vacuum. The crude product was purified by flash silica column chromatography to afford the desired product 2 (1.62 g, 82 % over 2 steps).

\[ R_f \text{ (ethyl acetate/haxane)}: \ 0.50 \ (25/75) \]

\[ ^1H \text{ NMR (CDCl}_3, 400 \text{ MHz)}: \ \delta \text{ (ppm)} \ 7.56-6.98 \text{ (m, 35H), 5.98-5.88 (m, 1H), 5.32 (dd, 1H, } J = 17.2, 1.6 \text{ Hz), 5.21 (dd, 1H, } J = 10.4, 1.2 \text{ Hz), 5.07 (d, 1H, } J = 11.2 \text{ Hz), 5.02 (d, 1H, } J = 10.8 \text{ Hz), 4.81-4.73 (m, 3H), 4.60-4.54 (m, 3H), 4.39-4.30 (m, 4H),} \]
4.13 (dd, 1H, $J = 12.8, 6.4$ Hz), 4.01 (d, 1H, $J = 2.8$ Hz), 3.88 (t, 1H, $J = 9.2$ Hz), 3.86 (d, 1H, $J = 12$ Hz), 3.81-3.64 (m, 4H), 3.446-3.44 (m, 1H), 3.41-3.33 (m, 3H), 3.24 (dd, 1H, $J = 9.2, 5.2$ Hz), 1.03 (s, 9H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) [139.2, 138.9, 138.7, 138.6, 138.4 (C$_q$-Aryl)], 135.5, 134.0, 133.2, [129.8-127.1 (m, CH-Aryl)], 117.8, [102.7, 101.5 (CH$_{anomeric}$)], 82.8, 82.4, 80.2, 77.4, 76.8, 76.1, 75.5, 75.3, 74.9, 74.3, 73.7, 73.2, 70.0, 68.1, 61.3, 27.0, 19.2.

HRMS-MALDI (m/z): [M+Na]$^+$ Calcd for C$_{66}$H$_{74}$NaO$_{11}$Si, 1093.4898; Found, 1093.4898.

Synthesis of Allyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-galactopyranosyl)-(1-4)-3,6-di-O-benzyl-2-O-hydroxy-β-D-mannopyranoside 3.

To a solution of allyl O-(2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-galactopyranosyl)-(1-4)-3,6-di-O-benzyl-2-O-hydroxy-β-D-glucopyranoside 2 (1.5 g, 0.14 mmol) in dichloromethane (10 mL) was added dess-martin periodinane (1.2 g, 0.28 mmol). The reaction mixture was stirred at 35 °C for 4 h and then diluted with
dichloromethane (10 mL). The diluted solution was washed with sat. NaHCO₃ (2 x 5 mL), H₂O (1 x 5 mL), and brine (1 x 5 mL). The organic layer was dried with Na₂SO₄ and then concentrated under reduced vacuum. The crude residue was dissolved in dichloromethane/MeOH (1/1) and cooled to 0 °C. NaBH₄ (0.11 mg, 0.28 mmol) was added and then the reaction mixture was allowed to 25 °C over 1 h. The mixture was diluted with dichloromethane (10 mL) and washed with H₂O (1 x 5 mL), 1 % aqueous citric acid (1 x 5 mL) and brine (1 x 5 mL). The solvent was evaporated under reduced vacuum and dried with Na₂SO₄. The crude product was purified by flash silica column chromatography to afford the desired product 3 (1.29 g, 86 % over 2 steps).

R_f (ethyl acetate/haxane): 0.47 (25/75)

¹H NMR (CDCl₃, 400 MHz): δ (ppm) 7.57-7.06 (m, 35H), 5.94-5.84 (m, 1H), 5.27 (dd, 1H, J = 17.2, 1.6 Hz), 5.18 (dd, 1H, J = 10.4, 1.2 Hz), 5.05 (d, 1H, J = 11.2 Hz), 4.79-4.74 (m, 4H), 4.70 (d, 1H, J = 12 Hz), 4.63 (d, 1H, J = 15.6 Hz), 4.59 (d, 1H, J = 12 v), 4.51 (d, 1H, J = 12 v), 4.45 (d, 1H anomicer, J = 0.8 Hz), 4.40-4.35 (m, 2H), 4.39 (d, 1H anomicer, J = 8 Hz), 4.08-3.98 (m, 4H), 3.86 (t, 1H, J = 9.2 Hz), 3.79-3.71 (m, 4H), 3.48-3.40 (m, 3H), 3.29 (dd, 1H, J = 8.8, 5.2 Hz), 1.01 (s, 9H).
\( ^{13} \text{C NMR (CDCl}_3, 100 \text{ MHz): } \delta (\text{ppm}) [139.2, 138.8, 138.6, 138.5, 138.4 (\text{C}_q-\text{Aryl})], 135.5, 133.9, 133.2, [129.8-127.2 (m, CH-Aryl)], 117.7, [103.1, 98.5 (CH}_\text{anomeric}), 82.5, 80.1, 79.1, 75.4, 75.2, 74.6, 74.3, 74.2, 73.7, 73.2, 72.8, 72.6, 69.8, 68.9, 27.0, 19.2. \)

**HRMS-MALDI (m/z):** \([\text{M+Na}]^+\text{Calcd for } \text{C}_{66}\text{H}_{74}\text{NaO}_{11}\text{Si}, 1093.4898; \text{Found, 1093.4898.}\)

**Synthesis of Allyl \(O-(2,3,4\text{-tetra-}O\text{-benzyl-6-}O\text{-}(\text{tert-butyl}diphenylsilyl})\text{-}\beta\text{-D-galactopyranosyl)-(1-4)-} 2\text{-}O\text{-trimethylacetyl-3,6-di-}O\text{-benzyl-\beta}D\text{-mannopyranoside 4.}\)**

To a allyl \(O-(2,3,4\text{-tetra-}O\text{-benzyl-6-}O\text{-}(\text{tert-butyl}diphenylsilyl})\text{-}\beta\text{-D-galactopyranosyl)-(1-4)-} 3,6\text{-}di-}O\text{-benzyl-2-}O\text{-hydroxy-\beta}D\text{-mannopyranoside 3 (1 g, 0.9 mmol) in dichloromethane (5 mL) was added DMAP (57 mg, 0.5 mmol), triethylamine (0.62 mL, 0.18 mmol) and trimethyl acetylchloride (0.23 mL, 0.18 mmol). The reaction mixture was stirred at 25 °C for 1 h and then concentrated under**
reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the desired product 4 (1.04 mg, 96 %).

**R<sub>f</sub>** (ethyl acetate/haxane): 0.65 (25/75)

**<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):** δ (ppm) 7.54-7.00 (m, 35H), 5.89-5.79 (m, 1H), 5.46 (d, 1H, J = 3.2 Hz), 5.25 (dd, 1H, J = 17.2, 1.6 Hz), 5.15 (dd, 1H, J = 10.4, 1.2 Hz), 5.05 (11.6), 4.78-4.69 (m, 4H), 4.60 (d, 2H, J = 12 Hz), 4.54 (d, 2H, J = 9.6 Hz), 4.48 (d, 1H, J = 5.2 Hz), 4.45 (d, 1H, J = 12 Hz), 4.32-4.27 (m, 1H), 4.05-3.98 (m, 2H), 3.94 (d, 1H, J = 2.4 Hz), 3.84-3.80 (m, 3H), 3.74 (dd, 1H, J = 9.6, 8 Hz), 3.55-3.50 (m, 2H), 3.46-3.45 (m, 1H), 3.42 (dd, 1H, J = 9.6, 2.8 Hz), 3.22 (dd, 1H, J = 8.8, 5.2 Hz), 1.05 (s, 9H), 1.01 (s, 9H).

**<sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz):** δ (ppm) 177.7 (C=O), [139.2, 138.9, 138.7, 138.6, 138.4 (C<sub>q</sub>-Aryl)], 135.5, 133.9, 133.2, [129.8-127.0 (m, CH-Aryl)], 117.7, [102.7, 97.6 (CH<sub>anomeric</sub>)], 82.6, 80.1, 77.7, 75.6, 75.1, 74.6, 74.2, 73.9, 73.6, 73.0, 72.9, 71.5, 69.5, 68.8, 68.5, 61.5, 38.9, 27.1, 27.0, 19.2.

**HRMS-MALDI (m/z):** [M+Na]<sup>+</sup> Calcd for C<sub>71</sub>H<sub>82</sub>NaO<sub>12</sub>Si, 1178.4788; Found, 1178.4167.
Synthesis of Vinyl $O$-(2,3,4-tetra-$O$-benzyl-6-$O$-(tert-butyldiphenylsilyl)-$\beta$-$D$-\text{galactopyranosyl})-(1-4)- $2-O$-trimethylacetyl-3,6-di-$O$-benzyl-$\beta$-$D$-\text{mannopyranoside 5}.

To a allyl $O$-(2,3,4-tetra-$O$-benzyl-6-$O$-(tert-butyldiphenylsilyl)-$\beta$-$D$-\text{galactopyranosyl})-(1-4)- $2-O$-trimethylacetyl-3,6-di-$O$-benzyl-$\beta$-$D$-manno\text{pyranoside 4}$ (1 g, 0.09 mmol) in THF (10 mL) was added catalytic amount of (1,5-\text{Cyclooctadiene})bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (10 mg, 0.01 mmol). The stirred solution was degassed, placed under $N_2$ and degassed. The reaction mixture was placed under $H_2$ for 5 min and degassed once more to prevent further reduction. The mixture was stirred at $25 \degree C$ for 30 min under $N_2$ and then concentrated under reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the desired product 5 (0.93 g, 93 %).

$R_f$ (ethyl acetate/haxane): 0.68 (25/75)

$^1H$ NMR (CDCl$_3$, 400 MHz): $\delta$ (ppm) 7.54-7.00 (m, 35H), 6.18 (dd, 1H, $J = 12.4$, 1.6 Hz), 5.46 (d, 1H, $J = 2.4$ Hz), 5.04-4.99 (m ,1H), 5.02 (d, 1H, $J = 11.6$ Hz), 4.76-
4.67 (m, 6H), 4.58-4.40 (m, 7H), 3.97 (t, 1H, $J = 9.2$ Hz), 3.93 (d, 1H, $J = 2.4$), 3.81-3.77 (m, 4H), 3.73 (dd, 1H, $J = 9.6$, 8 Hz), 3.54-3.48 (m, 4H), 3.42 (dd, 1H, $J = 9.6$, 2.8 Hz), 3.21 (dd, 1H, $J = 8.8$, 4.8 Hz), 1.50 (dd, 3H, $J = 6.8$, 1.2 Hz), 1.03 (s, 9H), 0.99 (s, 9H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 177.8 (C=O), 143.8, [139.5, 139.2, 139.0, 138.9, 138.7 (C$_q$-Aryl)], 135.9, 133.5, 133.5, [128.8-127.4 (m, CH-Aryl)], 104.4, [103.1, 98.0 (CH$_{\text{anomeric}}$)], 82.6, 80.1, 77.8, 76.2, 75.5, 75.0, 74.6, 74.1, 74.0, 73.3, 73.3, 72.0, 69.0, 68.5, 61.8, 79.3, 27.5, 72.4, 19.6, 12.8.

HRMS-MALDI (m/z): [M+Na]$^+$ Calcd for C$_{71}$H$_{82}$NaO$_{12}$Si, 1178.4788; Found, 1178.8628.

Synthesis of Triethylammonium (2,3,4-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)-β-D-galactopyranosyl)-(1-4)-2-O-trimethylacetyl-3,6-di-O-benzyl-β-D-mannopyranosyl hydrogen phosphonate 6.
To a vinyl \( O-(2,3,4\text{-tetra-O-benzyl-6-O-(tert-butyldiphenylsilyl)}\)-\(\beta\)-D-galactopyranosyl)-(1-4)- 2-O-trimethylacetyl-3,6-di-O-benzyl-\(\beta\)-D-mannopyranoside 5 (0.9 g, 0.8 mmol), and mercury oxide (0.24 g, 0.1 mmol) in 10 mL of acetone/H\(\text{H}_2\text{O}\) (10/1) was added a solution of mercuric chloride (0.23 g, 0.9 mmol) in 5 mL of acetone/H\(\text{H}_2\text{O}\) (10/1) for 1 min. The reaction mixture was stirred at 25 °C for 3 h. The crude residue was filtered through celite and diluted with dichloromethane (5 mL). The organic layer was washed with sat. KI (1 x 5 mL), H\(\text{H}_2\text{O}\) (1 x 5 mL) and brine (1 x 5 mL). The solvent was dried with Na\(\text{SO}_4\) and concentrated under reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the hydrolyzed product (0.79 g, 91 %). Hydrolyzed compound (0.7 g, 0.6 mmol) and phosphonic acid (57 mg, 0.7 mmol) were coevaporated with pyridine and dried under high vacuum for 30 min. To a solution of this mixture in pyridine (5 mL) was added a solution of pivaloyl chloride (0.085 mL, 0.7 mmol) in pyridine (2 mL) and then the mixture was stirred at 25 °C for 30 min under nitrogen gas environment. Prydine was removed under reduced vacuum and the crude product was purified by flash silica column chromatography (with triethylamine) to afford the desired product 6 (0.86 g, 83 %).
\[ \text{R}_f (10 \text{% MeOH in DCM}): 0.5. \]

\[ ^1H \text{ NMR (CDCl}_3, 400 \text{ MHz}): \delta (\text{ppm}) 7.51-7.15 (\text{m, 35H}), 6.98 (\text{d, 1H, } J_{\text{HP}} = 685 \text{ Hz}), 5.53 (\text{d, 1H, } J = 8.8 \text{ Hz}), 5.30 (\text{s, 1H}), 5.06 (\text{d, 1H, } J = 11.2 \text{ Hz}), 4.80-4.70 (\text{m, 5H}), 4.66-4.56 (\text{m, 4H}), 4.46 (\text{d, 1H, } J = 11.2 \text{ Hz}), 4.38-4.35 (\text{m, 2H}), 4.14 (\text{t, 1H, } J = 9.6 \text{ Hz}), 4.02-3.90 (\text{m, 5H}), 3.80-3.70 (\text{m, 3H}), 3.66 (\text{d, 1H, } J = 9.6 \text{ Hz}), 3.44 (\text{dd, 1H, } J = 9.2 \text{ Hz}), 3.38 (\text{dd, 1H, } J = 9.6, 2.4 \text{ Hz}), 0.99 (\text{s, 9H}), 0.93 (\text{s, 9H}). \]

\[ ^{13} \text{C NMR (CDCl}_3, 100 \text{ MHz}): \delta (\text{ppm}) 177.5 (\text{C=O}), [139.4, 139.2, 139.0, 138.0, 138.9 (\text{C}_q-\text{Aryl})], 135.6, 133.4, 133.4, [129.9-126.8 (\text{m, CH-Aryl})], [103.3, 93.5 (\text{CH}_{\text{anomeric}})], 82.7, 80.2, 75.5, 75.3, 74.8, 74.2, 74.1, 74.0, 73.1, 73.1, 73.0, 72.4, 68.6, 45.9 (\text{NEt}_3), 39.0, 27.3, 27.1, 19.4, 9.2(\text{NEt}_3). \]

\[ \text{HRMS-MALDI (m/z): [M-NEt}_3-\text{H}]\text{Calcd for C}_{68}H_{78}O_{14}PSi, 1177.4898; \text{ Found, 1177.0978.} \]

\[ ^{31} \text{P NMR (162 MHz, CDCl}_3): \delta 1.31. \]

Triethylammonium (2,3,4-tetra-\(O\)-benzyl-6-O-(tert-butyldiphenylsilyl)-\(\beta\)-D-galactopyranosyl)-(1-4)- 2-O-trimetylacetyl-3,6-di-\(O\)-benzyl-\(\beta\)-D-mannopyranosyl hydrogen phosphonate 6 (0.1 g, 0.08 mmol) and 3-(perfluorooctyl)propanoxybutenyl alcohol25 (43 mg, 0.08 mmol) were coevaporated with pyridine and dried under high vacuume for 30 min. To a solution of this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.02 mL, 0.16 mmol) in pyridine (0.5 mL) and then the mixture was stirred at 25 °C for 1 h under nitrogen gas environment. To the reaction mixture was added a solution of iodine (20 mg, 0.008) in pyridine/water mixture (0.2 mL, 10/1) and the reaction mixture was quenched with saturated Na\(_2\)S\(_2\)O\(_3\). Excess pyridine was evaporated under reduced pressure and then the crude product was purified by flash silica column chromatography (with triethyamine) to afford the desired product 7 (0.12 g, 87 %).

\(R_f\) (10 % MeOH in DCM): 0.6.

\(^1\)H NMR (CDCl\(_3\), 400 MHz): \(\delta\) (ppm) 7.33-6.89 (m, 35H), 5.72 (m, 1H), 5.54 (m,1H), 5.47 (d, 1H, \(J = 8.4\) Hz), 5.45 (s, 1H), 5.04 (d, 1H, \(J = 11.2\) Hz), 4.78-4.69
(m, 5H), 4.62 (d, 1H, J = 7.2 Hz), 4.57-4.54 (m, 3H), 4.49-4.41 (m, 3H), 4.37-4.34 (m, 2H), 4.10 (t, 1H, J = 9.6 Hz), 4.02-3.88 (m, 4H), 3.78-3.68 (m, 3H), 3.45-3.33 (m, 4H), 3.13 (dd, 1H, J = 9.2, 4.8 Hz), 2.13-2.09 (m, 2H), 1.80-1.76 (m, 2H), 0.98 (s, 9H), 0.91 (s, 9H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 177.3 (C=O), [139.5, 139.2, 139.1, 138.9, 138.9 (C$_q$-Aryl)], 135.6, 133.5, 133.4, [129.8-126.7 (m, CH-Aryl)], [103.3, 94.4 (CH$_{anomeric}$)], 82.6, 80.2, 74.2, 74.0, 73.0, 72.5, 70.7, 68.7, 68.7, 61.7, 61.2, 45.9 (NEt$_3$), 38.9, 28.4, 28.2, 28.0, 27.1, 19.4, 8.7 (NEt$_3$).

HRMS-MALDI (m/z): [M-NEt$_3$-H]$^-$ Calcd for C$_{83}$H$_{89}$F$_{17}$O$_{16}$PSi, 1723.5386; Found, 1722.8274.

$^{31}$P NMR (162 MHz, CDCl$_3$)$\delta$ -1.44

**ASW Leishmania-phosphoglycan repeats method run**

After FSPE, the methanol elution collected in the vial was removed from the instrument and concentrated. Solvent was removed under reduced pressure to obtain the crude product (30 mg) as colorless oil. In order to obtain pure product 8 (19 mg, 10 %) for $^1$H NMR, $^{13}$C NMR and mass spectrum, further purification was performed
using prep TLC.

- 2.5 cycles (24h 56 min 39 sec) completed for the synthesis of phosphoglycan repeats.

<table>
<thead>
<tr>
<th>Step</th>
<th>Task</th>
<th>Reagent/ Operation</th>
<th>Operation Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Coupling</td>
<td>2 equivalent donor (100 µmol) in 0.5 mL Pyridine, 1 equivalent F-tagged acceptor (50 µmol) in 0.5 mL Pyridine; 1 equivalent Piv-Cl</td>
<td>2 h</td>
</tr>
<tr>
<td>2</td>
<td>Oxidation</td>
<td>I$_2$ in Pyridine/Water (0.3 mL)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Quenching</td>
<td>Na$_2$S$_2$O$_3$ (0.2 mL)</td>
<td>1 h</td>
</tr>
<tr>
<td>4</td>
<td>Evaporation</td>
<td>Add TEA and Toluene 70 °C</td>
<td>2 h</td>
</tr>
<tr>
<td>5</td>
<td>TLC sample</td>
<td>30 µl of crude reaction mixture withdrawn</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>FSPE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Deprotection</td>
<td>5 equivalent of TBAF solution in THF</td>
<td>3 h</td>
</tr>
<tr>
<td>8</td>
<td>TLC sample</td>
<td>30 µl of crude reaction mixture withdrawn</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Evaporation</td>
<td>70 °C</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>FSPE</td>
<td>0.4 ml DMF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>preparation</td>
<td>0.7 ml crude sample transferred to cartridge</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>4.7 ml 80% methanol wash</td>
<td></td>
</tr>
<tr>
<td>Step</td>
<td>Description</td>
<td>Time</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>loading</td>
<td>1.5 ml methanol wash (repeated 3 times)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wash</td>
<td>4.7 ml collected sample transferred to clean vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wash</td>
<td></td>
<td>50 °C</td>
<td></td>
</tr>
<tr>
<td>Transfer</td>
<td></td>
<td>45 min</td>
<td></td>
</tr>
<tr>
<td>Evaporation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transfer</td>
<td>2 ml toluene added</td>
<td>50 °C</td>
<td></td>
</tr>
<tr>
<td>Evaporation</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Synthesis of Phosphoglycan repeats 8.**

\( R_f (10 \text{ % MeOH in DCM}): 0.55 \).

\(^1\text{H NMR (CDCl}_3, 400 \text{ MHz}): \delta (\text{ppm}) 7.50-6.85 \text{ (m, 85H), 5.75 \text{ (m, 1H), 5.53-5.47 (m, 3 H), 5.41 (s, 1H), 5.34 (s, 1H), 5.04 (d, 1H, } J = 8 \text{ Hz), 4.90 (d, 1H, } J = 12 \text{ Hz), 4.79-4.66 \text{ (m, 11H), 4.63-4.48 \text{ (m, 12H), 4.45-4.35 \text{ (m, 8H), 4.28 (d, 2H, } J = 12 \text{ Hz), 4.19-4.06 \text{ (m, 10H), 3.98-3.80 \text{ (m, 11H), 3.76-3.67 \text{ (m, 5H), 3.63-3.53 \text{ (m, 5H), 3.41-3.31 \text{ (m, 6H), 3.12-3.09 \text{ (m, 2H), 2.15-2.03 \text{ (m, 2H), 1.84-1.81 \text{ (m, 2H), 1.23 (s, 9H), 1.10 (s, 9H), 0.98 (s, 9H), 0.87 (s, 9H).}}}}}}}}

\(^{13}\text{C NMR (CDCl}_3, 100 \text{ MHz}): \delta (\text{ppm}) [178.2, 177.5, 177.1 (C=O)], 151.0, [139.7-138.7 (C\text{\_q}-\text{Aryl})], 133.4, 133.3, [129.8-126.7 \text{ (m, CH-Aryl)}, [103.2,103.2, 103.0, 94.5, 94.3, 94.2 (CH}\text{\_anomeric]), 82.6, 82.6, 80.2, 80.2,75.9,75.1, 74.8, 73.9, 72.9, 72.7, 72.4,
72.2, 68.9, 68.7, 68.0, 66.7, 62.7, 61.6, 61.1, 59.2, 57.0, 45.9 (NEt$_3$), 39.1, 38.9, 31.6, 28.7, 27.3, 27.1, 24.3, 21.0, 19.4, 19.2, 13.9, 18.9, 8.7 (NEt$_3$).

**HRMS-MALDI (m/z):** $[M-2\text{NEt}_3-3\text{H}]^3$- Calcd for C$_{189}$H$_{210}$F$_{17}$NO$_{44}$P$_3$Si, 3641.2936; Found, 3641.3557.

$^{31}$P NMR (162 MHz, CDCl$_3$) $\delta$ -0.76, -1.24, -1.32.

![Chemical structure](image)

**Synthesis of (perfluoroctyl)propanoyloxybutenyl- hydrogen phosphonate 9.**

(Perfluoroctyl)propanoyloxybutenyl alcohol$^{25}$ (0.1 g, 0.18 mmol) and phosphonic acid (30 mg, 0.36 mmol) were coevaporated with pyridine and dried under high vacuum for 30 min. To a solution of this mixture in pyridine (5 mL) was added a solution of pivaloyl chloride (0.045 mL, 0.36 mmol) in pyridine (2 mL) and then the mixture was stirred at 25 °C for 30 min under nitrogen gas environment. Pyridine was removed under reduced vacuum and the crude product was purified by flash silica column chromatography (with triethylamine) to afford the desired product 9 (0.11 g, 82%).
**Rf (10 % MeOH in DCM): 0.7**

**1H NMR (CDCl₃, 400 MHz):** δ (ppm) 6.83 (d, 1H, Jₜₜ = 685 Hz), 5.77-5.71 (m, 1H), 5.65-5.59 (m, 1H), 4.46 (t, 1H, J = 8 Hz), 4.04 (d, 1H, J = 6 Hz), 3.45 (d, 2H, J = 6 Hz), 2.21-2.07 (m, 2H), 1.86-1.79 (m, 1H).

**Synthesis of Vinyl-O-(3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-Dmannopyranosyl)-α-D-mannopyranoside 10.**

To a solution of allyl-O-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-Dmannopyranosyl)-α-D-mannopyranoside (0.15 g, 0.08 mmol) in THF (3 mL) was added catalytic amount of (1,5-Cyclooctadiene)bis(methylidiphenylphosphine)iridium(I) hexafluorophosphate (7 mg, 0.008 mmol). The stirred solution was degassed, placed under N₂ and degassed. The reaction mixture was placed under H₂ for 1 min and degassed once more to prevent further reduction. The mixture was stirred at 25 °C for 1 h under N₂ and then
concentrated under reduced vacuum. The crude residue was purified by flash silica
column chromatography to afford the desired product 10 (0.14, 95 %).

**R_f** (ethyl acetate/hexane): 0.63 (25/75)

\[ {^1}H \text{ NMR (CDCl}_3, 400 \text{ MHz):} \delta \text{ (ppm) 7.33-7.15 (m, 30H), 6.07 (d, 1H, } J = 12 \text{ Hz), 5.54 (s, 1H), 5.12 (d, 1H, } J = 20 \text{ Hz), 5.05-5.05 (m, 1H), 4.85-4.82 (m, 2H), 4.72-4.62 (m, 5H), 4.55 (d, 2H, } J = 12 \text{ Hz), 4.48-4.43 (m, 4H), 4.39 (d, 1H, } J = 8 \text{ Hz), 4.05 (d, 1H, } J = 16 \text{ Hz), 3.96-3.89 (m, 3H) 3.84-3.66 (m, 6H), 2.12 (s, 3H), 1.49 (d, 3H, } J = 8 \text{ Hz).} \]

\[ {^{13}}C \text{ NMR (CDCl}_3, 100 \text{ MHz):} \delta \text{ (ppm) 170.3 (C=O), 142.6, [138.7, 138.6, 138.5, 138.4, 138.2 (C}_q\text{-Aryl)], [128.6-127.6 (m, CH-Aryl)], 104.8, [99.9, 98.3 (CH}_\text{anomeric}), 79.7, 78.4, 75.4, 75.3, 74.6, 73.6, 73.4, 72.4, 72.2, 69.3, 69.2, 69.0, 21.4, 12.6.} \]

**HRMS-MALDI (m/z):** [M+Na]^+Calcd for C\text{59H}_{64}\text{NaO}_{12}, 988.1220; Found, 988.3250.

To a vinyl-O-(3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-Dmannopyranosyl)-α-D-mannopyranoside 9 (0.1 g, 0.1 mmol), and mercury oxide (31 mg, 0.14 mmol) in 4 mL of acetone/H₂O (10/1) was added a solution of mercuric chloride (31 mg, 0.11 mmol) in 4 mL of acetone/H₂O (10/1) for 1 min. The reaction mixture was stirred at 25 °C for 3 h. The crude residue was filtered through celite and diluted with dichloromethane (5 mL). The organic layer was washed with sat. KI (1 x 5 mL), H₂O (1 x 5 mL) and brine (1 x 5 mL). The solvent was dried with Na₂SO₄ and concentrated under reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the hydrolyzed product (90 mg, 94%).
The hydrolyzed product (50 mg, 0.05 mmol) and triethylammonium 3-(perfluorooctyl)propanoyloxybutenyl- hydrogen phosphonate (39 mg, 0.05 mmol) were coevaporated with pyridine and dried under high vacuume for 30 min. To a solution of this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.013 mL, 0.1 mmol) in pyridine (0.5 mL) and then the mixture was stirred at 25 °C for 30 min under nitrogen gas environment. To the reaction mixture was added a solution of iodine (13 mg, 0.05) in pyridine/water mixture (0.2 mL, 10/1) and the reaction mixture was quenched with saturated Na$_2$S$_2$O$_3$. Excess pyridine was evaporated under reduced pressure and then the crude product was purified by flash silica column chromatography (with triethylamine) to afford the desired product **10-1** (67 mg, 82 %).

R$_f$ (**10 % MeOH in DCM**): 0.65

$^1$H NMR (CDCl$_3$, 400 MHz): $\delta$ (ppm) 7.28-7.06 (m, 30H), 5.66-5.61 (m, 1H), 5.57-5.54 (m, 1H), 5.50 (s, 1H), 5.05 (s, 1H), 4.78 (t, 1H, $J = 10.4$ Hz), 4.68 (d, 1H, $J = 12$ Hz), 4.63-4.61 (m, 3H), 4.54 (d, 1H, $J = 16$ Hz), 4.47-4.34 (m, 7H), 4.02 (br, 1H), 3.94-3.89 (m, 6H), 3.86 (d, 1H, $J = 12$ Hz), 3.79-3.72 (m, 2H), 3.65 (d, 1H, $J = 12$ Hz), 3.59 (br, 2H), 3.40 (br, 1H), 3.34 (t, 2H, $J = 8$ Hz), 2.14-2.02 (m, 2H), 2.08 (s, 3H), 1.79-1.72 (m, 2H).
$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 170.2 (C=O), [138.4, 138.4, 138.2, 138.0, 138.0 (C$_q$-Aryl)], [128.5-127.4 (m, CH-Aryl)], [99.7, 95.0 (CH$_{anomeric}$)], 79.2, 78.1, 75.2, 75.1, 74.1, 73.2, 72.8, 72.2, 72.0, 71.9, 68.9, 68.8, 68.7, 68.4, 66.5, 61.8, 28.1, 27.9, 27.5, 21.0.

$^{31}$P NMR (162 MHz, CDCl$_3$): $\delta$ -3.84

HRMS-MALDI (m/z): [M-NEt$_3$] Calcd for C$_{71}$H$_{72}$F$_{17}$O$_{16}$P, 1535.2684; Found, 1535.4162.


To a solution of allyl-O-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-
D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-annopyranoside (0.11 g, 0.08 mmol) in THF (3 mL) was added catalytic amount of (1,5-Cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (3 mg, 0.004 mmol). The stirred solution was degassed, placed under N\textsubscript{2} and degassed. The reaction mixture was placed under H\textsubscript{2} for 5 min and degassed once more to prevent further reduction. The mixture was stirred at 25 °C for 30 min under N\textsubscript{2} and then concentrated under reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the desired product \textbf{11} (0.103 g, 94 %).

\textbf{R}\textsubscript{f} (ethyl acetate/haxane): 0.70 (25/75)

\textsuperscript{1}H NMR (CDCl\textsubscript{3}, 400 MHz): δ (ppm) 7.33-7.14 (m, 45H), 6.05 (d, 1H, \textit{J} = 12 Hz), 5.54 (s, 1H), 5.19 (d, 1H, \textit{J} = 8 Hz), 5.06-5.05 (m, 1H), 5.03 (s, 1H), 4.85 (d, 1H, \textit{J} = 12 Hz), 4.70-4.50 (m, 14H), 4.45-4.41 (m, 3H), 4.32 (d, 1H, \textit{J} = 12 v), 4.09 (br, 1H), 4.01-3.89 (m, 9H), 3.83-3.81 (m, 2H), 3.73-3.64 (m, 6H), 3.54 (d, 1H, \textit{J} = 12 Hz), 2.13 (s, 3H), 1.47 (d, 3H, \textit{J} = 4 Hz).

\textsuperscript{13}C NMR (CDCl\textsubscript{3}, 100 MHz): δ (ppm) 170.3 (C=O), 142.2, [138.8, 138.7, 138.6, 138.6, 138.5, 138.4, 138.2 (C\textsubscript{q}-Aryl)], [128.6-127.6 (m, CH-Aryl)], 104.6, [100.9, 99.6, 98.3 (CH\textsubscript{anomeric})], 79.4, 78.3, 75.4, 75.3, 75.2, 74.9, 74.7, 74.5, 73.6,
73.5, 73.4, 72.5, 72.3, 72.1, 69.8, 69.3, 69.1, 69.0, 21.4, 12.6.

**HRMS-MALDI (m/z):** $[\text{M+Na}^+]$ Calcd for $\text{C}_{86}\text{H}_{92}\text{NaO}_{17}$ 1420.6302; Found, 1420.4338.


To a vinyl-O-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranosyl [α-D-mannopyranoside 11 (0.1 g, 0.07 mmol), and mercury oxide (22 mg, 0.1 mmol) in 3 mL of acetone/H$_2$O (10/1) was added a solution of mercuric chloride (21 mg, 0.08 mmol) in 3 mL of
acetone/H₂O (10/1) for 1 min. The reaction mixture was stirred at 25 °C for 4 h. The crude residue was filtered through celite and diluted with dichloromethane (5 mL). The organic layer was washed with sat. KI (1 x 5 mL), H₂O (1 x 5 mL) and brine (1 x 5 mL). The solvent was dried with Na₂SO₄ and concentrated under reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the hydrolyzed product (92 mg, 95 %).

The hydrolyzed product (50 mg, 0.04 mmol) and triethylammonium 3-(perfluoroctyl)propanyloxybutenyl- hydrogen phosphonate (26 mg, 0.04 mmol) were coevaporated with pyridine and dried under high vacuum for 30 min. To a solution of this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.009 mL, 0.08 mmol) in pyridine (0.3 mL) and then the mixture was stirred at 25 °C for 30 min under nitrogen gas environment. To a solution of this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.013 mL, 0.1 mmol) in pyridine (0.5 mL) and then the mixture was stirred at 25 °C for 30 min under nitrogen gas environment. To the reaction mixture was added a solution of iodine (9 mg, 0.04) in pyridine/water mixture (0.2 mL, 10/1) and the reaction mixture was quenched with saturated Na₂S₂O₃. Excess pyridine was evaporated under reduced pressure and then the crude
product was purified by flash silica column chromatography (with triethylamine) to afford the desired product 11-1 (62 mg, 81%).

\begin{align*}
\textbf{R}_f (10 \% \text{ MeOH in DCM}) & : 0.68 \\
^{1}H \text{ NMR (CDCl}_3, 400 \text{ MHz}) & : \delta (\text{ppm}) 7.26-7.09 (m, 45H), 5.64-5.58 (m, 1H), 5.54-5.46 (m, 3H), 5.19 (s, 1H), 5.05 (s, 1H), 4.79 (d, 1H, J = 8 \text{ Hz}), 4.76 (d, 1H, J = 8 \text{ Hz}), 4.67 (d, 1H, J = 12 \text{ Hz}), 4.61 (d, 1H, J = 8 \text{ Hz}), 4.56 (d, 1H, J = 4), 4.53-4.50 (m, 4H), 4.47-4.44 (m, 4H), 4.39-4.32 (m, 4H), 4.25 (d, 1H, J = 12 \text{ Hz}), 4.10 (d, 1H, J = 28 \text{ Hz}), 3.95-3.85 (m, 9H), 3.81 (d, 1H, J = 8 \text{ Hz}), 3.74-3.69 (m, 2H), 3.65-3.56 (m, 4H), 3.44 (d, 1H, J = 8 \text{ Hz}), 3.39 (t, 1H, J = 4 \text{ Hz}), 3.30 (t, 2H, J = 8 \text{ Hz}), 2.12-1.99 (m, 2H), 2.09 (s, 3H), 1.76-1.69 (2H).
\end{align*}

\begin{align*}
^{13}C \text{ NMR (CDCl}_3, 100 \text{ MHz}) & : \delta (\text{ppm}) 170.3 (\text{C=O}), [138.4, 138.2, 138.2, 138.1, 138.1, 138.0, 137.9, 137.8 (Cq-Aryl)], [128.4-127.4 (m, CH-Aryl)], [100.2, 99.2, 95.1 (CH anomeric)], 79.1, 78.2, 75.1, 75.1, 74.5, 74.4, 74.3, 74.2, 74.1, 73.4, 73.2, 72.7, 72.5, 72.1, 72.1, 71.9, 71.8, 69.0, 68.7, 68.5, 61.7, 61.6, 49.2, 46.3 (\text{NEt}_3), 28.1, 27.8, 27.6, 21.1, 8.6 (\text{NEt}_3).
\end{align*}

\begin{align*}
^{31}P \text{ NMR (162 MHz, CDCl}_3) & : \delta -3.36
\end{align*}

\begin{align*}
\text{HRMS-MALDI (m/z)} & : [\text{M-NEt}_3] \text{ Calcd for } C_{98}H_{100}F_{17}O_{21}P 1967.7766; \text{ Found,}
\end{align*}
Synthesis of Vinyl-O-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-β-D-mannopyranoside 12.

To a solution of vinyl O-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-(1-4)-2-O-hydroxy-3,6-di-O-benzyl-β-D-mannopyranoside$^{24}$ (0.2 mg, 0.2 mmol) and 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl tricholoroacetimidate (0.15 g, 0.22 mmol) in dry toluene (5 mL) was added TMSOTf (3 µL, 0.02 mmol) at 25 °C. The reaction mixture was stirred at 25 °C for 10 min. The reaction was quenched with triethylamine (0.1 mL) and concentrated under reduced pressure. The crude product was purified by flash silica column chromatography to afford the desired product 12 (0.27 g, 89%).

$R_f$ (ethyl acetate/haxane): 0.63 (25/75)

$^1$H NMR (CDCl$_3$, 400 MHz): δ (ppm) 7.31-7.14 (m, 45H), 6.22 (d, 1H, $J = 8$ Hz),
5.59 (s, 1H), 5.15 (s, 1H), 5.03-4.98 (m 1H), 4.91-4.79 (m, 4H), 4.72-4.62 (m, 8H), 4.54-4.30 (m, 11H), 4.23 (d, 1H, J = 12 Hz), 4.12 (t, 1H, J = 8 Hz), 4.05 (dd, 1H, J = 8, 4 Hz), 3.91-3.88 (m, 4H), 3.83 (dd, 1H, J = 8, 4 Hz), 3.75-3.69 (m, 3H), 3.66-3.45 (m, 6H), 3.40-3.36 (m, 2H), 2.04 (s, 3H), 1.56 (dd, 3H, J = 16, 8 Hz).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 170.0 (C=O), 144.0, [139.3, 139.2, 139.0, 139.0, 138.9, 138.7, 138.6 138.4 (C$_q$-Aryl)], [128.6-127.1 (m, CH-Aryl)], 104.1, [103.5, 99.9, 98.8 (CH$_{ anomeric}$)], 82.9, 80.2, 79.9, 78.9, 76.2, 75.5, 75.1, 74.8, 74.6, 73.7, 73.6, 73.4, 73.1, 72.7, 72.3, 71.7, 69.4, 69.2, 68.9, 68.4, 21.4, 12.7.

HRMS-MALDI (m/z): [M]$^+$Calcd for C$_{86}$H$_{92}$O$_{17}$, 1397.6405; Found, 1397.3901.

![Diagrams of molecular structures]

Synthesis of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-\(\beta\)-D-galactopyranosyl]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl]-\(\alpha\)-D-mannopyranosyl phosphate 12-1.
To a vinyl-\(O\)-3,6-di-\(O\)-benzyl-4-\(O\)-[2,3,4,6-tetra-\(O\)-benzyl-\(\beta\)-D-galactopyranosyl]-2-\(O\)-[2-\(O\)-acetyl-3,4,6-tri-\(O\)-benzyl-\(\alpha\)-D-mannopyranosyl]-\(\alpha\)-D-mannopyranoside 11 (0.1 g, 0.07 mmol), and mercury oxide (22 mg, 0.01 mmol) in 5 mL of acetone/H\(2\)\(O\) (10/1) was added a solution of mercuric chloride (21 mg, 0.08 mmol) in 5 mL of acetone/H\(2\)\(O\) (10/1) for 1 min. The reaction mixture was stirred at 25 °C for 3 h. The crude residue was filtered through celite and diluted with dichloromethane (5 mL). The organic layer was washed with sat. KI (1 x 5 mL), H\(2\)\(O\) (1 x 5 mL) and brine (1 x 5 mL). The solvent was dried with Na\(2\)SO\(4\) and concentrated under reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the hydrolyzed product (85 mg, 88 %).

The hydrolyzed product (50 mg, 0.04 mmol) and triethylammonium 3-(perfluorooctyl)propanyloxybutenyl- hydrogen phosphonate (26 mg, 0.04 mmol) were coevaporated with pyridine and dried under high vacuum for 30 min. To a solution of this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.009 mL, 0.08 mmol) in pyridine (0.3 mL) and then the mixture was stirred at 25 °C for 30 min under nitrogen gas environment. To a solution of this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.013 mL, 0.1 mmol) in pyridine (0.5 mL) and
then the mixture was stirred at 25 °C for 30 min under nitrogen gas environment. To the reaction mixture was added a solution of iodine (9 mg, 0.04) in pyridine/water mixture (0.2 mL, 10/1) and the reaction mixture was quenched with saturated Na₂S₂O₃. Excess pyridine was evaporated under reduced pressure and then the crude product was purified by flash silica column chromatography (with triethylamine) to afford the desired product 12-1 (63 mg, 83%).

**Rₚ (10 % MeOH in DCM):** 0.68

**¹H NMR (CDCl₃, 400 MHz):** δ (ppm) 7.26-7.14 (m, 45H), 5.66-5.64 (m, 1H), 5.56-5.45 (m, 3H), 5.09 (d, 1H, J = < 1 Hz), 4.97 (d, 1H, J = 12), 4.76 (d, 1H, J = 12 Hz), 4.76 (d, 1H, J = 12 Hz), 4.67-4.56 (m, 5H), 4.52-4.35 (m, 8H), 4.31-4.24 (m, 4H), 4.17 (d, 1H, J = 8 Hz), 4.12 (t, 1H, J = 8 Hz), 4.03 (br, 1H), 3.94 (m, 8H), 3.74-3.60 (m, 5H), 3.51 (t, 1H, J = 8 Hz), 3.40-3.37 (m, 3H), 3.33 (t, 2H, J = 8 Hz), 2.15-2.06 (m, 2H), 2.01 (s, 3H), 1.79-1.72 (m, 2H).

**¹³C NMR (CDCl₃, 100 MHz):** δ (ppm) 169.8 (C=O), [139.1, 139.0, 138.8, 138.4, 138.3, 138.1, 138.1, 138.0, 137.9 (C_q-Aryl)], [128.3-127.0 (m, CH-Aryl)], [103.2, 99.6, 95.0 (CH_anomer)]; 82.0, 79.9, 78.4, 75.9, 75.2, 74.6, 74.0, 73.3, 73.2, 73.0, 72.7, 72.4, 71.9, 71.8, 68.7, 66.5, 61.8, 61.7, 46.2, 28.1, 27.7, 27.1, 21.0.
\(^{31}\)P NMR (162 MHz, CDCl\(_3\)): \(\delta\) -2.99

HRMS-MALDI (m/z): [M-NE\(_3\)] Calcd for C\(_{99}\)H\(_{100}\)F\(_17\)O\(_{21}\)P 1967.7766; Found, 1967.3716.


To a solution of allyl-O-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-\(\beta\)-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl)-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl]-\(\alpha\)-D-mannopyranoside (0.2 g, 0.11 mmol) in THF (5 mL) was added catalytic amount of (1,5-Cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate (10 mg,
0.011 mmol). The stirred solution was degassed, placed under N\textsubscript{2} and degassed. The reaction mixture was placed under H\textsubscript{2} for 5 min and degassed once more to prevent further reduction. The mixture was stirred at 25 °C for 30 min under N\textsubscript{2} and then concentrated under reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the desired product 13 (0.19 g, 93 %).

\textbf{R}_{f} (ethyl acetate/hexane): 0.70 (25/75)

\textbf{\textsuperscript{1}H NMR (CDCl\textsubscript{3}, 400 MHz):} \delta (ppm) 7.30-7.16 (m, 60H), 6.18 (d, 1H, \textit{J} =12 Hz), 5.50 (s, 1H), 5.17 (s, 1H), 5.02-4.98 (m 1H), 4.93 (t, 2H, \textit{J} = 6.4 Hz), 4.81 (t, 2H, \textit{J} = 10.4 Hz), 4.74 (br, 2H), 4.66-4.65 (m, 4H), 4.63 (d, 1H, \textit{J} = 10.4 Hz), 4.58 (d, 1H, \textit{J} = 11.2 Hz), 4.51-4.40 (m, 7H), 4.35 (d, 1H, \textit{J} = 10.8 Hz), 4.27-4.25 (m, 2H), 4.21-4.18 (m, 2H), 4.06 (t, 1H, \textit{J} = 8 Hz), 4.01-3.90 (m, 7H), 3.86 (d, 2H, \textit{J} = 9.2 Hz), 3.80-3.71 (m, 3H), 3.66 (d, 1H, \textit{J} = 10.4 Hz), 3.61-3.48 (m, 6H), 3.45 (dd, 1H, \textit{J} = 7.2, 2 v), 3.38 (d, 2H, \textit{J} = 4.4 Hz), 2.07 (s, 3H), 1.51 (d, 3H, \textit{J} = 6.8 Hz).

\textbf{\textsuperscript{13}C NMR (CDCl\textsubscript{3}, 100 MHz):} \delta (ppm) 170.2 (C=O), 144.0, [139.1, 139.1, 138.9, 138.9, 138.8, 138.8, 138.6, 138.3, 138.2 (C\textsubscript{q}-Aryl)], [128.5-127.3 (m, CH-Aryl)], 103.9, [103.0, 100.4, 99.6, 98.7 (CH\textsubscript{anomeric})], 80.0, 79.7, 79.2, 78.4, 75.8, 75.4, 75.1, 74.9, 74.6, 74.6, 73.5, 73.4, 73.3, 73.0, 72.9, 72.8, 72.2, 72.1, 72.1, 69.5, 69.4, 69.3,
69.1, 68.5, 21.4, 12.6.

**HRMS-MALDI (m/z):** \([M]^+\) Calcd for C\(_{113}H_{120}O_{22}\), 1828.8271; Found, 1828.4955.

![Diagram of molecular structure]

**Synthesis of 3-(perfluoroctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-\(\beta\)-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl)-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl]-\(\alpha\)-D-mannopyranosyl phosphate 13-1.**

To a vinyl-\(O\)-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-\(\beta\)-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl)-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl]-\(\alpha\)-D-mannopyranosyl phosphate 13-1 (0.1 g, 0.06 mmol), and mercury oxide (17 mg, 0.14 mmol) in 4 mL of acetone/H\(_2\)O (10/1) was added a solution of mercuric
chloride (16 mg, 0.06 mmol) in 3 mL of acetone/H$_2$O (10/1) for 1 min. The reaction mixture was stirred at 25 °C for 3 h. The crude residue was filtered through celite and diluted with dichloromethane (5 mL). The organic layer was washed with sat. KI (1 x 5 mL), H$_2$O (1 x 5 mL) and brine (1 x 5 mL). The solvent was dried with Na$_2$SO$_4$ and concentrated under reduced vacuum. The crude residue was purified by flash silica column chromatography to afford the hydrolyzed product (82 mg, 84%).

The hydrolyzed product (50 mg, 0.03 mmol) and triethylammonium 3-(perfluoroctyl)propanyloxybutenyl- hydrogen phosphonate (20 mg, 0.03 mmol) were coevaporated with pyridine and dried under high vacuum for 30 min. To a solution of this mixture in pyridine (3 mL) was added a solution of pivaloyl chloride (0.007 mL, 0.06 mmol) in pyridine (0.3 mL) and then the mixture was stirred at 25 °C for 30 min under nitrogen gas environment. Prydine was removed under reduced vacuum and the crude product was purified by flash silica column chromatography (with triethyamine) to afford the desired product 13-1 (59 mg, 84%).

$R_f$ (10 % MeOH in DCM): 0.69

$^1$H NMR (CDCl$_3$, 400 MHz): δ (ppm) 7.26-7.05 (m, 60H), 5.64-5.59 (m, 1H), 5.53-5.45 (m, 3H), 5.13 (d, 1H$_{anomeric}$, $J = < 1$ Hz), 4.91 (d, 1H, $J = 12$ Hz), 4.79 (d, 1H, $J =$
8 Hz), 4.74 (d, 1H, J = 8 Hz), 4.67-4.57 (m, 5H), 4.54-4.36 (m, 11H), 4.29 (t, 2H, J = 12 Hz), 4.23 (d, 1H, J = 8 Hz), 4.20 (d, 1H, J = 8 Hz), 4.14 (d, 1H, J = 12 Hz), 4.09-4.05 (m, 2H), 4.00-3.94 (m, 2H), 3.90-3.78 (m, 11H), 3.73-3.52 (m, 6H), 3.41 (d, 2H, J = 12 Hz), 3.34-3.27 (m, 4H), 2.12 (m, 2H), 2.03 (s, 3H), 1.76-1.69 (m, 2H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 170.1 (C=O), [139.1, 139.0, 138.7, 138.5, 138.4, 138.2, 138.1, 138.0, 138.0, 138.0 (C$_q$-Aryl)], [128.3-127.0 (m, CH-Aryl)], [103.2, 100.8, 99.3, 95.0 (CH$_{anomeric}$)], 82.6, 79.9, 79.6, 75.2, 75.1, 74.7, 74.3, 74.1, 73.2, 73.1, 73.0, 72.6, 72.5, 72.0, 71.9, 71.8, 68.7, 68.7, 68.5, 68.1, 66.4, 61.7, 61.7, 49.5, 46.2 (NEt$_3$), 28.1, 27.9, 27.7, 21.1, 8.6 (NEt$_3$).

$^{31}$P NMR (162 MHz, CDCl$_3$): $\delta$ -2.39

HRMS-MALDI (m/z): [M-NEt$_3$] Calcd for C$_{125}$H$_{128}$F$_{17}$O$_{26}$P 2400.2848; Found, 2400.7329.

References


24 Chapter 3 in thesis.

CHAPTER 5

Synthesis of multivalent tuberculosis and Leishmania-associated capping carbohydrates and evaluation of structure-dependent immune responses in IL-12 production

A paper to be submitted to Journal of the American Chemical Society

Eun-Ho Song, Alex O. Osanya, Christine A. Petersen, and Nicola L. Pohl

Microbacterium tuberculosis is an intracellular pathogen which survives in macrophages and remains as one of the severe infectious diseases due to large number of infections with more than 2 million deaths annually worldwide.\(^1\) Leishmaniasis is also an infectious disease caused by protozoan parasites of the genus Leishmania. Leishmaniasis is endemic over much of 88 countries in Africa, India, southern Europe, and Central and South America.\(^2\) Importantly, \(M.\) tuberculosis\(^3\) and leishmaniasis\(^4\) are particularly problematic in these areas as a reactivating infection in AIDS patients. Despite considerable progress devoted to preventing and controlling tuberculosis and leishmaniasis, the disease still remains beyond efficient medical treatments such as vaccines. Therapies, including vaccines, have to deal with the parasites’ ability to hide
in human macrophage cells—the white blood cells that usually engulf and eliminate foreign materials. Herein we present the synthesis and development of new chemical tools which demonstrates that only simple changes in parasite-associated surface oligosaccharides are sufficient to change cellular immune responses and thereby let a parasite hide from immune surveillance.

The most abundant molecules found on the cell surfaces of bacteria, parasites and viruses are carbohydrates.\(^5\) Due to structural distinctions among host cells and the distribution of carbohydrates on the outer surface of the cell, structure-function relationships involving carbohydrates have drawn attention amongst both synthetic organic chemists and immunologists. However, obtaining well-defined carbohydrate structures has been challenging due to limitations associated with current isolation protocols.\(^6\) Simple commercially available sugars can be readily attached to beads for the identification of monosaccharide-dependent immunity\(^7\); however, these protocols do not lend themselves readily to larger structurally well-defined oligosaccharides.
Figure 1. Capping structure in lipoarabinomannan (LAM) of *M. tuberculosis* and lipophosphoglycan (LPG) of *Leishmania*.

As shown in Figure 1, trimannose is one of the major components both in LPG of *Leishmania* parasites\(^8\) and LAM of *M. tuberculosis* cell wall.\(^9\) To date, several synthetic approaches have been reported to construct *Leishmania* capping structures including oligomannose\(^10\) and branched oligosaccharide\(^11\) for the purpose of synthetic challenge or vaccine development\(^12\). We wanted to develop a viable route to a range of *Leishmania* capping structures including trimannose and lactose as a control.

With this purpose, we envisioned making essentially artificial parasites of the same size (one micron) as *Leishmania* that contain only the structurally well-defined
capping polysaccharide associated with pathogens. The key challenge in the synthesis of artificial pathogens is construction of multivalent effect on latex beads in order to give more chance to induce immune responses.

**Results and discussion**

Trimannose can be prepared fluorous solid-phase extraction (FSPE)-based iterative synthesis as reported in literature\(^\text{10}\) (Scheme 1). Mannose trichloroacetimidate \(\textbf{1}\) was prepared from tri-\(O\)-benzyl orthoester intermediate\(^\text{13}\). Acid (TMSOTf)-activated glycosylation of mannose trichloroacetimidate with fluorous-tag gave fluorous-tagged disaccharide for further iterative synthesis of capping structures. This iterative synthesis using fluorous-solid-phase extraction (FSPE) takes advantage of the fact that desired oligosaccharide can be prepared without conventional silica-column purification.\(^\text{14}\) The fluorous-tag in trimannose \(\textbf{2}\) was then cleaved with ozonolysis and subsequent oxidation with Jones reagent facilitates further coupling reaction of carboxylated-sugar with amine-functionalized beads. Global deprotection under \(\text{Na/NH}_3\) at \(-78\, ^{\circ}\text{C}\) furnished fully deprotected trimannose \(\textbf{4}\) in good yield.

Carboxylated-lactose was also efficiently prepared through conventional silica-
column purification. (see Supporting information)

With the capping sugar and the control sugar lactose in hand, a suitable one micron-sized support was required for multivalent display of these sugars. Latex beads are commonly used in immunoassays due to their inertness and commercial availability. Moreover, beads with high concentrations of imbedded fluorophores enable various fluorescent assays. For example, such beads have been utilized for agglutination tests for the detection of antibodies or investigation of heparin-binding properties, for the analysis of blood cell populations, for the identification of specific cell membrane markers and for the measurement of sugar particle-induced immunity.
Scheme 1. Synthesis of multivalent tuberculosis and *Leishmania* capping structures on latex beads.

In this regard, we used commercially available Latex beads B0 (microspheres, 1µm diameter and yellow-green fluorescent) derivatized with carboxylate groups (3.5 x 10^-4 mmol carboxylate groups per mL). The chosen size of FITC-labeled latex beads mimics the size of the *Leishmania* parasite and allows use of a common immunofluorescent assay for the observation of the possible uptake of beads by macrophages. In order to avoid spatial proximity of sugars on the surface of the beads and improve the accessibility of sugars to possible macrophage binding partners, ethylenediamine as a spacer was attached to the carboxylated bead surface under standard peptide coupling conditions. Unfortunately, solvents for the coupling reaction were severely limited due to difficulties associated with the stability of the apparently noncovalent FITC linkage in organic solvents. Therefore, the choice of suitable solvent was an important consideration for both obtaining quantitative yield in coupling reaction and designing synthetic routes for sugars. Combined condition for coupling using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
(EDC) and N-hydroxysuccinimide (NHS)\textsuperscript{20} in deionized water was utilized to make peptide linkages (Scheme 2).

The subsequent coupling reaction of various capping structures containing the carboxylic acid linker with amine spacer on the beads gave \textit{Leishmania}-associated capping carbohydrate coated-beads (Figure 1). Each coupling step was repeated twice with 30 ~ 50 equivalent of sugars to obtain a complete reaction. The density of sugar was calculated by given density of carboxylates (1.296 x 10\textsuperscript{-14} mmol / bead). As for coupling steps, Kaiser colorimetric test was used as an indicator of coupling reaction progress.\textsuperscript{21}

To evaluate structure-dependent immune responses, lactose coated beads B\textsubscript{1} and trimannose-coated beads B\textsubscript{2} were initially incubated with murine macrophages for the analysis of cytokine production including Interleukin-12 (IL-12).\textsuperscript{22} IL-12 plays a significant role in the link between innate and adaptive immunity
**Figure 2.** Effect of cap sugar coated-latex beads (B0 = latex bead, B1 = lactose coated beads, and B2 = trimannose-coated beads) on the production of IL-12p40 by murine macrophage cell line (J774) (mφ) stimulated by LPS and IFNγ. [Asterisks denote a significant change between the TLR2 blocking from control isotype and/or non-blocking-stimulation only treated cells (p<0.05) via Student’s *t*-
As shown in Figure 2, comparable levels of IL12-p40 under two different environments including no blocking agents and isotype IgG1 antibody were produced when murine macrophages were stimulated by lactose-coated beads, whereas IL12 production stimulated by trimannose-coated beads was significantly diminished. These results indicate that structure differences in carbohydrates exhibit clear differences in the activation of innate immune responses induced by only differences in the carbohydrate structure.

In order to obtain more information about structure-dependent immune responses, other capping structures were also efficiently prepared through conventional silica-column purification for galactose\textsuperscript{23} or FSPE-based purification for dimannose\textsuperscript{7}, branched tri-and tetrasaccharide.\textsuperscript{24}
Scheme 2. Iterative synthesis of fluorous-tagged *Leishmania* tetrasaccharide

Branched *Leishmania* capping structures including trisaccharide 3 and tetrasaccharide 4 was also prepared either through iterative synthesis or automation platform. The fluorous-tag in tetrasaccharide was then cleaved with ozonolysis and subsequent oxidation with Jones reagent facilitates further coupling reaction of carboxylated-sugar with amine-functionalized beads. Global deprotection under Na/NH$_3$ at $-78 \, ^\circ$C furnished fully deprotected saccharides (3-2 and 4-2) in good yield (Scheme 3).

Other capping structures were also efficiently prepared through conventional silica-column purification for galactose 5 or FSPE-based purification for dimannose 6.

Carboxylated-*Leishmania* capping structures were then displayed on the latex beads under optimized coupling conditions (Figure 3).
**Conclusion**

In conclusion, we demonstrated that the protocol of preparation of artificial parasites including well defined tuberculosis and *Leishmania*-associated capping structures such as trimannose and lactose enabled the study of structure-dependent immune responses. In particular, fluorous phase-based iterative synthesis provides not only a convenient purification step but also an easy transformation to carboxylic acid in order to display capping structures on the latex beads surface.
More importantly, our results with preliminary IL-12 production studies showed that structure differences in carbohydrates produced a distinct differences in IL-12 p40 producton.

These results could provide a standard strategy for unveiling innate immune mechanisms induced by specific carbohydrate structure

**Experimental section**

**General methods**

Solvents were reagent grade and in most cases dried prior to use. All other commercially available reagents were used as received unless otherwise noted. The organic extracts were dried over anhydrous MgSO$_4$. Tetrahydrofuran (THF) was distilled from lithium aluminum hydride (LiAlH$_4$) prior to use. Methylene chloride (CH$_2$Cl$_2$), and triethylamine (Et$_3$N) were distilled from calcium hydride. Diethyl ether (Et$_2$O) was distilled from sodium-benzophenone ketyl.

$^1$H and $^{13}$C NMR spectra were obtained at 400 MHz and 100 MHz on Varian VXR-400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosytems
QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per million downfield relative to tetramethylsilane (δ 0.00) and coupling constants are reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.

Synthesis of Fully deprotected carboxylated-\textit{Leishmania} capping structures.

\[
\begin{align*}
\text{Synthesis of Carboxymethyl-4-O-[2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyl]-2,3,6-tri-O-acetyl-\beta-D-galactopyranoside 1.}
\end{align*}
\]

To a solution of 2-propynyl-4-O-[2,3,4,6-tetra-O-acetyl-\beta-D-glucopyranosyl] -2,3,6- tri-O-acetyl-\beta-D-galacto-pyranoside\textsuperscript{25} (0.5 g, 0.7 mmol) in the mixture of CCl\textsubscript{4} (3 mL), CH\textsubscript{3}CN (3 mL), and H\textsubscript{2}O (4 mL) is added NaIO\textsubscript{4} (1.27 g, 5.6 mmol). To this mixture was added RuCl\textsubscript{3}.H\textsubscript{2}O (3.1 mg, 2.2 mol %) and the reaction mixture was stirred at 25 °C for 2 h. After dilution with 10 mL of DCM, the reaction mixture was filtered through a Celite pad. The aqueous layer was extracted with twice with DCM and then organic layer was washed with water and brine. The crude mixture was
obtained after drying with Na$_2$SO$_4$ followed by concentration under reduced vacuum.

The crude product was purified to obtain the desired product 1 (0.47 g, 91 %) by silica column chromatography

$R_f$ (ethyl acetate/haxane): 0.30 (70/30)

$^1$H NMR (CDCl$_3$, 400 MHz): $\delta$ (ppm) 5.34 (d, 1H, $J = 2.4$ Hz), 5.22 (t, 1H, $J = 9.2$ Hz), 5.09 (t, 1H, $J = 8$ Hz), 4.97-4.93 (m, 2H), 4.62 (d, 1H, $J = 7.6$ Hz), 4.50-4.47 (m, 2H), 4.29 (s, 2H), 4.11-4.04 (m, 3H), 3.87 (t, 1H, $J = 6.4$ Hz), 3.80 (t, 1H, $J = 9.2$ Hz), 3.65-3.61 (m, 1H), 2.14 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.03 (s, 3H), 1.93 (s, 3H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 170.6, 170.6, 170.3, 170.3, 170.1, 169.9, 169.2, [101.2, 100.4 (CH$_{\text{anomeric}}$)], 76.2, 73.1, 72.5, 71.4, 71.1, 70.9, 69.2, 66.8, 65.5, 61.9, 61.0, 21.0, 21.0, 20.9, 20.9, 2.08, 20.7.

HRMS-MALDI (m/z): [M+Na]$^+$ Calcd for C$_{28}$H$_{38}$NaO$_{20}$, 717.5791; Found, 717.6184.

Synthesis of Carboxymethyl-4-O-(β-D-galactopyranosyl)-β-D-glucopyranoside

2.
To a carboxymethyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl]-2,3,6-tri-O-acetyl-β-D-galactopyranoside (1) (0.4 g, 0.57 mmol) in MeOH (5 mL) was added Na (27 mg, 1.14 mmol) and stirred at 25 °C for 2 h. The reaction mixture was neutralized with Dowex-ion-exchange resin. The desired (2) was obtained through Celite filtration followed by evaporation of solvent under reduced pressure in good yield (0.21 g, 89%).

\(^1\text{H} \text{NMR (CDCl}_3, \text{ 400 MHz)}: \delta (\text{ppm}) 4.46 (d, 1H, \text{ } J = 16.4 \text{ Hz}), 4.30-4.23 (m, 2H), 3.81 (d, 1H, \text{ } J = 3.2 \text{ Hz}).

\(^{13}\text{C} \text{NMR (CDCl}_3, \text{ 100 MHz):} \delta (\text{ppm}) 173.0, 170.8, 170.5, 17.4, 170.2, 100.4 (\text{CH}_{\text{anomeric}}), 71.1, 70.7, 68.6, 67.1, 65.0, 61.4, 21.0, 20.9, 20.8, 20.8.

HRMS-EI (m/z): [M+Na]^{+}\text{Calcd for C}_{14}\text{H}_{24}\text{NaO}_{13}, 423.1115; \text{Found, 423.0942.}

Synthesis of Carboxymethyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 3.

To a solution of 2-propynyl-2,3,6-tri-O-acetyl-β-D-galacto-pyranoside\textsuperscript{20} (0.5 g, 1.29 mmol) in the mixture of CCl\textsubscript{4} (3 mL), CH\textsubscript{3}CN (3 mL), and H\textsubscript{2}O (4 mL) is added
NaIO₄ (2.2 g, 10.3 mmol). To this mixture was added RuCl₃·H2O (6 mg, 2.2 mol %) and the reaction mixture was stirred at 25 °C for 2 h. After dilution with 10 mL of DCM, the reaction mixture was filtered through a Celite pad. The aqueous layer was extracted with twice with DCM and then organic layer was washed with water and brine. The crude mixture was obtained after drying with Na₂SO₄ followed by concentration under reduced vacuum. The crude product was purified to obtain the desired product (3) (0.42 g, 81 %) by silica column chromatography.

**Rf** (ethyl acetate/hexane): 0.25 (70/30)

**¹H NMR (CDCl₃, 400 MHz):** δ (ppm) 5.41 (d, 1H, J = 2.8 Hz), 5.25 (dd, 1H, J = 7.9, 2.5 Hz), 5.06 (dd, 1H, J = 10.4, 3.3 Hz), 4.62 (d, 1H, J = 7.9), 4.36 (s, 2H), 4.20-4.09 (m, 2H), 3.94 (t, 1H, J = 6.7 Hz), 2.16 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H).

**¹³C NMR (CDCl₃, 100 MHz):** δ (ppm) 173.0, 170.8, 170.5, 170.4, 170.2, 100.4 (CHanomeric), 71.1, 70.7, 68.6, 67.1, 65.0, 61.4, 21.0, 20.9, 20.8, 20.8.

**HRMS-MALDI (m/z):** [M+Na]^⁺ Calcd for C_{16}H_{22}NaO_{12}, 429.1009; Found,
Synthesis of Carboxymethyl-β-D-galactopyranoside 4.

To a carboxymethyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (3) (0.4 g, 0.99 mmol) in MeOH (5 mL) was added Na (45 mg, 1.98 mmol) and stirred at 25 °C for 2 h. The reaction mixture was neutralized with Dowex-ion-exchange resin. The desired product (4) was obtained through Celite filtration followed by evaporation of solvent under reduced pressure in good yield (0.21 g, 89 %).

$^1$H NMR (CD$_3$OD, 400 MHz): δ (ppm) 4.46 (d, 1H, $J = 16.4$ Hz), 4.30-4.23 (m, 2H), 3.81 (d, 1H, $J = 3.2$ Hz), 3.75-3.68 (m, 2H), 3.60-3.53 (m, 1H), 3.51-3.47 (m, 2H).

$^{13}$C NMR (CD$_3$OD, 100 MHz): δ (ppm) 173.1, 103.4 (CH$_{\text{anomeric}}$), 75.7, 73.4, 71.1, 69.0, 65.5, 61.3.

HRMS-ESI (m/z): [M+Na]$^+$ Calcd for C$_8$H$_{14}$NaO$_8$, 261.0586; Found, 261.0463.

To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (0.2 g, 0.15 mmol) in DCM was bubbled O₃ at -78 °C for 5 min. The light-blue solution was treated with PPh₃ (58 mg, 0.23 mmol) and was allowed to warm to room temperature. After 30 min, the crude aldehyde product was obtained after concentration under reduced vacuum. To a solution of aldehyde product in acetone was added Jones reagent (0.16 mL, 0.13 mmol) and the mixture was stirred for 30 min. After TLC analysis, excess reagent was quenched with 2-propanol and sold was filtered off through a Celite pad. The pure product 5 (0.12 g, 89 %) was obtained after concentration under reduced vacuum followed by purified through silica column chromatography (Hexane:Ethyl Acetate = 1:2).

\[ R_f \text{ (ethyl acetate/haxane): 0.30 (70/30)} \]

\[ ^1H \text{ NMR (CDCl}_3, 400 MHz): \delta \text{ (ppm) 7.33-7.15 (m, 30H), 5.52 (s, 1H), 5.07 (s, 1H), 4.98 (s, 1H), 4.83 (dd, 2H, } J = 10.8, 6 \text{ Hz), 4.68 (s, 2H), 4.67-4.60 (m, 3H), 4.53-4.39 (m, 5H), 4.10-4.02 (m, 3H), 3.96-3.90 (m, 3H), 3.80-3.65 (m, 7H), 2.11 (s, 3H).} \]
$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 173.5 (C=O), 170.5 (C=O), [138.7, 138.6, 138.4, 138.3 (C$_q$-Aryl)], 128.7-127.8 (m, CH-Aryl), [99.8, 99.0 (CH$_{anomeric}$)], 79.7, 78.4, 75.4, 74.7, 73.7, 73.6, 72.7, 72.4, 72.3, 72.2, 69.4, 69.2, 69.1, 63.7, 21.4 (CH$_3$).

HRMS-MALDI (m/z): [M+Na]$^+$ Calcd for C$_{58}$H$_{62}$NaO$_{14}$, 1005.4037; Found, 1005.4289

Synthesis of Carboxymethyl-2-O-(2-O-$\alpha$-D-mannopyranosyl)-$\alpha$-D-mannopyranoside 6

To a carboxymethyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-$\alpha$-D-mannopyranosyl)-$\alpha$-D-mannopyranoside (5) (0.1 g, 0.11 mmol) was dissolved in THF (8 mL) and MeOH (0.5 mL) in a flask. Liquid ammonia (20 mL) was then condensed into the flask at -78 $^\circ$C. Sodium metal was added in several portions until the solution was dark blue. The dark blue solution was stirred at -78 $^\circ$C for 30 min. Following
disappearance of the dark blue color, EtOH (3 mL) was added and ammonia was blown off with a stream of air. The solution was then neutralized with acidic Dowex-resin to pH 7 and the resin was filtered off through a Celite pad. The desired (6) was obtained through evaporation of solvent under reduced pressure in good yield (34 mg, 75%).

$^1$H NMR (CD$_3$OD, 400 MHz): $\delta$ (ppm) 5.15 (s, 1H), 4.98 (s, 1H), 4.24 (m, 2H), 3.96-3.57 (m, 12H).

$^{13}$C NMR (CD$_3$OD, 100 MHz): $\delta$ (ppm) 172.3 (C=O), [102.9, 98.7 (CH$_{\text{anomeric}}$)], 78.8, 78.8, 74.0, 73.7, 71.2, 70.6, 67.4, 63.7, 63.4, 61.8, 61.7.

HRMS-ESI (m/z): [M+Na]$^+$ Calcd for C$_{14}$H$_{24}$NaO$_{13}$, 423.1115; Found, 423.0923.

To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (0.2 g, 0.11 mmol) in DCM was bubbled O₃ at -78 °C for 5 min. The light-blue solution was treated with PPh₃ (42 mg, 0.16 mmol) and was allowed to warm to room temperature. After 30 min, the crude aldehyde product was obtained after concentration under reduced vacuum. To a solution of aldehyde product in acetone was added Jones reagent (0.11 mL, 0.08 mmol) and the mixture was stirred for 30 min. After TLC analysis, excess reagent was quenched with 2-propanol and sold was filtered off through a Celite pad. The pure product (7) (0.13 g, 87 %) was obtained after concentration under reduced vacuum followed by purified through silica column chromatography (Hexane:Ethyl Acetate = 1:2).

Rₛ (ethyl acetate/haxane): 0.13 (50/50)

¹H NMR (CDCl₃, 400 MHz): δ (ppm) 7.26-7.12 (m, 45H, aromatics), 5.52 (t, 1H, J = 2.0 Hz), 5.17 (s, 1H), 5.03 (d, 1H, J = 8.0 Hz), 4.83 (d, 1H, J = 10.8 Hz), 4.80 (d, 1H,
$J = 10.8 \text{ Hz}$, 4.62-4.41 (m, 14H), 4.33 (d, 1H, $J = 12.0 \text{ Hz}$), 4.10-4.05 (m, 3H), 4.05-3.88 (m, 6H), 3.77-3.63 (m, 8H), 3.53 (d, 1H, $J = 10.4 \text{ Hz}$), 2.12 (s, 3H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): \( \delta \) (ppm) 172.4, 170.2, [138.6, 138.5, 138.5, 138.4, 138.3, 138.3, 138.1 (C$_q$-Aryl)], 134.1 (CH$_2CH=CH_2$), 128.5 – 127.6 (m, CH-Aryl), [100.9, 99.5, 99.3 (CH$_{anomeric}$)], 79.1, 78.1, 75.2, 75.2, 75.0, 74.9, 74.6, 74.3, 73.4, 72.6, 72.5, 72.3, 72.2, 72.0, 71.9, 69.8, 69.2, 68.9, 68.8,

HRMS-ESI (m/z): [M+Na]$^+$ Calcd for C$_{85}$H$_{90}$NaO$_{19}$, 1437.5974; Found, 1437.5097.

\[
\begin{align*}
\text{Synthesis of Carboxymethyl-2-O-[2-O-(2-O-\alpha-D-mannopyranosyl)-\alpha-D-mannopyranosyl]-\alpha-D-mannopyranoside 8.}
\end{align*}
\]

To a carboxymethyl-3,4,6-O-benzyl-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-\alpha-D-mannopyranosyl)-3,4,6-tri-O-benzyl-\alpha-D-mannopyranosyl]-\alpha-D-mannopyranoside 7
(0.1 g, 0.07 mmol) was dissolved in THF (8 mL) and MeOH (0.5 mL) in a flask. Liquid ammonia (20 mL) was then condensed into the flask at -78 °C. Sodium metal was added in several portions until the solution was dark blue. The dark blue solution was stirred at -78 °C for 30 min. Following disappearance of the dark blue color, EtOH (3 mL) was added and ammonia was blown off with a stream of air. The solution was then neutralized with acidic Dowex-resin to pH 7 and the resin was filtered off through a Celite pad. The desired (8) was obtained through evaporation of solvent under reduced pressure in good yield (29 mg, 72 %).

$^1$H NMR (CD$_3$OD, 400 MHz): δ (ppm) 5.29 (s, 1H), 5.11 (s, 1H), 4.97 (s, 1H), 4.02-3.53 (m, 20H).

$^{13}$C NMR (CD$_3$OD, 100 MHz): δ (ppm) 176.3 (C=O), [102.7, 101.1, 98.4 (CH$_{anomeric}$)], 79.1, 78.9, 73.7, 73.7, 73.5, 71.2, 70.8, 70.7, 70.7, 67.9, 67.8, 67.5, 66.0, 61.8, 61.7, 61.6.

HRMS-ESI (m/z): [M+Na]$^+$ Calcd for C$_{20}$H$_{34}$NaO$_{18}$, 585.1643; Found, 585.1528.
Synthesis of Carboxymethyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside 9.

To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside (0.2 g, 0.11 mmol) in DCM was bubbled O₃ at -78 °C for 5 min. The light-blue solution was treated with PPh₃ (42 mg, 0.16 mmol) and was allowed to warm to room temperature. After 30 min, the crude aldehyde product was obtained after concentration under reduced vacuum. To a solution of aldehyde product in acetone was added Jones reagent (0.11 mL, 0.08 mmol) and the mixture was stirred for 30 min. After TLC analysis, excess reagent was quenched with 2-propanol and solid was filtered off through a Celite pad. The pure product 9 (0.13 g, 85 %) was obtained after concentration under reduced vacuum.
followed by purified through silica column chromatography (Hexane:Ethyl Acetate = 1:2).

$R_f$ (ethyl acetate/hexane): 0.12 (50/50)

$^1$H NMR (CDCl$_3$, 400 MHz): $\delta$ (ppm) 7.29-7.13 (m, 45H, aromatics), 5.45 (s, 1H), 5.08 (s, 1H), 4.94 (d, 1H, $J = 4$ Hz), 4.90 (d, 1H, $J = 12$ Hz), 4.84-4.76 (m, 3H), 4.71-4.44 (m, 9H), 4.41-4.25 (m, 7H), 4.19-4.15 (m, 3H), 3.95-3.87 (m, 3H), 3.80-3.64 (m, 7H), 3.50 (t, 1H, $J = 12$ Hz), 3.43-3.38 (m, 2H), 2.07 (s, 3H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 173.3, 170.0, [139.2, 139.1, 139.0, 138.8, 138.6, 138.5, 138.3, 138.2, 138.1 (C$_q$-Aryl)], 128.5–127.2 (m, CH-Aryl), [103.7, 99.3, 99.1 (CH$_{anomeric}$)], 82.8, 80.0, 78.5, 75.4, 75.3, 75.1, 74.8, 74.5, 73.5, 73.3, 73.1, 72.9, 72.8, 72.5, 72.2, 72.1, 69.1, 69.0, 68.6, 68.4, 84.1, 21.3.

HRMS-MALDI (m/z): [M+Na]$^+$ Calcd for C$_{85}$H$_{90}$NaO$_{19}$, 1437.5974; Found, 1437.7109.
Synthesis of Carboxymethyl-4-\(O\)-[β-D-galactopyranosyl]-2-\(O\)-[2-\(O\)-α-D-mannopyranosyl]-α-D-mannopyranoside 10.

To a carbpxymethyl-3,6-di-\(O\)-benzyl-4-\(O\)-[2,3,4,6,-tetra-\(O\)-benzyl-β-D-galactopyranosyl]-2-\(O\)-[2-\(O\)-acetyl-3,4,6-tri-\(O\)-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside (9) (0.1 g, 0.07 mmol) was dissolved in THF (8 mL) and MeOH (0.5 mL) in a flask. Liquid ammonia (20 mL) was then condensed into the flask at -78 °C. Sodium metal was added in several portions until the solution was dark blue. The dark blue solution was stirred at -78 °C for 30 min. Following disappearance of the dark blue color, EtOH (3 mL) was added and ammonia was blown off with a stream of air. The solution was then neutralized with acidic Dowex-resin to pH 7 and the resin was filtered off through a Celite pad. The desired (10) was obtained through evaporation of solvent under reduced pressure in good yield (31 mg, 78 %).

\(^1\)H NMR (CD\(_3\)OD, 400 MHz): 5.10 (s, 1H), 5.02 (s, 1H), 4.34 (d, 1H, \(J = 7.6\) Hz), 4.19 (br, 1H), 4.04-3.48 (m, 18H).

\(^{13}\)C NMR (CD\(_3\)OD, 100 MHz): δ (ppm) 171.0 (C=O), [103.9, 102.7, 99.0 (CH\(_{\text{anomeric}}\)], 77.3, 75.7, 73.8, 73.6, 72.4, 70.6, 69.0, 67.4, 64.0, 61.7, 61.2, 60.8.

HRMS-MALDI (m/z): [M+Na]\(^+\) Calcd for C\(_{20}\)H\(_{34}\)NaO\(_{18}\), 585.1643; Found, 585.6198
Synthesis of Carboxymethyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside 11.

To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside (0.2 g, 0.09 mmol) in DCM was bubbled O₃ at -78 °C for 5 min. The light-blue solution was treated with PPh₃ (34 mg, 0.13 mmol) and was allowed to warm to room temperature. After 30 min, the crude aldehyde product was obtained after concentration under reduced vacuum. To a solution of aldehyde product in acetone was added Jones reagent (0.11 mL, 0.08 mmol) and the mixture was stirred
for 30 min. After TLC analysis, excess reagent was quenched with 2-propanol and sold was filtered off through a Celite pad. The pure product (9) (0.13 g, 85%) was obtained after concentration under reduced vacuum followed by purified through silica column chromatography (Hexane:Ethyl Acetate = 1:2).

$R_f$ (ethyl acetate/hexane): 0.15 (50/50)

$^1$H NMR (CDCl$_3$, 400 MHz): $\delta$ (ppm) 7.31-7.14 (m, 60H, aromatics), 5.46 (s, 1H), 5.15 (s, 1H), 4.99 (d, 2H, $J = 8$ Hz), 4.94 (d, 1H, $J = 12$ Hz), 4.81 (dd, 2H, $J = 8$, 4 Hz), 4.71-4.64 (m, 3H), 4.68 (s, 2H), 4.59-4.56 (m, 3H), 4.51-4.41 (m, 9H), 4.34-4.23 (m, 5H), 4.13 (d, 1H, $J = 16$ Hz), 4.00-3.83 (m, 10H), 3.73-3.61 (m, 6H), 3.59-3.50 (m, 4H), 3.42-3.37 (m, 3H), 2.11 (s, 3H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 173.1, 170.3, [139.3, 139.1, 138.9, 138.8, 138.7, 138.7, 138.6, 138.6, 138.5, 138.5, 138.3, 138.1 (C$_q$-Aryl)], 128.6–127.3 (m, CH-Aryl), [103.6, 100.6, 99.8, 99.5 (CH$_{anomeric}$)], 82.8, 80.1, 79.6, 75.6, 75.5, .75.3, 74.9, 74.8, 74.5, 73.5, 73.5, 73.3, 73.1, 72.9, 72.8, 72.7, 72.4, 72.2 72.1, 68.6, 69.0, 68.6, 64.5, 21.4.

HRMS-MALDI (m/z): [M+Na]$^+$ Calcd for C$_{112}$H$_{118}$NaO$_{24}$, 1869.7911; Found, 1870.5026.
Synthesis of Carboxymethyl-4-O-[β-D-galactopyranosyl]-2-O-[2-O-(2-O-α-D-mannopyranosyl)-α-D-mannopyranosyl]-α-D-mannopyranoside 12.

To a solution of carboxymethyl-3,6-di-O-benzyl-4-O-[2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl]-2-O-[2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl]-α-D-mannopyranoside (11) (0.1 g, 0.05 mmol) was dissolved in THF (8 mL) and MeOH (0.5 mL) in a flask. Liquid ammonia (20 mL) was then condensed into the flask at -78 °C. Sodium metal was added in several portions until the solution was dark blue. The dark blue solution was stirred at -78 °C for 30 min. Following disappearance of the dark blue color, EtOH (3 mL) was added and ammonia was blown off with a stream of air. The solution was then neutralized with acidic Dowex-resin to pH 7 and the resin was filtered off through a
The desired (12) was obtained through evaporation of solvent under reduced pressure in good yield (36 mg, 90%).

\[ ^1H \text{ NMR (CD}_3\text{OD, 400 MHz)}: \delta (\text{ppm}) 5.33 \text{ (s, 1H), 5.08 (s, 1H), 4.97 (s, 1H), 4.35 (d, 1H, } J = 7.2 \text{ Hz), 4.13 (s, 2H), 4.05-3.96 (4H), 3.85-3.82 (m, 8H), 3.73-3.49 (13H).} \]

\[ ^{13} \text{C NMR (CD}_3\text{OD, 100 MHz): } \delta (\text{ppm}) 172.4 \text{ (C=O), [103.9, 102.7, 100.9, 98.9 (CH}_\text{anomeric})], 79.0, 77.3, 77.3, 75.7, 73.8, 73.6, 73.5, 72.3, 71.3, 71.1, 70.6, 70.6, 69.6, 69.2, 67.9, 67.4, 63.8, 61.8, 61.3, 60.8. \]


**Synthesis of sugar-conjugated latex beads**

\[
\text{mmol of COOH per 1mL of beads solution: } (2.7 \times 10^{10} \text{ bead/mL}) \times (1.296 \times 10^{-14} \text{ mmol/bead}) = 3.5 \times 10^{-4} \text{ mmol/mL.}
\]

To a solution of latex beads (1mL, 2.7 x 10^{10} beads/mL) was added EDC (8 mg, 0.004 mmol) solution (100 µL) in deionized water (DI water) followed by ethylenediamine in MES buffer (200 µL). The reaction mixture was stirred at 26 °C for
18 h (X 2) and then beads were washed with DI water 2 ~ 3 times for the Kaiser test. 10 µL of Beads solution was used to perform a Kaiser test (positive: deep purple color). To a solution of sugar (30 equiv of dimannose, trimannose, branched trisaccharide and tetrasaccharide; 50 equiv of lactose and galactose) in DI water (200 µL) was added EDC solution (DI water, 100 µL) followed by NHS solution (DI water, 100 µL). The reaction mixture was stirred for 10 min and then combined with amine-functionalized latex beads in MES buffer (200 µL). The mixture was stirred at 26 °C for 18 h (X 2) and then performed the Kaiser test with 10 µL of Beads solution (negative: dark brown color). Sugar-coated latex beads (2.65 x 10^{10} beads in 1mL of DI water) were stored 4 °C refrigerator.

References


5 Varki A, Cumming RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW,


24 Chapter 3 In thesis.

CHAPTER 6

Modification of degradable polymeric particles with carbohydrates
for the study of in vitro activation of dendritic cells

Eun-Ho Song\textsuperscript{1}, Brenda R. Carrillo-Conde\textsuperscript{2}, Balaji Narasimhan\textsuperscript{2} and Nicola L. Pohl\textsuperscript{1}
(1) Department of Chemistry, Iowa State University,(2)Department of Chemical and Biological Engineering, Iowa State University.

Introduction

Despite extensive efforts on the development of efficient delivery systems for drugs, an efficient carrier for drug to specific areas in the human body has been highlighted as a prerequisite for the optimization of drug efficiency\textsuperscript{1, 2} More recently, attention has been focused on the development of vaccine delivery system in order to prevent severe bacterial, viral, parasitic and respiratory infectious diseases both in human and animal\textsuperscript{3, 4}.

Several polymers such as copolymers\textsuperscript{5} of sebacic anhydride (SA) and 1,6-bis-(p-carboxyphenoxy)hexane (CPH), copolymers\textsuperscript{6} of 1,6-bis-(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and poly(propylacrylic acid) (PPAA)\textsuperscript{7} as vaccine delivery vehicles have been extensively studied in various biomedical researches due to their biocompatibility and degradation properties under certain pH ranges and temperatures.

Among these polymers, polyanhydride copolymers including CPH:SA and CPTEG:CPH have been well characterized in order to facilitate bulk-erodible property,
induced by hydrophilic-polymers (CPTEG), into the surface erodible polyanhydrides (CPH and SA). Important features using polyanhydride copolymers are the enhancement of controlling erosion kinetics, determined by a combination of erosion mechanisms between bulk-eroding and surface-eroding, for controlled drug release kinetics and the non-acidic microenvironment produced by degradation of polymers. Moreover, recent study with polyanhydride nanoparticles has shown that size and chemistry of particles are important factors in cellular internalization of polymers by monocytes.

To examine carbohydrate antigen-mediated activation of Dendritic cells (DCs), more research has been performed with synthetic carbohydrate ligands as antigens capable of activating DCs. DCs are immune cells that are the most important antigen-presenting cells (APCs) in the early stage of immune responses. Importantly, DCs are not only capable of stimulating T cells, but also essential for connecting innate and adaptive immunities through Th1 cell or Th2 stimulation. Although importance of carbohydrate antigens has been addressed in terms of immune stimulation, accessibility of carbohydrates on polymeric vehicles is still limited by lack of suitable conjugation chemistry and degradable property of polymeric particles. Previous erosion studies with polyanhydride copolymers showed that 50:50 CPTEG:CPH copolymer was significantly degraded (67% of molecular weight loss) in water for 2 days. This degradation property provides harsh conditions for the modification of polymeric particles.
In this study, we demonstrated modification of degradable polyanhydride copolymers with lactose and dimannose in order to investigate carbohydrate antigen-dependent immune responses on uptake and activation of DCs.

**Results and discussion**

In order to enhance immune responses of copolymers through activation of DCs, carbohydrate antigen coated polymers were prepared.

**Synthesis of carboxylated-lactose and dimannose.**

Mercury (II)-catalyzed allylation\(^\text{13}\) of penta-\(O\)-acetyl-1-\(O\)-bromide lactose using Hg(II)CN and all alcohol produced \(\beta\)-1-\(O\)-allylated lactose 1 in high yield (92 % three steps) as a precursor for oxidation. One-step oxidation of olefin for the construction of carboxylic acid in 2-acetamido-2-dexoy-D-glucose has been reported by using ruthenium-catalyzed Sharpless conditions.\(^\text{14,15}\) As expected, using excess amounts of NaIO\(_4\) (8 eq) under ruthenium-catalyzed Sharpless conditions produced the desired acid 2 in 91 % yield. But, this oxidation is not suitable in the presence of benzyl protections due to transformation of benzyl to benzoyl. Subsequent deacetylation under mild condition using K\(_2\)CO\(_3\) provided fully deprotected disaccharide 3.
Iterative synthesis of linear α-1,2-linked dimannose 8 has been reported by using fluorous-solid phase extraction (FSPE). Each glycosylation was performed with 1.1 equivalent of trichloroacetimidate donor 4 in toluene at 25 °C for 5 min. Facile purification of crude product by FSPE enabled easy preparation of desired linear α-1,2-linked dimannose 8 in high yield.
Scheme 2. Iterative synthesis of fluorous–tagged $\alpha$-1,2-linked dimannose.

Fully deprotected $\alpha$-1,2-linked dimannose $10$ was obtained by ozonolysis$^{18}$ of $8$, followed by global deprotection of $9$ under Birch reduction conditions$^{19}$ (Na, NH$_3$).


Modification of micro- and nanoparticles with lactose and dimannose.

Polyanhydride copolymers$^{5,6}$ and FITC-dextran loaded copolymers$^{20}$ for confocal images of the internalization of polymer in DCs were prepared as reported in literatures.
Surface modification of polymeric particles is obviously challenging due to physical properties of polymers such as degradation and aggregation. In addition, FITC-labeling can be detached from particles during coupling steps under certain conditions such as high temperature and organic solvent because it is not chemically attached to polymeric particles. To overcome these unfavorable properties of polymeric particles, optimization of coupling reaction conditions should be a prerequisite for efficient modification.
homogeneous density of carbohydrates on the surface.

Sugar coated polymeric particles were synthesized from carboxylic acid-functionalized lactose 3 and dimannose 10 using a procedure that has been used for the peptide-type coupling reaction. The control compound, glycolic acid, was also carried through same steps to work out a viable protocol (Scheme 1). In order to avoid fast degradation of polymeric particles, we performed coupling reactions under aqueous conditions rather than under DMF or DCM which is common solvent for solid-phase synthesis. Although 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC)\textsuperscript{21} has been used as a coupling agent for the purpose of forming amide bonds in peptide synthesis, amine reactive O-acylisourea intermediate which is activated by EDC can be hydrolyzed by water. In order to increase the efficiency of coupling reaction in aqueous condition, we added N-hydroxysuccinimide (NHS)\textsuperscript{22} to form an amine reactive NHS-ester after activating carboxyl group with EDC. Ethylenediamine as a spacer molecule was attached to carboxylated polymeric particles in order to increase accessibility of carbohydrates to the surface of particles. Peptide-type coupling reaction was repeated twice with relatively short reaction time (8 ~ 9 hours) to accomplish a complete coupling reaction. Carbohydrate-coated
polymeric particles were prepared through second coupling reaction with carboxylic acid-functionalized lactose 3 and dimannose 10 followed by dry under high-vacuum. The Kaiser test\textsuperscript{23} (Ninhydrin color test) was employed as an indicator of coupling reaction progress. Quantitative monitoring of reaction can verify sugar loading on the beads.\textsuperscript{24} Surface characterization by X-ray photoelectron spectroscopy (XPS) clearly showed an increase of N/C % in carbohydrate modified particles. (by Brenda R. Carrillo-Conde).

In order to evaluate the effect of surface modification with carbohydrate on immune responses, DC activation studies such as cell surface marker expression analysis, cytokine production analysis and particle uptake studies have been done by collaboration partner (Brenda R. Carrillo-Conde) in Chem. Eng. (Dr. Balaji Narasimhan). Although significant difference between unmodified particles and carbohydrate-modified particles was not observed in cytokine production studies, carbohydrate-modified particles showed higher up-regulation in the expression of MHC II, CD40, CD86, CD206, and CD209 as well as greater uptake of lactose by DCs, a marker for DC stimulation. Because cells that are associated with immune system, display a unique set of cell surface markers, identification of cell surface
markers plays a significant role in unveiling the type of immune response.

**Conclusion**

We demonstrated that the Surface modification of erodible polymeric particles by carbohydrates including lactose and dimannose could play an important role in activation of innate immunity. Conjugation chemistry using EDC and NHS provided a viable route of modification of erodible polymeric beads without significant loss of polymeric particles caused by degradation.

Importantly, we observed that carbohydrate-modified particles are closely related with several important cell surface markers that are capable of inducing adaptive immunity (MHC II, CD40, and CD86) or acting as a cell adhesion receptor (CD209). These preliminary results showed great promise for the study of the effect carbohydrate-modified particles on the regulation of immune responses.

In order to support to these results, using branched-/linear trisaccharide and longer spacer might be helpful to clarify carbohydrate antigen effect on immune responses.

**Experimental section**
General methods

Solvents were reagent grade and in most cases dried prior to use. All other commercially available reagents were used as received unless otherwise noted. The organic extracts were dried over anhydrous MgSO$_4$. Tetrahydrofuran (THF) was distilled from lithium aluminum hydride (LiAlH$_4$) prior to use. Methylene chloride (CH$_2$Cl$_2$), and triethylamine (Et$_3$N) were distilled from calcium hydride. Diethyl ether (Et$_2$O) was distilled from sodium-benzophenone ketyl.

$^1$H and $^{13}$C NMR spectra were obtained at 400 MHz and 100 MHz on Varian VXR-400 NMR or on Bruker DRX-400 NMR. Mass spectra (MS) were recorded on an Applied Biosytems DE-Pro MALDI mass analyzer or an Applied Biosytems QSTAR® XL Hybrid LC/MS/MS System. Chemical shifts are reported in parts per million downfield relative to tetramethylsilane (δ 0.00) and coupling constants are reported in Hertz (Hz). The following abbreviations are used for the multiplicities: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br = broad.

Synthesis of carboxylated-lactose and dimannose.
Synthesis of Carboxymethyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl]-2,3,6-tri-O-acetyl-β-D-galactopyranoside 2.

To a solution of 2-propynyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl] -2,3,6- tri-O-acetyl-β-D-galacto-pyranoside (1)\textsuperscript{25} (0.5g, 0.7 mmol) in the mixture of CCl\textsubscript{4} (3 mL), CH\textsubscript{3}CN (3 mL), and H\textsubscript{2}O (4 mL) is added NaIO\textsubscript{4} (1.27 g, 5.6 mmol). To this mixture was added RuCl\textsubscript{3}.H\textsubscript{2}O (3.1 mg, 2.2 mol %) and the reaction mixture was stirred at 25 °C for 2 h. After dilution with 10 mL of DCM, the reaction mixture was filtered through a Celite pad. The aqueous layer was extracted with twice with DCM and then organic layer was washed with water and brine. The crude mixture was obtained after drying with Na\textsubscript{2}SO\textsubscript{4} followed by concentration under reduced vacuum. The crude product was purified to obtain the desired product (2) (0.47 g, 91 %) by silica column chromatography

\textbf{R}_{f} (ethyl acetate/haxane): 0.30 (70/30)

\textbf{\textsuperscript{1}H NMR (CDCl\textsubscript{3}, 400 MHz):} \(\delta\) (ppm) 5.34 (d, 1H, \(J = 2.4\) Hz), 5.22 (t, 1H, \(J = 9.2\) Hz), 5.09 (t, 1H, \(J = 8\) Hz), 4.97-4.93 (m, 2H), 4.62 (d, 1H, \(J = 7.6\) Hz), 4.50-4.47 (m, 2H), 4.29 (s, 2H), 4.11-4.04 (m, 3H), 3.87 (t, 1H, \(J = 6.4\) Hz), 3.80 (t, 1H, \(J = 9.2\) Hz),
3.65-3.61 (m, 1H), 2.14 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.03 (s, 3H), 1.93 (s, 3H).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 170.6, 170.6, 170.3, 170.3, 170.1, 169.9, 169.2, [101.2, 100.4 ($\text{CH}_{\text{anomeric}}$)], 76.2, 73.1, 72.5, 71.4, 71.1, 70.9, 69.2, 66.8, 65.5, 61.9, 61.0, 21.0, 21.0, 20.9, 20.9, 20.8, 20.7.

HRMS-MALDI (m/z): $[\text{M+Na}]^+$ Calcd for C$_{28}$H$_{38}$NaO$_{20}$, 717.5791; Found, 717.6184.

Synthesis of Carboxymethyl-4-O-(β-D-galactopyranosyl)-β-D glucopyranoside

3.

To a carboxymethyl-4-O-[2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl]-2,3,6-tri-O-acetyl-β-D-galacto-pyranoside (2) (0.4 g, 0.57 mmol) in MeOH (5 mL) was added Na (27 mg, 1.14 mmol) and stirred at 25 °C for 2 h. The reaction mixture was neutralized with Dowex-ion-exchange resin. The desired (3) was obtained through Celite filtration followed by evaporation of solvent under reduced pressure in good yield (0.21 g, 89%).

$^1$H NMR (CDCl$_3$, 400 MHz): $\delta$ (ppm) 4.46 (d, 1H, $J = 16.4$ Hz), 4.30-4.23 (m, 2H),
3.81 (d, 1H, J = 3.2 Hz).

$^{13}$C NMR (CDCl$_3$, 100 MHz): $\delta$ (ppm) 173.0, 170.8, 170.5, 17.4, 170.2, 100.4 (CH$_{\text{anomeric}}$), 71.1, 70.7, 68.6, 67.1, 65.0, 61.4, 21.0, 20.9, 20.8, 20.8.

HRMS-ESI (m/z): [M+Na]$^+$ Calcd for C$_{14}$H$_{24}$NaO$_{13}$, 423.1115; Found, 423.0942.


To a solution of 3-(perfluorooctyl)propanyloxybutenyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-\(\alpha\)-D-mannopyranosyl)-\(\alpha\)-D-mannopyranoside (8) (0.2 g, 0.15 mmol) in DCM was bubbled O$_3$ at -78 °C for 5 min. The light-blue solution was treated with PPh$_3$ (58 mg, 0.23 mmol) and was allowed to warm to room temperature. After 30 min, the crude aldehyde product was obtained after concentration under
reduced vacuum. To a solution of aldehyde product in acetone was added Jones reagent (0.16 mL, 0.13 mmol) and the mixture was stirred for 30 min. After TLC analysis, excess reagent was quenched with 2-propanol and solid was filtered off through a Celite pad. The pure product (9) (0.12 g, 89 %) was obtained after concentration under reduced vacuum followed by purified through silica column chromatography (Hexane:Etyl Acetate = 1:2).

Rf (ethyl acetate/haxane): 0.30 (70/30)

1H NMR (CDCl3, 400 MHz): δ (ppm) 7.33-7.15 (m, 30H), 5.52 (s, 1H), 5.07 (s, 1H), 4.98 (s, 1H), 4.83 (dd, 2H, J = 10.8, 6 Hz), 4.68 (s, 2H), 4.67-4.60 (m, 3H), 4.53-4.39 (m, 5H), 4.10-4.02 (m, 3H), 3.96-3.90 (m, 3H), 3.80-3.65 (m, 7H), 2.11 (s, 3H).

13C NMR (CDCl3, 100 MHz): δ (ppm) 173.5 (C=O), 170.5 (C=O), [138.7, 138.6, 138.4, 138.3 (Cq-Aryl)], 128.7-127.8 (m, CH-Aryl), [99.8, 99.0 (CH_anomeric)], 79.7, 78.4, 75.4, 74.7, 73.7, 73.6, 72.7, 72.4, 72.2, 69.4, 69.2, 69.1, 63.7, 21.4 (CH3).

HRMS-MALDI (m/z): [M+Na]+ Calcd for C58H62NaO14, 1005.4037; Found, 1005.4289

To a carboxymethyl-3,4,6-tri-O-benzyl-2-O-(2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl)-α-D-mannopyranoside (9) (0.1 g, 0.11 mmol) was dissolved in THF (8 mL) and MeOH (0.5 mL) in a flask. Liquid ammonia (20 mL) was then condensed into the flask at -78 °C. Sodium metal was added in several portions until the solution was dark blue. The dark blue solution was stirred at -78 °C for 30 min. Following disappearance of the dark blue color, EtOH (3 mL) was added and ammonia was blown off with a stream of air. The solution was then neutralized with acidic Dowex-resin to pH 7 and the resin was filtered off through a Celite pad. The desired (10) was obtained through evaporation of solvent under reduced pressure in good yield (34 mg, 75%).

$^1$H NMR (CD$_3$OD, 400 MHz): δ (ppm) 5.15 (s, 1H), 4.98 (s, 1H), 4.24 (m, 2H),
3.96-3.57 (m, 12H).

$^{13}$C NMR (CD$_3$OD, 100 MHz): δ (ppm) 172.3 (C=O), [102.9, 98.7 (CH anomeric)], 78.8, 78.8, 74.0, 73.7, 71.2, 70.6, 67.4, 63.7, 63.4, 61.8, 61.7.

HRMS-ESI (m/z): [M+Na]$^+$ Calcd for C$_{14}$H$_{24}$NaO$_{13}$, 423.1115; Found, 423.0923.

Modification of polymeric particles with sugars.

To a solution of microspheres (20 mg, 1.34 x 10$^{-2}$ mmol of COOH) was added EDC (31 mg, 0.16 mmol: 12 eq) solution (100 µL) in deionized water (DI water) and NHS (19 mg, 0.16 mmol) solution (DI water, 100 µL) followed by ethylenediamine (8.9 µL, 0.13 mmol: 10 eq) in DI water (100 µL). The reaction mixture was stirred at
25 °C for 8 ~ 9 h (X 2) and then microspheres were washed with DI water 2 ~ 3 times for the Kaiser test. 1 mg of particles was used to perform a Kaiser test (positive: deep purple color). To a solution of sugar (53 mg, 0.13 mmol: 10 eq) in DI water (200 µL) was added EDC (31 mg, 0.16 mmol) solution (100 µL of DI water) followed by NHS (19 mg, 0.16 mmol) solution (DI water, 100 µL). The reaction mixture was stirred for 10 min and then combined with amine-functionalized particles in DI water (200 µL, pH = 9). The mixture was stirred at 25 °C for 8 ~ 9 h (X 2) and then performed the Kaiser test with 1 mg of particles (negative: dark brown color). Di water was removed and wet sugar-coated particles were dried under high vacuum. (Particle aggregation was prevented by using probe sonicator during coupling reaction.)

References


Carlsen PHJ, Katsuki T, Martin VS, Sharpless KB. *J. Org. Chem.* 46, 3936-3938


19 McCloskey CM. Adv Carbodhydr Res. 12, 137-156 (1957).

20 McCloskey CM. Adv Carbodhydr Res. 12, 137-156 (1957).


CHAPTER 7

Conclusions and Future Directions

In this dissertation, the first automated solution-phase syntheses of oligosaccharides that are related to infectious disease such as HIV, leishmaniasis and tuberculosis are reported. The use of a new fluorous-based automation platform enabled the facile synthesis of HIV-associated linear α-(1,2)-pentamannose as well as a Leishmania-capping tetrasaccharide. In addition, chemistry for the construction of phosphate-linked sugars was successively programmed and applied to the synthesis of lipophosphoglycans associated with Leishmania. The new automated methods developed herein and featured in the construction of complicated oligosaccharides not only opens up a new era for oligosaccharide library synthesis—capable of facilitating diversity both in structure and sequence—but also easier access to carbohydrates for systematic structure-function relationship studies. The combination of the fluorous-based automation platform with fluorous-based microarrays should be a powerful tool for accelerating research progress in glycomics.

In addition to the development of automated methods for the synthesis of several
bioactive oligosaccharides, this thesis demonstrates the importance of systematic structure-function evaluations for carbohydrate structures in understanding innate immune responses to these structures. Methods to attach synthetic sugars to latex beads or erodable polymeric particles for multivalent displays are reported. Collaborative studies show that these synthetic structures exhibit clear differences in the activation of innate immune responses based solely on differences in the carbohydrate structure. Further studies on the effect of carbohydrate structures on immune responses will aid the development of carbohydrate-based antigens as vaccine adjuvants and vaccines. Future studies should also aim to evaluate the immunomodulatory effects of structurally different cap sugars in vivo. Ultimately, significant progress both in the synthetic tools available and in the study of immunity induced by carbohydrates will provide the necessary background to fully develop and evaluate the therapeutic potential of carbohydrate-based vaccines as immunomodulatory adjuvants.
ACKNOWLEDGEMENTS

I would like to say many thanks to my advisor, Dr. Nicola L. B. Pohl for her great supports throughout entire my graduate research at Iowa State University. I also want to thank all my committee members, Dr. Richard C. Larock, Dr. Christine A. Petersen, Dr. Emily A. Smith, and Dr. Malika Jeffries-EL for guiding me to right direction in my research.

I would like to thank all previous and current Pohl group members for their help in making me smile in the lab.

Finally, I cannot thank enough my beloved wife (Sunkyung Chung), Joseph (Youngjun Song) and parents (Jae-ik Song, Young-sup Lee, Nam-young Chung and Kyung-ja Koo) for their great supports and prayers. They are my primary supporters who have helped me to accomplish my Ph.D study at Iow State University.
APPENDIX A.

CHAPTER 2 $^1$H AND $^{13}$C NMR SPECTRA
APPENDIX B.

CHAPTER 3 \textsuperscript{1}H AND \textsuperscript{13}C NMR SPECTRA
ehs0544 (CD3OD)
-Deprotected Di-mani-F tail

13-1

C₈F₁₇
217
ebs057C (CD3OD)
-Deprotected Gal-F tail
ehs9070C (C2,3OEt)
-Deprotected Ga-F tail
Deprotected Lectase F tail

carb655 (D30N)

![Chemical Structure](image)

**NMR Spectrum**

- **r1 (ppm)**
  - 9.0
  - 8.5
  - 8.0
  - 7.5
  - 7.0
  - 6.5
  - 6.0
  - 5.5
  - 5.0
  - 4.5
  - 4.0
  - 3.5
  - 3.0
  - 2.5
  - 2.0
  - 1.5
  - 1.0
  - 0.5
  - 0.0
ahs0655C (CD3OD)
-Deprotected Lactose-F tail

![Chemical Structure Diagram](image-url)
APPENDIX C.

CHAPTER 4 \( ^1H \) AND \( ^{13}C \) NMR SPECTRA
eh5i(0.3)
(Lel-Tri-Phosphodiestar-C13)
APPENDIX D.

CHAPTER 5 $^1$H AND $^{13}$C NMR SPECTRA
dms05561 (CD30D)
-Deprotected Lactose-carboxylic acid

![Chemical Structure Image]

![NMR Spectrogram Image]
"\text{D-Disordered Lactose-carboxylic acid}"

---

**Chemical Structure:**

![Chemical Structure Image]

---

**Graph:**

![Graph Image]
ehSO\textsubscript{3}\textsuperscript{+}/C (CD\textsubscript{3}OD)

-Deprotected Galactose-carboxylic acid

\begin{center}
\includegraphics[width=0.3\textwidth]{image.png}
\end{center}

\begin{center}
\includegraphics[width=\textwidth]{spectrum.png}
\end{center}
eds0557 (CD3OD)
-Deprotected D-mannonic acid
ensB57C (CD3OD)
-Degraded D-mannuronic acid
cd30556 (CD309)

- Deprotected TH-man-sulfonate acid
eh00535C (CD3OD)
-Deprotonated Tri-nan-carboxylic acid
APPENDIX E.

CHAPTER 6 $^1$H AND $^{13}$C NMR SPECTRA
ens0561 (CD30D)
-Deprotected Lactose-carboxylic acid
ehs0561K (CD30D)
-Degradation lactose-carboxylic acid
dps8557 (CD3OD)
-Deprotected D-mannuronic acid
eesS557C (CD2OD)
-deprotected D-man-carboxylic acid